Study Title: 
Sponsor: 
IND Number: 
Eudra CT N umber: 
Clinical Trial s.gov 
Identifier: 
Indication: 
Protocol ID: (rJ GILEAU 
CLINICAL STUDY PROTO COL 
A Phase 2, Rando mized, Double-Blin d, Placebo -Contrnlled Study 
Evaluating the Safety and E fficacy of Selonse1iib, GS-0976 , 
GS-9674, and Combinations in Subject s with Bridging (F3) Fibrosis 
or Compensated CnThosis (F4) due to Nonalcoholic Steato hepatiti s 
(NAS H) 
Gilead Science s, Inc. 
333 Lake side Drive 
Foster City, CA 94404 
141683 
Not Applicable 
[STUDY_ID_REMOVED] 
Nonalco holic Steato hepatiti s 
GS-US-454-4378 
Gilead Study Director Name: PD 
PD 
PD 
PD 
PD 
PD 
PD 
PD Telephone: 
Fax: 
Email: 
Gilead Medical Name: 
Monitor: Telephone: 
Fax: 
Email: 
Protocol Version/Date: Original: 
Ame ndment 1: 
Ame ndment 2: 
Ame ndment 3: 
Ame ndment 4: 08 Januai y 2018 
31 Januaiy 2018 
22 Febrnaiy 2018 
10 May20 18 
25 April 2019 
CONFIDENTIALITY STAT EMENT 
The info1mation contained in this docume nt, paiiic ulai· ly unpublished data, is the prope 1iy or 
unde r control of Gilead Sciences, Inc., and is prov ided to you in confidence as an investigato r, 
potential investigato r, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committ ee. The infonnation is only to be used by you in 
connectio n with author ized clinical studies of the investigational drng described in the protocol. 
You will not disclose any of the infonnatio n to others without written a uthorizatio n from 
Gilead Sciences, Inc., except to the extent necessa1 y to obtain infonned consent from those 
perso ns to whom the drng may be admin istered. 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
TABL E OF CONT ENTS 
TABL E OF CONT ENTS .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 2 
LIST OF IN-TEXT TABLES ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 5 
LIST OF IN-TEXT FIGURES .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 5 
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ............ .......... ................ ........ ................ ...... 16 
1. INTRODUCTI ON ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 22 
1.1. B ackground .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 22 
1.2. Selonsertib (SEL) ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 23 
1.2.1. Gene ral Infonnation for SEL ............... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 23 
1.2.2. Nonclinica l Phrumacology and Toxico logy ........ .......... ........ ................ ........ .......... ........ ..... 24 
1.2.3. Clinical Trials ofSEL .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 24 
1.3. GS-0976 ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 28 
1.3.1. Gene ral Infonnation for GS-0976 ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 28 
1.3.2. Nonclinica l Phrumacology and Toxico logy ........ .......... ........ ................ ........ .......... ........ ..... 28 
1.3.3. Clinical Trials ofGS -0976 .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 29 
1.4. GS-9674 ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 37 
1.4.1. General Infonnation for GS-9674 ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 37 
1.4.2. Nonclinica l Phrumacology and Toxico logy ........ .......... ........ ................ ........ .......... ........ ..... 38 
1.4.3. Clinical Trials ofGS -9674 .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 38 
1.5. Combina tion Studies ofSEL, GS-0976, and GS-9674 .................. ................ .......... ........ ................ ...... 44 
1.5.1. Nonclinical Pha1macology , Phrumacokinetic s, Drng Metaboli sm, and 
Toxicology ......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 44 
1.5.2. Clinical Trial s .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 46 
1.6. Rationale for This Study ............... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 52 
1.6.1. Rationale for Dose Selection of SEL. ........... ........ ......... ........ ........ ......... ........ ........ ......... ..... 54 
1.6.2. Rationale for Dose Selection of GS-0976 .................... ................ .......... ........ ........ .............. 54 
1.6.3. Rationale for Dose Selection of GS-9674 .................... ................ .......... ........ ........ .............. 55 
1.6.4. Rationale for Dose Selection of Combination s ............ ................ .......... ........ ................ ...... 55 
1. 7. Risk/Benefit Assessment for the Study ......... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 56 
1.8. Comp liance .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 57 
2. OB JECTIVES .......... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 58 
3. STUDY DES IGN .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 59 
3.1. 
3.2. 
3.3. 
3.4. 
3.5. Study Design ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 59 
Study Treatmen ts ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 59 
Duration of Study ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 60 
End of Study ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ..... 60 
Post Stud Cru· e ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ......... ............. 60 
4. SUBJECT POPULAT ION ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 63 
4.1. Number of Subjects and Subject Select.ion .. .......... ........ ................ ................ .......... ........ ................ ...... 63 
4.2. Inclu sion Criteria .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 63 
4.3. Exclusion Criteria ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 64 
5. INVESTIGATIO NAL MEDICINAL PRODUCTS ........... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 67 
5.1. Random ization, Blinding and Treatment Codes ............ ................ ................ .......... ........ ................ ...... 67 
CONFIDENTIAL Page2 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
5.1.1. Proced ures for Breaking Treatmen t Code s ........... ......... ........ ........ ......... ........ ......... ........ ..... 67 
5.2. Description and Handling of SEL, GS-0976, GS-9674 .................. .......... ................ ........ ........ .............. 68 
5.2.1. Foimulation ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 68 
5.2.2. Packaging and Labe ling .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 69 
5. 2. 3. Storage and Handling .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 69 
5.2.4. Dosage and Adininisti·ation ......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 69 
5.3. Prior and Conconu tant Medica tions .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 70 
5.4. Accoun tability for SEL, GS-0976, and GS-9674 ............ ................ ........ ................ .......... ................ ..... 72 
5 .4.1. Investigational Medicinal Product Retwn or Disposal .......... ................ ........ ................ ...... 72 
6. STUDY PROCEDURES .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 73 
6.1. 
6.2. 
6.3. 6.4. 
6.5. 
6.6. 
6.7. 
6.8 . .. 
6.11. 
6.12. Subject Enrollment and Treatment Assignmen t ............. ........ ......... ........ ........ ......... ........ ........ ......... ..... 73 
Preti·eahnent Assessments ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 73 
6.2.1. Screening Visit ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 73 
Day 1 Assessmen ts ............... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 75 
6.3.1. Day 1: Randomization and Assessment s ...................... .......... ................ ........ ................ ...... 75 
On-Treahnent Assessments ........... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 77 
6.4.1. Week 1 Visit(± 3 days) ........ ................ ........ ................ .......... ................ ........ ................ ...... 77 
6.4.2. Week 4, Wee k 12, and Week 36 Visits (±3 days) ........ .......... ................ ........ ................ ...... 78 
6.4.3. Week 8, Wee k 16, Week 20, Week 28, Wee k 32, Week 40, and Wee k 44 
6.4.4. 
6.4.5. 
6.4.6. Visits (±3 days) ........... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 79 
Week 24 and Week 48 (±7 days) ........ .......... ................ ........ ................ .......... ................ ..... 80 
Early Te1mina tion (ET) Visit ............... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 82 
Unscheduled Visits .............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 84 
Post-ti·eatmen t Assessment s .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 85 
6.5.1. Follow- Up Visit (±5 days) .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ..... 85 
Criteria for Discontinuation of Study Dmg ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 86 
Inte1111ption of Study D1ug ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 87 
Assessment s for Premature Discontinuation from Stud ................ ........ ........ ......... ........ ......... ........ ..... 87 
Descnph on o Assess1 nents .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 88 
6.11.1. Clinical Labo rato1 y Analyte s .............. .......... ................ ........ ................ .......... ................ ..... 88 
6.11.2. Physical Examination .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 89 
6.11.3. Vital Signs , Hip and Waist Circumfe rence .................. .......... ................ ........ ........ .............. 89 
6.11.4. Medical Histo1y ........... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 90 
6.11.5. Clinical Liver As sessment s .................. ........ ................ .......... ................ ........ ................ ...... 90 
6.11.6. 
6.11.7. 
6.11.14. Abdo 1ninal Ultras ound ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 94 
6.11.15. Liver Biopsy ................ ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ..... 94 
6.11.16. Lifes le Modification Counselin ................ ................ ........ ................ .......... ................ ..... 94 
. Storage ............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ..... 95 
7. ADVERSE EVENTS AND TOX ICITY MANAGEMENT ........ ................ ........ ................ .......... ................ ..... 96 
7 .1. Defini tions of Adverse Events, Adverse Reaction s, and Serious Adverse Ev ents ............ ................ ..... 96 
7 .1.1. Adverse Ev ents ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 96 
CONFIDENTIAL Page3 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
7.1.2. Serious Adverse Events ....... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 96 
7.1.3. Clinical Labora to1y Abnonnalities and Other Abno1mal Assessments as 
Adverse Events or Serious Adverse Even ts .................. ........ ................ .......... ................ ..... 97 
7.2. Asse ssment of Adverse Even ts and Serious Adverse Even ts .......... ........ ................ .......... ................ ..... 97 
7.2.1. Assessmen t of Causa lity for Study Drngs and Procedw-es .................... .......... ................ ..... 97 
7.2.2. Asse ss1nentofSeverity ....... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 98 
7.3. Investigator Requiremen ts and Instrnctions for Reporting Adverse Events and Serious 
Adverse Events to Gilead .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 98 
7 .4. Gilead Repo1 ting Requiremen ts ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 100 
7.5. Toxicity Management .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ... 100 
7 .5 .1. Observation for Drng Induced Liver Injwy (DILi ) ................ ................ ........ ................ .... 100 
7.5.2. Close Observa tion ............... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 101 
7.5.3. CP Score ............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 103 
7.5.4. Hype111·iglyceridelllia ........... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 103 
7.5.5. Pruritus Management .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 104 
7.6. Special Situations Repoits ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 104 
7 .6.1. Defini tions of Specia l Situations .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 104 
7.6.2. Instiuctions for Reporting Specia l Situations ................ ........ ................ .......... ................ ... 105 
8. STATISTICAL CONS IDERATIONS ............... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 107 
8.1. 
8.2. 
8.3. 
8.4. 
8.5. 
8.6. 
8.7. 
8.8. 
.. 
8.11. 
8.12. Analysis Objectives and Endpoin ts ....... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 107 
8.1.1. Analysis Objectives ............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 107 
8.1.2. Endpoints ............ ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ... 108 
Analysis Conventions ........... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ... 109 
Analysis Sets ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ... 109 
8.3.1. Efficacy .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 109 
8.3.2. Safety .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 109 
Interi1n Analysis ........... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 110 
Data Hand ling Conventions .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 110 
Demographic Data and Baseline Charac teristics ........... ........ ......... ........ ........ ......... ........ ........ ......... ... 110 
Efficacy Analysis ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 111 
8. 7 .1. Primru Efficac End oints Anal sis .......... ................ .......... ................ ........ ................ .... 111 
• Ana ys1s ............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ......... ........ ... 111 
8.8.1. ExtentofExposw·e .............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 111 
8.8.2. Adverse Events ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 111 
8.8.3. Labora to1 Evaluations ....... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 112 
Samp e Size .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 112 
Data Moni toring Comlllittee ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 113 
9. RESPONS IBILI TIES ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 114 
9.1. Investigator Responsibilities ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 114 
9 .1.1. Good Clinical Practice ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 114 
9.1.2. Institu tional Review Board (IRB)/Independent Ethics Committee (IEC) / 
9.1.3. 
9.1.4. 
9.1.5. 
9.1.6. 
9.1.7. 
9.1.8. 
9.1.9. Ethics Committee (EC) Review and Approval ............ .......... ................ ........ ................ .... 114 
Info1med Consent ........ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 114 
Confidentiality ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 115 
Study Files and Retention of Records .......... ................ .......... ................ ........ ................ .... 115 
Electi ·onic Case Repo1 1 F onns .............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 116 
Investigational Medicinal Product Accountability and Retwn .............. .......... ................ ... 117 
Inspections .......... ......... ........ ........ ......... ........ ......... ........ ........ ........ ......... ........ ........ ......... ... 117 
Protoco l Compliance ........... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ... 118 
CONFIDENTIAL Page4 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 5 25 April 20199.2. Sponsor Responsibilities ...................................................................................................................... 118
9.2.1. Protocol Modifications ....................................................................................................... 118
9.2.2. Study Report and Publications ........................................................................................... 118
9.3. Joint Investigator/Sponsor Responsibilities ......................................................................................... 119
9.3.1. Payment Reporting ............................................................................................................. 119
9.3.2. Access to Information for Monitoring ................................................................................ 119
9.3.3. Access to Information for Auditing or Inspections ............................................................ 119
9.3.4. Study Discontinuation ........................................................................................................ 119
10. REFERENCES ................................................................................................................................................. 120
11. APPENDICES .................................................................................................................................................. 123
Appendix 1. Investigator Signature Page .................................................................................................. 124
Appendix 2. Study Procedures Table ........................................................................................................ 125
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 129
Appendix 4. West Haven Criteria ............................................................................................................. 133
LIST OF IN -TEXT TABLES
Table 1-1. Pharm acokinetic Results from Study GS -US-384-4266 Evaluating DDE betw een 
SEL 18 mg QD and Representative Hormonal Contraceptive, Ethinyl 
Estradiol/Levonorgestrel ...............................................................
......................................... 25
Table 1-2. Preliminary Pharmacokinetic Results from Study GS -US-426-4074 Evaluating 
DDIs with GS -0976 (20 mg or 50 mg)................................
................................................... 31
Table 1-3. GS-US-426
-3988: Preliminary GS -0976 and GS -834773 PK Parameters Following 
a Single Dose of GS -0976 20 mg in Subjects with Mild or Moderate Hepatic 
Impairm ent or Normal Hepatic Function ............................................................................... 34
Table 1-4. GS-US-454-4315: Summary of Changes in Primary PK Parameters for GS -9674 
and GS -716070 Following Administration of GS -9674 Single Agent Tablets with a 
Light Meal or High -Fat Meal as Compared to Fasted State ................................................... 41
Table 1
-5. GS-US-402-3885: Preliminary GS -9674 and GS -716070 PK Parameters Following 
a Single Dose of GS -9674 30 mg in Subjects with Hepatic Impairment or Normal 
Hepatic Function ................................
.................................................................................... 43
Table 1
-6. GS-US-402-2101: Changes in primary PK parameters for SEL, GS -9674, and GS -
0976 and their respective metabolites (GS -607509, G S-716070, and GS -834773) 
following once daily administration of SEL, GS -9674, and/or GS -0976 in 
combination for 7 days compared with the single agent for 7 days ........................................ 48
Table 1
-7. GS-US-384-3914: Safety Summary ....................................................................................... 51
Table 1-8. GS-US-384
-3914: Treatment -Emergent Grade 3 and 4 Lab Abnormality Summary ............ 52
Table 5
-1. List of Representative Disallowed and Use with Caution Medicationsa................................ 71
LIST OF IN -TEXT FIGURES
Figure 1-1. ASK1 Signaling in NASH ................................
...................................................................... 23
Figure 3-1. Overall Study Design ............................................................................................................. 59
Figure 7-1. On-Treatment ALT/AST Monitoring Requiring Close Observation .................................... 101
Figure 7-2. On-Treatment Monitoring Requiring Withholding of Study Drugs ..................................... 102
Figure 7-3. Algorithm for Monitoring and Treatment of Hypertriglycerid emia ..................................... 104
CCI
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 6 25 April 2019PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Dr.
Foster City, CA 94404 USA
Study Title: A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study  
Evaluating the Safet y and Efficacy of Selonsertib , GS-0976, GS -9674, 
and Combinations in Subjects with Bridging (F3) Fibrosis or 
Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis 
(NASH )
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:141683
Not A pplicable
[STUDY_ID_REMOVED]
Study Centers 
Planned:Approximately  135 centers in the United States, Canada, Australia, 
New Zealand, and Hong Kong
Objectives: The primary objective sof this study are: 
To assess the safet y and tolerability  of selonsertib (SEL ), GS -0976, 
and GS -9674, administered alone or in combination, in subjects 
with bridging fibrosis or compensated cirrhosis due to NASH 
To evaluate changes in liver fibrosis ,as measured by  the NASH 
Clinical Research Network ( CRN ) classification, without 
worsening of NASH (defined as an y increase in hepatocellular 
ballooning or lobular inflammation) 
Study Design: This is a Phase 2, randomized, double -blind, placebo -controlled stud y 
evaluating the safet y and efficacy of SEL , GS-0976, GS -9674, and 
combinations in subjects with bridging fibrosis or compensated 
cirrhosis due to NASH.
Subjects meeting the study ’s entry  criteria will be randomly  assigned in 
a 2:2:1:1:1:1 : 2 ratio to 1 of 7 treatment groups, with approximately  
70subjects in each combination treatment group and approximately  
35subjects in each single agent or placebo group , as shown in the 
figure below:
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
8We eks 
C 
.,. 0 
C i 
'f --~ 
0 .... -a 
Ill C 
ra a:: 48Weeks 
_,. I A: SEL18mg + GS-097620 mg+ PTM GS-96743 0 mg {N ~ 70) 
_,. I B: SEL18mg + PTM GS-097620 mg+ GS-967430 mg {N ~ 70) 
_,. I C: SEl 18 mg+ PTMGS-0 97620 mg+ PTMGS -967430mg (N ~ 35) 
-1 D: PTM SEL 18 mg• GS-097620 mg+ PTM GS·967430mg (N ~ 35) 
-I E : PTM SEL18 mg + PTM GS-097620 mg +GS-967430mg (N-3 5) 14 Weeks I 
-I 
I 
I .. 
C ., 
E 
1i 
I~ w -I F: PTM SEL 18 mg+ PTM GS-097620 mg+ PTM GS-9674 30 mg (N • 35) I 
-+I G: PTM SEl 18 mg+ GS-097620mg + GS-967430 mg {N ~ 70) I -
Randomized Study Phase 
Randomization will be stratified by the presence or absence of diabete s 
mellitu s, as detennin ed by medical histo1 y or based on the Scree ning 
laborato 1 y values if previou sly undiagnosed (hemoglobin A 1 c [ HbA 1 c] 
:::: 6.5% or fasting plasma glucose :::: 126 mg/dL), and by the presence or 
absence of ciIThosis (F4) as detennined by the central biopsy reader at 
Scree ning. Study dmgs will be adm inistered for a total of 48 weeks . 
Subjects who develop evidence of hepatic decompen sation, including a 
Child-Pugh (CP) score:::: 7 on at least two consecutive occasio ns at 
least two weeks apart , or undergo liver transplan tation, must 
discontinue study dmgs. 
Num ber of Approxnnate ly 350 subjects 
Subjects Planned: 
Target Population: Males and non-pregnant , non-lactating females between 18 - 80 years 
of age with bridging fibrosis or compe nsated ciIThosis due to NAS H. 
Duration of Study: Paiiicipation can last up to 60 weeks, which includes an 8-week 
Scree ning period , a 48-week On-Treatment period , and a 4-week 
Follow-Up period. 
CONFIDENTIAL Page7 25 Apri l 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 8 25 April 2019Diagnosis and 
Main Eligibility  
Criteria:Key Inclusion Criteria
1)Males and non- pregnant, non -lactating females between 
18 - 80 years of age inclusive ,based on the date of the Screening 
visit;
2)Bridging fibrosis or cirrhosis due to NASH as defined by  one of 
the following ; all subjects must not have documented weight loss 
>5% between the date of the biopsy and Screening :
a)NASH (defined as the presence of a steatosis grade ≥ 1, 
hepatocellular ballooning grade ≥ 1, and lobular inflammation 
grade ≥ 1, according to the nonalcoholic fatty  liver disease
[NAFLD] Activity  Score [NAS]) and bridging fibrosis (F3) 
within 6 months of S creening , in the opinion of the central 
reader ;
b) Compensated cirrhosis (F4) due to NASH (defined as the 
presence of a steatosis grade ≥ 1, hepatocellular ballooning 
grade ≥ 1, and lobular inflammation grade ≥ 1, according to the 
NAS) within 12 months of Screening ,in the opinion of the 
central reader ;
c)Compensated cirrhosis (F4) due to NASH wi th <5% s teatosis 
(defined as a steatosis grade of 0, hepatocellular ballooning 
grade ≥ 1, and lobular inflammation grade 
≥ 1,according to the 
NAS )within 12 months of Screening, in the opinion of the 
central reader ; and at least two of the following crit eria for 
metabolic sy ndrome, modified from the National Cholesterol 
Education Program Adult Treatment Plan III {Grundy  2005}
Guidelines at Screening
:
i. Fasting glucose ≥ 100 mg/dL or receiving drug 
treatment for elevated glucose ;
ii. Fasting HDL cholesterol < 40 mg/dL in men and 
< 50 mg/dL in women or receiving drug treatment for 
low HDL cholesterol ;
iii. Fasting trigl ycerides ≥ 150 mg/dL or receiving drug 
treatment 
for elevated trigl ycerides;
iv. Waist circumference ≥102 cm for men or ≥ 88 cm for 
women or BM I ≥ 30 kg/m2;
v. Systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg or receiving drug treatment for 
hypertension;
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 9 25 April 2019d)In subjects who have never had a liver biopsy , liver stiffness by  
FibroScan ® XL probe ≥ 14.0 kPa, Enhanced Liver Fibrosis 
(ELF ™) Test score ≥ 9.8, and at least two of the criteria for 
metabolic sy ndrome modified from the NCEP ATP III 
Guidelines, at Screening. I n subjects eligible based on this 
criterion, a liver biops y must be performed during Screening 
and must be deemed evaluable for fibrosis stage and NAS by  
the central reader; however, the reported stage of fibrosis will 
not determine eligibility  for the study ;
3)Screening laboratory  parameters, as determined by  the central 
laboratory :
a)Estimated glomerular filtration rate (eGFR) ≥
60mL/min, a s 
calculated b y the Cockcroft -Gault equation;
b)HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 µmol if HbA1c is 
unable to be resulted);
c)Hemoglobin ≥ 10.6 g/dL; 
d)International normalized ratio (INR) ≤ 1.4, unless due to 
therapeutic anticoagulation;
e)Total bilirubin ≤ 1.3 x upper limit of normal (ULN), unless due 
to an alternate etiology  such as Gilbert’s s yndrome or 
hemoly tic anemia;
f)Platelet count ≥ 125,000/µL ;
g)Serum trigl yceride level ≤ 250 mg/dL ;
h)Alanine aminotransferase (ALT) < 5x UL N.
Key Exclusion Criteria
1)Prior history  of decompensated liver disease including ascites, 
hepatic encephalopath y (HE), or variceal bleeding;
2)CP score > 6 at Screening, unless due to an alternative etiology  
such as Gilbert’s syndrome or therapeutic anticoagulation;
3)Model for End- Stage Liver Disease (MELD) score > 12 at 
Screening, unless due to an alternate etiology  such as therapeutic 
anticoagulation;
4) Chronic hepatitis B virus (HBV) infection (hepatitis B surface 
antigen [HBsAg] positive);
5) Chronic hepatitis C virus (HCV) infection (H CV antibody  [Ab] 
and HCV ribonucleic acid [RNA] positive). Subjects cured of 
HCV infection less than 2 years prior to the Screening visit are not 
eligible;
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Study Proced ures/ 
Freque ncy: 
CONFIDE NTIAL 6) Othe r causes of liver disease based on medical histo1 y an d/or 
centralized review of liver histology , including but n ot limited to: 
alcoho lic liver disease, hepatitis B, hepatit is C, autoimm une 
disorders (eg, primaiy biliaiy cholang itis [PBC] , primaiy 
scleros ing cholangitis [PSC], autoimm une hepatitis) , mug -induced 
hepatotox icity, Wilso n disease , clinically significan t iron overload , 
or alpha-1- antitiysp in deficiency requ iring treatme nt; 
7) Histo1y of liver ti·ansplantat ion; 
8) CmTe nt or pr ior histo1y of hepatocellular cai·cinoma (HCC) ; 
9) Any weight r eduction surge1 y within 2 yeai· s prior to Screening or 
malabsorptive weight loss surge 1 y (eg, Roux -en-Y or distal gasti·ic 
bypass) at any time prior to Screening. Weig ht reduct ion surge 1 y is 
disallowed during the study ; 
10) Intes tinal resection that could result in malabso1ption of study 
diug ; 
11) Weight loss > 10% within 6 months of Screening; 
12) Human immunodeficiency vims (HIV) infectio n; 
13) Un stable cardiovascu lar disease . 
Scree ning assessme nts will include comp lete medical histo1y, complete 
phys ical exam ination (P E) includin assessme nt of ascites and HE, 
vital si gns including weight , height, 
laborato 1 y assessme nts includin a 
of childbeai·in otentia l 
Eligible subjects will be randomized to one of seven treatme nt groups, 
with approxima tely 70 subjects in each combination ti·eatme nt group 
and approximately 35 subjects in each single agent or place bo group: 
Group A: SEL 18 mg, GS-0976 20 mg, and placebo to matc h 
(PTM) GS-9674 30 mg 
Group B: SEL 18 mg, PTM GS-0976 20 mg, and 
GS-9674 30 mg 
Group C: SEL 18 mg, PTM GS-0976 20 mg, and 
PTM GS-9674 30 mg 
Group D: PTM SEL 18 mg, GS-0976 20 mg, and 
PTM GS-9674 30 mg 
Page 10 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454-4378 
Gilead Sciences , Inc. Final 
Amendmen t 4 
CONFIDENT IAL Group E: PTM SEL 18 mg, PTM GS-0976 20 mg, and 
GS-9674 30 mg 
Group F: PTM SEL 18 mg, PTM GS-0976 20 mg, and 
PTM GS-9674 30 mg 
Group G: PTM SEL 18 mg, GS-0976 20 mg, and 
GS-9674 30 mg 
Prior to initial dosing , the following Day 1 assessme nts will be 
peifonned: symptom driven PE includin assessment of ascites and 
HE, vital signs , body weigh t, , laborato1y 
assess ment s includin g a urine a es of 
childbearin otential 
After the randomization visit at Day 1, st udy visits w ill occur on 
Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48. 
While on study, subjects w ill undergo the following procedures and 
laborato 1 y assess ments: 
• Symptom driven PE at Weeks 1, 4, 8, 12, 16, 20, 28, 32, 36, 40, 44 
• Complete PE at Weeks 24 and 48 
• Vital signs includin g body weight at each visit 
I 
• 12-lead ECG at Wee k 48 
• C hemi stry, hemat ology, and coag ulation at each visit 
• HbAlc at Weeks 4, 12, 24, 36, and 48 
• Insulin and lipids at Weeks 4, 12, 24, 36, and 48 
I 
Page 11 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Test Produ ct and 
Dose 
Reference Therap y 
and Dose 
CONFIDENTIAL I 
• U rine pregnancy test (for fema les of childbear ing potentia l) at 
I 
I 
I 
I Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 
• Lifesty le qu estionnaire at each visit 
I 
I 
I 
• Liver biopsy at Week 48 
I 
I 
All sub jects will complete a Follow-Up visit 4 weeks after the date of 
last dose of study diugs . At this visit sub· ects will have a symptom 
di·iven PE, vital signs, weight , 12-lead 
ECG review of concomi tant me 1cat10 ns an AEs, 
_ , and laborato1y assessme nts mc u mg a urine 
~ es of childbear ing potentia l). 
SEL 18 mg, GS-0976 20 mg, and GS-9674 30 mg oral tablets 
once daily , alone or in combination 
PTM SEL 18 mg, PTM GS-0976 20 mg, and PTM GS-9674 30 mg 
oral table ts once daily 
Page 12 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 13 25 April 2019Treatment Groups 
andMode of 
Administration:Treatment Group A: one SEL  18 mg tablet , one GS -0976 20 mg 
tablet, and one PTM GS -9674 30 mg tablet administered orall y 
once dailywith or without food
Treatment Group B: one SEL  18 mg tablet , one PTM GS -0976 
20mgtablet , one GS -9674 30 mg tablet administered orally  
once dailywith or without food
Treatment Group C: one SEL  18 mg tablet, one PTM GS -0976 
20mg tablet, and one PTM GS -9674 30 mg tablet administered 
orally  once daily with or without food
Treatment Group D: o ne PTM SEL  18 mg tablet, one GS -0976 
20mg tablet, and one PTM GS -9674 30 mg tablet admini stered 
orally  once daily with or without food
Treatment Group E: one PTM SEL  18 mg tablet, one PTM 
GS-0976 20 mg tablet, and one GS -9674 30 mg tablet 
administered orall y once daily  with or without food
Treatment Group F: one PTM SEL  18 mg tablet, one PTM 
GS-0976 20 mg tablet, and one PTM GS -9674 30 mg tablet 
administered orall y once daily  with or without food
Treatment Group G: PT M SEL  18 mg, GS- 0976 20 mg, and 
GS-9674 30 mg administered orally  once daily  with or without 
food
Criteria for 
Evaluation:
Safety : The safet y of SEL , GS-0976, and GS -9674, alone or in combination, in 
subjects with bridging fibrosis or compensated cirrhosis due to NASH 
will be assessed during the study  through the reporting of AEs, clinical 
laboratory  tests, vital sign assessme nts, pruritus questionnaires, and 
concomitant medication usage.
An external Data Monitoring Committee (DMC) that consists of 
twohepatologists and a statistician will review the progress of the 
study . The DMC will convene after 35 s ubjects (approximately  5 per 
treatment group) have completed the Week 4 assessments and 
approximately  every  6 months thereafter to monitor for safet y events.
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Primary En dpoint: The primaiy endpoints ai·e the safety and anti-fibro tic effects of SEL, 
GS-0976 , and GS-9674, administered alone or in comb ination, in 
subjects with bridging fibrosis or compensated cinhosis due to NASH . 
Statistical Method s Anti-fibrot ic response will be evalua ted by the propo 1 iion of subjects at 
Week 48 who achieve a ::::: I -stage improvement in fibrosis 
(acco rding to the NASH CRN classificat ion) wi thout worse ning of 
NASH ( defined as a::::: I-point increase in hepatoce llular ballooning or 
lobular inflammatio n). 
I 
I 
Safety Analysis: Safety analyses include summaries of extent of expos me, AEs, 
laborato 1 y evaluations, and vital sign assessme nts. 
Efficacy Analysis: Primar y Effica cy Endpoint s Analysis: 
CONFIDENTIAL The point estimates and 95% confide nce intervals for the propo 1 iion of 
subjects who achieve a::::: I-stage improveme nt in fibrosis without 
worsening of NASH at Week 48 will be calcu lated by treatme nt group. 
Page 14 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 15 25 April 2019Sample Size: Due to the exploratory  nature of this study , no formal power 
calculations were used to determine sample size. The number of 
subjects was chosen based on clinical experience with other similar 
proof of concept studies; however, with a sample size of approxi mately  
70 subjects in each active combination treatment arm and 
approximately  35 in the placebo arm, the study  has over 80% power to 
detect a difference in the proportion of subjects with a 
≥ 1-stage 
improvement in fibrosis without worsening of NASH of 25% or more 
at Week 48 at a significance level of 0.05 (two -sided), assuming the 
proportion of subjects that meet the endpoint in the placebo arm is 
7.2%.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 16 25 April 2019GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
-SMA alpha smooth muscle actin
g Microgram
ACC acetyl -CoA carboxylase
AE adverse event
AH alcoholic hepatitis
AICD automatic implantable cardioverter defi brillator
aPTT activated partial thromboplastin t ime
ASK1 apoptosis signal -regulating kinase 1
AUC area under the plasma/serum concentration versus time curve
AUC 2-12hr partial area under the plasma/serum concentration versus time curve from time 2 to 
time 12
AUC 24hr area under the plasma/serum concentration versus time curve from time zero to time 24
AUC inf area under the plasma/serum concentration versus time curve extrapolated to infinite time, 
calculated as AUC 0last+(Clast/z)
AUC last area under the plasma/serum concentration versus time curve from time zero to the last 
quantifiable concentration
AUC tau area under the plasma/serum concentration versus time curve from time zero to the last 
quantifiable concentration
BAP Biomarker Analysis Plan
BID twice daily
BL Baseline
BMI body mass index
BUN blood urea nitrogen
CAP controlled attenuation parameter
CCR Chemokine Receptor
CDHFD choline -deficient high-fat diet
CFR Code of Federal Regulations
CI confidence interval
c
-Jun c-Jun protein
CK 18 cytokeratin 18
Clast last observed quantifiable plasma/serum concentration of the drug
CL cr creatinine clearance
CLDQ- NAFLD Chronic Liver Disease Questionnaire -Nonalcoholic Fatty Liver Disease
Cmax maximum observed plasma/serum concentration of drug
CMH Cochran -Mantel -Haenszel
COL1A1 collagen type 1 alpha 1
CCI
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 17 25 April 2019CPK creatine phosphokinase
CRN Clinical Research Network
CRO contract research organization 
CRP c-reactive protein
CsA single dose cyclosporine
CSR clinical study report
CT computerized tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome
CYP3A cytochrome P4503 A
CYP3A4 cytochrome P4503 A4
CYP7A1 cytochrome P450 7A1
DDI drug-drug interaction
DILI Drug Induced Liver Injury
DKD Diabetic Kidney Disease
dL Deciliter
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
DNL de novo lipogenesis
DRSP Drospirenone
EC ethics committee
ECG Electrocardiogram
eCRF electronic case report form
EDC electronic data capture
EE ethinyl estradiol
EFS event -free survival
eg Example
eGFR estimated glomerular filtration rate
ELF™Enhanced Liver Fibrosis 
ESA erythropoiesis -stimulating agents
EU European Union
EudraCT European clinical trial database
F2 Moderate Fibrosis
F3 Bridging Fibrosis
F4 Com pensated Cirrhosis
FDA (United States) Food and Drug Administration
FDC fixed dose combination
CCI
CCI
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 18 25 April 2019FGF19 fibroblast growth factor 19
FSH follicle stimulating hormone
fu unbound fraction
FXR farnesoid X receptor
GCP Good Clinical Practice
GCSF granulocyte colony stimulating factor
GGT gamma glutamyl transferase
GI gastrointestinal 
GMR geometric mean ratio
GSI Gilead Sciences, Inc.
HA hyaluronic acid
HbA1c hemoglobin A1c
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC Hepatocellular Carcinoma
Hct Hematocrit
HCV hepatitis c virus
HCV Ab hepatitis c virus antibody
HCV RNA hepatitis c virus ribonucleic acid
HDPE high-density polyethylene
HE hepatic encephalopathy
Hgb Hemoglobin
HIV human immunodeficiency virus
HIV Ab human immunodeficiency virus antibody
HIV RNA human immunodeficiency virus ribonucleic acid
HLGT high-level group term
HLT high-level term
HOMA -IR homeostatic assessment of insulin resistance
HR hazard ratio
HRQoL Health Related Quality of Life
IB Investigator’s Brochure
IBD inflammatory bow el disease
ICF Informed Consent Form
ICH International Council on Harmonisation of Technical Requirements for Registration of 
Pharm aceuticals for Human Use
ID Identification
IDE investigational device exemption
IEC independent ethics committee
IMP Inves tigational Medicinal Product
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 19 25 April 2019IRB institutional review board
IU international units
IUD intrauterine device
IV Intravenous
IXRS interactive mobile/web response system
JNK c-JunN-terminal kinase
kg Kilogram
kPa Kilopascal
LDH lactate dehydrogenase
LDL low-density lipoprotein
LEVO Levonorgestrel
LLT lower-level term
LOXL2 lysyl oxidase- like 2
LSM least squares mean
M30 capsase -cleaved fragment of CK 18
M65 intact fragment of CK 18
MATE1 multidrug and toxin extrusion protein 1
MCV mean corpuscular volume
MDZ Midazolam
MedDRA Medical Dictionary for Regulatory Activities
MELD Model for End -stage Liver Disease
mg Milligram
MH Mantel- Haenszel
min Minute
mL Milliliter
mm Millimeter
mmHg millimeter of Mercury
MPQR2 multidrug resistance -associated protein
MQC morphom etric quantitative collagen
MRI magnetic resonance imaging
MRI -PDFF magnetic resonance imaging –proton density fat fraction
MRP2 multidrug resistance -associated protein 2
N Number
NAFLD nonalcoholic fatty liver disease
NaNO 2 sodium nitr ite
NAS NAFLD Activity Score
NASH nonalcoholic steatohepatitis
NCEP ATP III National Cholesterol Education Program Adult Treatment Plan III
NOAEL no observed adverse event level
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 20 25 April 2019OATP organic anion -transporting polypeptide
OCT1 organic cation transporter 1
OCT2 organic cation transporter 2
OL Open -Label
OST -α organic solute transporter alpha
OST -β organic solute transporter beta
p38 mitogen -activated protein kinase p38
PAH pulmonary arterial hypertension
PBC primary biliary cholangitis / probenecid
PD pharmacodynamic
PDGF platelet -derived growth factor
PE physical exam
P-gp Perm eability -glycoprotein
PIIINP procollagen III amino terminal peptide
PK pharmacokinetic 
p-p38 phospho -p38
PPAR Peroxisome Proliferator -Activated Receptor
PSC primary sclerosing cholangitis
PSR picrosirius red
PT prothrombin time / Preferred Term
PTM placebo to match
PVE Pharm acovigilance & Epidemiology
PVR pulmonary vascular resistance
Q Quarter
QD once daily
QT electrocardiographic interval betw een the beginning of the Q w ave and termination of the 
Twave, representing the time for both ventricular depolarization and repolarization to 
occur
QTc QT interval corrected for heart rate
rBA relative bioavailability
RBC red blood cell count
RIF Rifampin
RNA ribonucleic acid
ROC receiver operating characteristic
ROS reactive oxygen species
SADR serious adverse drug reaction
SAE serious adverse event
SAF steatosis, activity, fibrosis
SAP statistical analysis plan
SAS®Statistical Analysis System
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 21 25 April 2019SD standard deviation
SEL Selonsertib
SF-36 Short Form 36 Health Survey
SIM Simtuzumab
SOC System  Organ Class
SOP standard operating procedure
SREBP -1c sterol regulatory element binding protein -1c
SUSAR Suspected Unexpected Serious Adverse Reaction
Sx Symptoms of drug -related hepatotoxicity (eg, jaundice, right upper quadrant pain, nausea, 
vomiting, etc.)
t½ An estimate of the termi nal elimination half -life of the drug in serum/plasma/PBMC, 
calculated by dividing the natural log of 2 by the terminal elimination rate constant (λ z)
TEAE treatment -emergent adverse event
TGF -β transforming growth factor beta
TIMP1 tissue inhibitor of metalloproteinase 1
Tlast last measured concentration
Tmax time (observed time point) of C max
TPO Thrombopoietin
UGT UDP -glucuronosyltransferase
ULN upper limit of the normal range
US United States
VAS Visual Analog Scale
VORI Voriconazole
WBC white blood cell count
WPAI Work Productivity and Activity Impairment Questionnaire 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 22 25 April 20191. INTRODUCTION
1.1. Background
Chronic liver disease and the consequences of end- stage liver disease are increasing globall y 
despite improved prevention and treatment of viral hepatitis. This is due to the emerging 
epidemics of obesit y and metabolic syndrome that are leading to an increased incidence of 
NASH. Prevalence rates of hepatic steatosis or fatty  liver, an entity  that has been termed 
NAFLD, range from 6% to 37% worldwi de {Ong 2007 , Vernon 2011} with a recent pooled 
overall global preva lence of 25% reported 
{Younossi 2016}. NASH, the form of NAFLD 
associated with increased liver -related mortality , affects approximately  30% of all patients with 
NAFLD {Ong 2007, Williams 2011 , Younossi 2016 }. In the United States (US), it has been 
estimated that 2% to 5% of the population have NASH 
{Vernon 2011}, which is equivalent to 
approximately  16million adults. Furthermore, as NASH is a manifestation of the metabolic 
syndrome, associated elevated cardiovascular risk factors (eg, atherosclerotic disease, cardiac 
arrhythmogenicit y) likely coexist in patients with NASH {Dietrich 2014 , Faramawi 2008 , 
Voulgari 2010 }. NASH represents a significant and growing unmet medical need for which there
are no currentl y approved therapies.
NASH is primarily  thought to occur as the result of the metabolic s yndrome: the impact of 
obesity , hepatic insulin resistance, and d yslipidemia. Fatt y liver, or simple steatosis, is not 
sufficient to cause liver injur y; it is the presence of inflammation and hepatocellular injury  on the 
background of steatosis that produces NASH and may  result in the progression to cirrhosis and 
its complications including end -stage liver disease. The “2 -hit” hy pothesis of NASH suggest s 
that in the setting of steatosis and metabolic dy sfunction, increased oxidative stress and the 
generation of reactive oxygen species (ROS) likely  mediate the inflammatory  changes in the 
liver (steatohepatitis) with progressive liver fibrosis {Dowman 2010, Koek 2011, Rolo 2012 , 
Sumida 2013 }. The major pathway s in NASH disease progress ion include those involved in 
metabolic dy sfunction in the hepatocy te, activation of hepatic stellate cells, and activation and 
recruitment of macrophages leading to hepatic inflammation and fibrosis. Advanced fibrosis and 
cirrhosis are characterized by  extensive collagen deposition and remodeling of the extracellular 
matrix. Additionally , there is evidence which suggests that lipotoxic intermediates of fatty  acids 
likely  contribute to the etiology  of NASH {Neuschwander -Tetri 2010 }.
Over time, NASH may  result in progressive liver fibrosis, ultimately  resulting in cirrhosis. 
Advanced liver fibrosis (bridging fibrosis or cir rhosis) is associated with increased morbidity  and 
mortality  {Ekstedt 2014, Yeh 2014 }. Cirrhosis increases the risk of developing HCC and o ther 
complications of end -
stage liver disease, including jaundice, fluid retention (edema and ascites), 
portal hy pertension and variceal hemorrhage, impaired coagulation, and HE. Decompensated 
liver disease, as defined by  the development of one of the abov e complications, has a high 
mortality  rate and the only  effective treatment is liver transplantation. With the increasing 
prevalence of obesity  and obesity -related diseases, NASH is expected to become the leading 
indication for liver transplantation and th e leading etiology  of HCC among liver transplant 
recipients in the US {Afzali 2012, Wong 2014}.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 23 25 April 20191.2. Selonsertib (SEL)
1.2.1. General Information for SEL
SEL is a potent and selective small molecule inhibitor of apo ptosis signal -regulating kinase 1 
(ASK1). ASK1 is a ubiquitously  expressed serine/threonine kinase that is primarily  activated b y 
pathological oxidative stress {Makie 2007 , Takeda 2008, Tobiume 2002} . ASK1 in turn 
phosphory lates and activates mitogen -activated protein kinase (p38) and c -Jun N -terminal 
kinases (JNK) . p38 and JNK mediate metabolic, pro -inflammatory , and pro -fibrotic changes in 
the liver, which are central to disease progression in NASH. By inhibiting ASK1 signaling in 
patients with NASH, SEL is expected to halt progressive liver fibrosis and reverse existing 
fibrosis, thus preventing the development of cirrhosis -related complications. The mechanism of 
ASK1 signaling in NASH is presented graphically in Figure 1
-1.
Figure 1-1. ASK1 Signaling in NASH
Increased ASK1 signaling is observed in liver biopsy  specimens of patients with NASH, as 
demonstrated b y increased levels of phosphorylated p38, which correlates with progression of 
fibrosis. ASK1 promotes a pathological cycle between oxidative stress, metabolic dysfunction, 
and hepatocellular damage and inflammation tha t ultimately  promotes fibrosis and organ failure.
These effects are the result of known roles of p38 and JNK signaling in hepatocy tes, 
macrophages, hepatic stellate cells and fibroblasts, which have been demonstrated in preclinical 
studies.
  
    
   
  
     
   
  
   
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 24 25 April 2019Therefore, ASK 1 signaling through p38 and JNK in hepatocy tes, macrophages, and hepatic 
stellate cells promotes hepatocellular steatosis, apoptosis, necrosis, inflammation and fibrosis. 
SEL, by inhibiting oxidative stress -driven ASK1 signaling characteristic of NASH, is expected 
to halt progressive fibrosis and lead to regression of pre -existing fibrosis, thereb y reducing 
progression to cirrhosis and its associated complications.
Please refer to the SEL Investigator’s Brochure (IB) for additional details .
1.2.2. Nonclinical Pharmacology and Toxicology 
SEL has been extensively  evaluated in nonclinical toxicology  studies. Findings attributed to SEL 
administration were primarily  related to the cardiovascular s ystem (mild decrease blood pressure 
and mild QT interval corrected f or heart rate [QTc] prolongation), gastrointestinal ( GI)tract 
(profuse diarrhea) ,kidney  (tubular basophilia, eosinophilic droplets, and pigment), and 
embr yofetal effects (visceral and/or skeletal malformations) occurred at exposures that were in 
excess of the targeted human exposure at 18 mg/day . Self - limiting diarrhea has been observed in 
subjects across the clinical studies. However, the low grade and self -limiting nature of the 
diarrhea suggests the diarrhea in the clinical studies is different from wh at was observed in 
monkey s.
Please refer to the SEL IB for additional details.
1.2.3. Clinical Trials of SEL
Asof 28 November 2017, 15 Phase 1 and 2 clinical studies have been conducted/are ongoing in 
which 359 health y subjects, 248 subjects with diabetic kidne y disease (DKD), 113 subjects with 
pulmonary  arterial hy pertension (PAH), and 72subjects with NASH have been dosed with SEL . 
In an ongoing Phase 2 study  for severe alcoholic hepatitis (GS -US-
416-2124), 50additional 
subjects are planned for dosing .Phase 
3 clinical studies have initiated in which an additional 
640NASH subject s with bridging fibrosis (Stud y GS- US-384- 1943) and 640NASH subjects 
with cirrhosis (Study GS-US-384- 1944) are planned to be dosed. 
Information on the completed and ongoing Phase 1 clinical studies and Phase 2 studies of DKD,
PAH , and alcoholic hepatitis can be found in the IB.
1.2.3.1. Study  GS
-US-384- 4266: A Phase 1 Drug Interaction Study  Evaluating the Effect 
of Selonsertib on the Pharmacokinetics of a Representative Hormonal 
Contraceptive Medication, Ethiny
l Estradiol/Levonorgestrel
Study  GS-US-384- 4266 was a Phase 1, open -label study  designed to evaluate the safet y of SEL 
and the effect of SEL on the PK of a representative hormonal contraceptive, ethiny l 
estradiol/levonorgest rel (EE/L EVO), in healthy  female subjects of childbearing potential. 
Subjects received a single oral dose of EE/LEVO (0.03/0.15 mg) alone and coadministered with 
SEL following 14 day s of once dail y dosing of SEL 18 mg.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 25 25 April 20191.2.3.1.1. Subject Disposition 
A total of 16 su bjects were enrolled. All 16 subjects (100%) completed the study .
1.2.3.1.2. Safety  Results
No deaths, SAEs, Grade 3 or 4 AEs, AEs leading to discontinuation of study drug or study  
participation, or pregnancies were reported during the study. A total of 5 of 16 subjects (31.3%) 
experienced at least 1 AE during the stud y. All of the events were Grade 1 in severit y, and no AE 
was experienced b y more than 1 subject. Two subjects (12.5%) experienced AEs considered b y 
the investigator to be related to study  drug (mens truation irregularit y [EE/LEVO] and headache 
[EE/L EVO + SEL ]), both of which resolved prior to the end of the study . No clinically  
meaningful changes in laboratory  values were noted, and there were no notable changes in vital 
sign measurements.
1.2.3.1.3. Pharmacokin etic Results
As shown in Table 1-1, similar sy stemic exposures (AUC inf, AUC last, and C max) of LEVO and EE 
were observed following administration of L EVO/EE alone or in combination with SEL  (18 mg 
once dail y). All 90% CIs of the GL SM ratios for AUC inf, AUC last, and C maxwere within the 
typical lack of PK alteration boundaries of 70% to 143%. No loss of contraceptive efficacy  is 
expected upon administration of SEL  with oral contraceptives like EE/LEVO.
Table 1-1. Pharmacokinetic Results from Study GS -US-384-4266 Evaluating 
DDE between SEL 18 mg QD and Representative Hormonal 
Contraceptive, Ethinyl 
Estradiol/Levonorgestrel
Ethinyl Estradiol PK 
ParameterMean (%  CV)
%GLSM Ratio (90% CI)
Test/ReferenceSEL + EE 
(Test)
(N = 16 )EE 
(Reference)
(N = 16)
AUC inf(h*ng/mL)778.7
(29.2)769.7
(45.6)105.25
(94.72, 116.95)
AUC last(h*ng/mL)700.0
(31.2)623.5
(35.9)113.71
(106.20, 121.75)
Cmax(ng/mL) (%)88.8
(32.1)74.2
(26.8)117.76
(108.68,127.61)
Levonorgestrel PK 
ParameterMean (%  CV)
%GLSM Ratio (90% CI)
Test/ReferenceSEL + LEVO
(Test)
(N = 16)LEVO
(Reference)
(N = 16)
AUC inf(h*ng/mL)40.8
(45.7)40.1
(42.9)99.82
(89.49, 111.34)
AUC last(h*ng/mL)37.2
(43.7)36.4
(40.1)100.39
(90.16, 111.78)
Cmax(ng/mL) (%)3.7
(45.8)3.3
(40.7)112.74
(99.58, 127.64)
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 26 25 April 20191.2.3.2. Study  GS-US-384- 1497: A Phase 2, Randomized, Open Label Stud y Evaluating 
the Safet y, Tolerability, and Efficacy of Selonsertib alone or in Combination with 
Simtuzumab (SI M) in Subjects with Nonalcoholic Steatohepatitis (NASH) and 
Fibrosis (F2 -F3)
This multicenter, randomized, open -label study  evaluated the safet y, tolerability , and efficacy  of 
SEL (6mg or 18 mg) alone or in combination with simtuzumab (SI M, a monoclonal antibody  
directed against lysyl oxidase -
like 2 ( LOXL2 ) evaluated for the treatment of NASH) versus SI M 
alone for 24 weeks in subjects with NASH and fibrosis stages F2 orF3. 
1.2.3.2.1. Subject Disposition 
A total of 72 subjects were randomized; 67 subjects (93.1%) completed study  treatment. Of the 
5subjects who did not complete study  treatment, 3 subjects discontinued due to AEs, 1 subject 
withdrew consent, an d 1 subject was lost to follow-up.
1.2.3.2.2. Safety  Results 
Treatment with SEL (6 mg or 18 mg with or without SI M 125 mg) and SIM 125 mg was 
generall y well tolerated. The 3 most common AEs were headache, nausea, and sinusitis. Most 
AEs were Grade 1 or Grade 2 in se verity. Overall, 5 subjects had a Grade 3 AE; none of the 
Grade 3 AEs was reported in > 1 subject, and all but 1 were assessed as unrelated to study  drug. 
No Grade 4 AEs were reported. Serious adverse events (SAEs) were reported for 5 subjects.
There were no trends in SAE ty pe or time of onset, and no SAE was reported in > 1subject. 
Overall, 1 subject had an SAE that was assessed as related to study  drug, and 3 subjects had AEs 
leading to premature discontinuation of study  drug. No subjects died during the study .
The majority  of subjects in each treatment group had at least 1 graded laboratory  abnormalit y. 
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . The most common 
Grade 3 laboratory  abnormality  was increased serum glucose. All of the subjects with Grade 3 
increased glucose had graded elevations in glucose at baseline and at every study  visit thereafter;
all had a history  of diabetes and were currentl y taking medication for diabetes. The onl y other 
Grade 3 laboratory  abnormalities that were reported for ≥ 2 subjects were increased trigly cerides 
(N= 3), increased ALT ( N= 2), and increased aspartate aminotransferase ( AST ) (N = 2). 
Two subjects had Grade 4 increased gamma -glutamy l transferase ( GGT ). One of these subject s 
discontinued study  drug due to Grade 1 increased hepatic enz ymes. The other subject had 
elevated GGT throughout the study . 
Across treatment groups, no clinically  relevant changes from baseline to Week 24 were observed 
in measures of liver biochemistry , including alkaline phosphatase, ALT, AST, GGT, and total 
bilirubin. For all treatment groups, median values for ALT, AST, and GGT were in the high 
normal or above normal ranges at baseline and Week 24, although values for those parameters 
tended to decreas e from baseline to Week 24.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 27 25 April 2019No notable changes in vital sign measurements (temperature, pulse, s ystolic blood pressure, 
diastolic blood pressure, and respiration rate) or body  weight were reported during the study . No 
trends in ECG findings suggestive of cardiac abnormalities were observed. No subject 
pregnancies were reported.
1.2.3.2.3. Summary  of Efficacy  Results
Treatment with SEL in GS -US-384- 1497 resulted in histologic improvements in subjects with 
biopsy  proven NASH and F2
-F3 fibrosis. Although the small size of the study  precluded formal 
statistical comparisons between treatment groups, numericall y superior improvements were also 
consistently  observed in the following endpoints i n SEL  treated compared with SI M-treated 
subjects:
Subjects treated with SEL (18 or 6 mg) ± SIM 125 mg had a ≥ 1 stage decrease in NASH 
CRN fibrosis stage from baseline in 43.3 % and 29.6 % of subjects, respectively , compared 
with 20.0% of subjects treated with SIM 125 mg alone.
Subjects treated with SEL (18 or 6 mg) ± SIM 125 mg were le ss likel y to have worsening of 
fibrosis (6.7% and 14.8%, respectivel y) or progression to cirrhosis (3.3% and 7.4%, 
respectivel y) compared with subjects treated with SI M 125 mg alone (40.0% with worsening 
of fibrosis and 20.0% with progression to cirrhosis) .
Consistent with fibrosis stage improvement, subjects treated with SEL (18 or 6 mg) ± SIM 
125mg had reductions in hepatic collagen content as measured b y morphometric quantitative 
collagen ( MQC ) (−8.7% and −8.2%, respectively ) versus an increase of 2.1% in subjects 
treated with SIM 125 mg alone .
Greater reductions in cytokeratin 18 (CK18) capsase- cleaved fragment of CK 18 ( M30 )and 
intact fragment of CK 18 ( M65) fractions in subjects treated with SEL (18 or 6 mg) ± SIM 
125 mg versus SI M 125 mg alone, indicate reduced rates of hepatocellular apoptosis and 
necrosis, and are consistent with improvements in fibrosis stage and liver biochemistry  tests. 
The dose -dependent reductions in CK18 M30 and M65 fractions also support the mechanism 
of action of SEL.
Across all treatment groups, no clinically  significant worsening in metabolic or cardiovascular 
risk factors from baseline and no significant change in weight were observed at Week 24.
Collectively , these data support that SEL  treatment results in fibrosis regression, improvements 
in liver biochemistry , and reductions in hepatic fat, inflammation, and apoptosis in subjects with 
NASH and moderate to severe liver fibrosis.
For further information on SEL in Phase 2 NASH clinical trials, refer to the SEL IB.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 28 25 April 20191.3. GS-0976
1.3.1. General Information for GS -0976
GS-0976 is a small molecule allosteric inhibitor of acet yl-CoA carboxy lase (ACC). ACC 
catal yzes the conversion of acet yl-CoA to malonyl -CoA, the rate -limiting and first committed 
step in fatty acid s ynthesis. GS -0976 is being developed for the treatment of NASH, a metabolic 
disorder characterized b y dysregulated fatty acid metabolism.
Dysregulated fatty  acid metabolism occurs via elevated fatty  acid s ynthesis, impaired fatt y acid 
oxidation, or both. Therefore, inhibition of fatt y acid synthesis and/or stimulation of fatty acid 
oxidation have the potential to favorabl y affect several metabolic diseases and sequelae. ACC is 
a critical enz yme in both fatty  acid s ynthesis and fatty acid oxidation. Due to this unique position 
in intermediary  metabolism {Harwood 2005 , Tong 2006}, pharmacologic inhibition of ACC 
presents an attractive strategy  for limiting fatt y acid synthesis in lipogenic tissues while 
simultaneously  stimulating fatty  acid oxidation in oxidative tissues {Harwood 2005 }.
Please refer to the GS-0976 IB for additional details.
1.3.2. Nonclinical Pharmacology andToxicology
GS-0976 has been characterized in several biochemical and cellular assay s to enhance the 
understanding of the mechanism of action and has been well characterized in vivo in several 
mechanistic models to demonstrate target engagement and in anima l disease models to 
demonstrate specific activity  on endpoints relevant to metabolic disease. Moreover, extensive 
safet y pharmacology and receptor screening studies have been conducted.
The results of these pharmacod ynamic (PD) studies indicate that GS -0976 can reduce the 
denovo lipogenesis ( DNL ), hepatic steatosis, insulin resistance, and fibrosis produced in 
nonclinical models of metabolic disease and fibrosis without affecting food consumption or 
markers of liver function. I n total, these studies confir m the potential for GS -
0976 to impact 
important metabolic endpoints associated with NASH.
The nonclinical toxicologic profile of GS -0976 has been well characterized in single -and 
repeat -dose toxicity  studies up to 39 weeks in duration and in genetic toxicity , embry o -fetal 
developmental toxicity , and local tolerance studies. 
GS-0976 was well tolerated for up to 13 weeks in the mouse, 26 weeks in the rat, and 3 9weeks 
in the dog. The primary  target organ toxicity  was the presence of cataracts and/or le ns 
degeneration in the mouse and dog after 2 and 13 weeks, respectivel y. In the 2 -week mouse 
study , while 1 of 10 female mice at the lowest dose (5 mg/kg/day ) had lens degeneration, none of 
the male mice at the same dose did, whereas they  did at 3 -times hi gher mean GS -0976 exposure. 
In the females, the lowest exposure where lens degeneration was observed was 5 -times higher 
than the clinical exposure at 20 mg GS-0976. 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 29 25 April 2019In contrast, in the 13 -week mouse study, there were no ey e findings that were attributed t o 
GS-0976 at exposures approximately  8-fold above the clinical exposure at 20 mg. While the 
relevance to humans of the lens degeneration observed in the mouse is currently  unknown, the 
lack of ey e findings attributable to GS -0976 in the 13- week mouse study and the differences in 
the ey e anatomy  between mouse and human suggest that ey e findings at lower exposures in the 
2-week stud y ma y not be clinically relevant. In the dog, lens degeneration/cataracts were first 
observed after 13 weeks of GS -0976 administr ation. While lens degeneration/cataracts were also 
observed in the chronic dog stud y, these findings occurred at exposures > 168-times the clinical 
exposure at 20 mg. There were no adverse ey e findings in the chronic dog study  at mean 
exposures at least 48 -times the clinical exposure at 20 mg.
GS-0976 was not genotoxic and there was no embry o
-fetal developmental toxicity  at exposures 
approximately  50-times the clinical exposure. GS -0976 was considered non -corrosive and does 
not require classification as an eye irritant.
Based on the s ystemic concentrations of GS -0976 measured in the repeat -dose toxicity  studies in 
mice, rat ,and dog at the projected clinically  efficacious area under the plasma/serum
concentration versus time curve ( AUC )(88ng•h/mL ), the mar gins of exposure at the no 
observed AElevels (NOAEL s
) are 8, 206, and 48 in the mouse, rat and dog, respectivel y. Thus, 
data from the nonclinical studies support the continued clinical evaluation of 20 mg GS -0976.
Please refer to the GS -0976 IB for additional details.
1.3.3. Clinical Trials of GS-0976
As of 27November 2017, 12 Phase 1 and 2 Phase 2 clinical studies have been completed or are 
ongoing .
Information about completed and ongoing clinical studies can be found in the GS -0976 IB. 
1.3.3.1. Study  GS-US-426-4074: A Phase 1 Study  to Evaluate Transporter and 
Cytochrome (CYP) 450
-Mediated Dr ug-Drug Interactions Between GS -0976 and 
Probe Drugs
Study  GS-US-426- 4074 is an ongoing, open -label, multiple -cohort study  designed to evaluate 
transporter and CYP -mediated drug -drug interactions (DDIs) between GS -0976 (10, 20, or 
50mg) and various probe drugs in health y subjects. The effect of an organic anion
-transporting 
polypeptide ( OATP )1B1/1B3 inhibitor on the PK/PD relationships of GS- 0976, as assessed b y 
changes in fractional DNL, will also be evaluated.
1.3.3.1.1. Subject Disposition 
As of 1 November 2017, a total of 90 subjects were dosed; 88 subjects had completed study  
treatment. Two subjects discontinued earl y.One subject withdrew on Study Day  23 due to 
personal reasons, and the second subject withdrew on Study  Day  8 following a positive 
pregnancy  test.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 30 25 April 20191.3.3.1.2. Preliminary  Safet y Results 
Forty-eight out of 90 subjects (53.3%) experienced an AE.Of these subjects, 10 subjects 
experienced AE (s)that were deemed related to the study  drug .The most common AE was 
headache (20%). All of these AEs were Grade 1 or 2, and no subject discontinued the study  due 
to an AE.
Fourteen subjects (15.6%) experienced a Grade 3 lab abnormalit y.Thirteen of these subjects had 
asymptomatic hematuria (3+) on their urine dipstick, and all were menstruating female s.One 
subject had a Grade 3 asy mptomatic elevation of their total and low-density  lipoprotein ( LDL)
cholesterol, and one subject had a transient Grade 3 decrease in hemoglobin. There were no 
Grade 4 lab abnormalities.
1.3.3.1.3. Preliminary  PK Results
Preliminary  PK results from the following cohorts are presented below and in Table 1-2.
Cohort 1: I mpact of OATP/ multidrug resistance -associated protein 2 ( M
RP2)/permeabilit y 
glycoprotein ( P-gp)inhibition (single dose cyclosporine [CsA] 600 mg: CsA) or OATP1B1/1B3 
inhibition (single dose rifampin [RIF] 600 mg: RIF) on single dose of GS-0976 20 mg (N=28). 
Single doses of CsA and RIF significantl y increased G S
-0976 exposure (21.2 -and 18.4- fold, 
respectivel y) and resulted in even greater increases in GS -834773 exposures (64.5- and 
55.4- fold, respectivel y). These data indicate GS -0976 is a sensi tive substrate of hepatic OATP 
with intestinal P -gp play ing a minimal role in GS
-0976 absorption as seen by  a smaller increase 
in GS-0976 C maxby CsA compared to single dose RIF.
Cohort 2: I mpact of pan-UGT inhibition (probenecid [PBC] 500 mg: PBC) and CYP 3A4 
inhibition (voriconazole [VORI ] 200 mg: VORI) on single dose administration of GS-0976 
20mg (N=14). Co -administration of GS -0976 with PBC resulted in a moderate increase in 
GS-0976 exposure (61%) indicating UGTs are involved in the metabolism of GS-0976. The 
moderate increase in GS -834773 exposure (74%) with PBC may  be due to inhibition of other 
enzy mes/transporters involved in the clearance of GS -834773. Co
-administration of GS -0976 
with VORI  increased GS -0976 and GS -834773 exposures (37% and 44%, res pectivel y) 
indicati ngCYP3A4 plays a small role in the elimination of both parent and metabolite. 
Cohort 5: I mpact of single and multiple doses of GS -0976 50 mg once daily  on a sensitive 
CYP3A4 probe substrate ( midazolam [MDZ] 2 mg: MDZ; N=12 ). Neither si ngle dose nor 
multiple doses of GS-0976 altered MDZ exposure (90% CIs of the % geometric mean ration 
(GMR )for AUC and C maxwith lack of effect bounds of 70- 143%) indicating GS -0976 is not an 
inhibitor or inducer of CYP3A4.
Cohort 6: I mpact of single and m ultiple doses of GS -0976 50 mg once daily  on a representative 
combined oral contraceptive ( drospirenone [DRSP] /EE3/0.02 mg: DRSP/EE; N=16 ). There was 
no effect of single dose GS -0976 on DRSP or EE exposure (90% CIs of the %GMR for AUC 
and C maxwith lack of effect bounds of 70 -
143%) .Multiple doses of GS -0976 slightly  increased 
EE exposure (AUC infincreased ~34%) with no effect on DRSP exposure indicating GS -0976 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 31 25 April 2019does not induce enzymes/transporters involved in the clearance of DRSP or EE. No loss of 
contraceptive efficacy  is expected upon administration of GS-0976 with oral contraceptives like 
DRSP/EE. The slight increase in EE exposure is not considered clinically  significant and does 
not warrant dose modification.
Table 1-2. Preliminary Pharmacokinetic Results from Study GS- US- 426-4074 
Evaluating DDIs with GS -
0976 (20 mg or 50 mg)
Inhibitor/Inducer 
DrugGS-0976
%GMR (90% CIs)GS-834773
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
CsA2120 
(1810, 2480)2000 
(1590, 2520)6450 
(5260, 7900)7870
(6130, 10100)
RIF1840 
(1570, 2150)2710 
(2160, 3400)5540
(4520, 6790)10100
(7890, 13000)
PBC161 
(144, 180)160 
(132, 195)174 
(148, 204)176
(145, 214)
VORI137 
(123, 152)145 
(119, 176)144 
(123, 170)140
(116, 171)
MDZ  + SD GS -0976
%GMR (90% CIs)MDZ  + MD GS -0976
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
GS-0976 (50 mg)111 
(99.8, 123)102 
(91.6, 115)102 
(91.4, 113)106
(94.9, 119)
DRSP + SD GS -0976
%GMR (90% CIs)DRSP + MD GS -0976
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
GS-0976 (50 mg)96.4 
(86.5, 107)103 
(91.5, 116)105 
(94.0, 117)116
(102, 131)
EE + SD GS -0976
%GMR (90% CIs)EE + MD GS -0976
%GMR (90% CIs)
AUC inf Cmax AUC inf Cmax
GS-0976 (50 mg)102 
(87.6, 119)112 
(104, 122)134 
(114, 156)121
(111, 131)
SD = single dose
MD = multiple dose
Data reported to 3 significant figures
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 32 25 April 20191.3.3.2. Study  GS-US-426-3988: A Phase 1 Ope n-Label, Parallel -Group, Single -Dose 
Study  to Evaluate the Pharmacokinetics of GS -0976 in Subjects with Normal and 
Impaired Hepatic Function
Study  GS-US-426- 3988 is an ongoing Phase 1, open -label, parallel -group, single dose stud y 
evaluating the safet y, tolerability, and PK of GS -0976 in subjects with normal hepatic function 
and mild, moderate, or severe he patic impairment (CPclass A, B, or C, respectivel y). Up to 
60
subjects are planned for enrollment in 1 of 3 hepatic imp airment cohorts: Cohort 1 
(mild hepatic impairment), Cohort 2 (moderate hepatic impairment), and Cohort 3 
(severe hepatic impairment). W ithin each cohort, each subject with impaired hepatic function 
(N=10 percohort) will be matched for age (± 10 y ears), sex, race, and body  mass index 
(BMI ): ± 15% with a control subject with normal hepatic function (N=10 per cohort). Data from 
healthy  subj ects may  be used in >1 cohort if a subject was an appropriate match for a subject 
with hepatic function in >1 cohort. Subjects in Cohorts 1 and 2 will receive a single oral dose of 
GS-0976 20 mg in a fasted state on Day  1. Subjects in Cohort 3 will receive a single oral dose of 
GS-0976 5 mg in a fasted state on Day  1.
1.3.3.2.1. Subject Disposition and Demographics
As of 17November 2017, a total of 36subjects were dosed; 34 subjects had completed study  
treatment. No subjects prematurel y discontinued study  treatment. No subjects withdrew consent, 
and no subjects were lost to follow-up.
1.3.3.2.2. Preliminary  Safet y Results 
In the mild hepatic impairment cohort, 1 subject (10%) had a treatment -related AEof facial 
flushing that was Grade 1. One other mild hepatic impairment subject had a Grade 1 headache.
Two health y matched controls experienced Grade 1 AEs of headache and herpes simplex virus 
type
2.In the moderate hepatic impairment cohort, 1 subject had a Grade 1 headache that was 
deemed not -related to study  drug. T here were no Grade 3 or 4 AEs in either cohort. No AEs led 
to dose modification, interruption, or premature discontinuation of study  drug. There were no
SAEs , pregnancies, or deaths.
In the mild hepatic impairment cohort, 4 subjects had Grade 3 lab abnormalities. Elevation sin 
GGT (2 subjects) and LDL cholesterol (2 subjects) were the most common , and all Grade 3 lab 
abnormalities of GGT and L DL were present at Screening .In the healthy  matched controls, 
2subjects also had Grade 3 L DL cholesterol lab abnormalities that were present at Day 1.In the 
moderate hepatic impairment cohort, 3 subjects had Grade 3 lab abnormalities 
(decreased lymphocy tes, hy pomagnesemia, and h yponatremia). There were no Grade 4 lab 
abnormalities. 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 33 25 April 20191.3.3.2.3. Preliminary  PK Results
Preliminary  PK results from Cohort s 1and 2 are presented below and in Table 1-3:
Cohort 1 (Mild Hepatic Impairment; CP A): GS
-0976 exposure (AUC infand C max) was 
higher in subjects with mild hepatic impairment (approximately  84% and 69%, respectively ) 
as compared to subjects with normal hepatic function. I n subjects with mild hepatic 
impairment, exposure (AUC infand C max) of the metabolite GS -834773 was also higher 
(appro ximately  3.9-fold higher for both). Plasma protein binding of both parent and 
metabolite were similar in subjects with mild hepatic impairment as compared to subjects 
with normal hepatic function. GS-
0976 is a hepatic OATP substrate and OATP 
expression/act ivity may  be reduced in patients with cirrhosis. Thus, altered OATP 
expression/activity  may  contribute to the observed higher s ystemic exposure of GS -0976. At 
a dose of 20 mg once daily (QD)in subjects with mild hepatic impairment, exposure margins 
relative to preclinical NOAEL exposures for both parent and metabolite are expected to 
remain adequate.
Cohort 2 (Moderate Hepatic I mpairment; CP B): GS-0976 exposure (AUC infand C max) was 
higher in subjects with moderate hepatic impairm ent (approximately  8.7- and 9.1 -fold higher, 
respectivel y) as compared to subjects with normal hepatic function. Exposure (AUC infand 
Cmax) of the metabolite GS
-834773 was also highe r (approximately  37.5- and 44.7 -fold 
higher, respectivel y).Plasma protein binding of both parent and metabolite were similar in 
subjects with moderate hepatic impairment as compared to subjects with normal hepatic 
function. 
The increased exposure of GS -0976 and GS -834773 in subjects with moderate 
hepatic impairment is likely  due to further decreases in OATP expression/activity relative to 
mild hepatic impairment as well as decreases in expression/activity  of enzymes in volved in 
GS-0976 metabolism (ie, UGTs and CYP3A4). At a dose of 20 mg QD, GS-0976 plasma 
exposures in subjects with moderate hepatic
impairment are ≥ 5- fold and ≥ 25- fold lower 
than exposures at the NOAEL  in the chronic toxicology  studies in dogs and rats, respectivel y.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 34 25 April 2019Table 1-3. GS-US- 426-3988: Pr eliminary GS -0976 and GS -834773 PK 
Parameters Following a Single Dose of GS
-0976 20 mg in Subjects 
with Mild or Moderate Hepatic Impairment or Normal Hepatic 
Function
Cohort AnalyteMean (%CV) PK 
Param eterMatched Healthy 
Control (N=10 )Mild Hepatic 
Impairment (N=10)%GMR
(90% CI)
1GS-0976AUC inf(hr ng/mL)70.4 
(55.2)166 
(98.2)184 
(101, 336)
AUC last(hr ng/mL)69.6 
(55.7)161 
(98.5)181 
(99.3, 331)
Cmax(ng/mL)25.4 
(80.6)50.9 
(90.3)169 
(87.5, 325)
GS-834773AUC inf(hr ng/mL)8.29 
(69.6)48.1 
(123)387 
(177, 846)
AUC last(hr ng/mL)7.38 
(79.0)46.3 
(125)430 
(187, 990)
Cmax(ng/mL)2.29 
(91.8)12.9 
(125)391 
(164, 935)
2GS-0976AUC inf(hr ng/mL)65.9 
(52.3)687 
(72.8)867
(484, 1550)
AUC last(hr ng/mL)64.5 
(51.5)681 
(72.9)879
(491, 1580)
Cmax(ng/mL)20.1 
(60.2)198 
(60.0)905
(539, 1520)
GS-834773AUC inf(hr ng/mL)5.9 
(57.5)399 
(135)3750
(1640, 8560)
AUC last(hr ng/mL)5.1 
(62.9)396 
(136)4410
(1900, 10200)
Cmax(ng/mL)1.4
(81.2)77.3 
(72.5)4470
(2190, 9130)
Data presented to 3 significant figures
Based on the preliminary PK data from this study  as well as the overall safety  profile of 
GS-0976, dose adjustments are not considered necessary  in subjects with mild hepatic 
impairment.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 35 25 April 20191.3.3.3. A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study  Evaluating the 
Safety , Tolerabilit y, and Efficacy of GS -0976 in Subjects with Nonalcoholic 
Steatohepatitis (GS-US-426-3989)
Study  GS
-US-426-3989 is a completed Phase 2, ra ndomized, double -blind, placebo -controlled 
study  designed to evaluate the safety , tolerability , and efficacy  of GS -0976 in subjects with 
NASH. To be eligible to participate, subjects were required to have a clinical diagnosis of 
NAFLD with imaging or a l
iver biopsy  documenting fatty  liver within 2 y ears prior to S creening, 
MRI -PDFF with ≥ 8% steatosis, and MRE with liver stiffness ≥ 2.5 kPa at Screening, or a 
historical liver biopsy  within 12 months of S creening consistent with NASH and no documented 
weig ht loss > 5% between the date of the liver biopsy  and Screening.
The primary  endpoint was the safet y of GS -0976. Exploratory  efficacy  endpoints included 
changes from baseline in steatosis as measured b y MRI -PDFF, liver stiffness as measured by  
both MRE and FibroScan®, noninvasive markers of fibrosis including ELF™Test,markers of 
liver injury  and function (ALT, AST, bilirubin, GGT and alkaline phosphatase [ ALP]), 
homeostatic assessment of insulin resistance (HOMA -IR), serum lipid profiles, andHbA1c 
levels .
1.3.3.3.1. Subject Disposition
A total of 127 subjects were randomized (50 in the GS- 0976 20 mg group, 51 in the GS - 0976 
5mg group, and 26 in the placebo group). Of the 127 randomized subjects, 126 received at least 
1 dose of study  drug (49 in the GS -0976 20 mg gr oup, 51 in the GS -0976 5 mg group, and 26 in 
the placebo group).
A total of 121 subjects (96.0%) completed stud y drug treatment : 48 (98.0%) in the GS-0976 
20 mg group, 47 (92.2%) in the GS-0976 5 mg group, and 26 (100.0%) in the placebo group. A 
total of 118 subjects (93.7%) completed the stud y: 46 (93.9%) in the GS -0976 20 mg group, 
46(90.2%) in the GS -0976 5 mg group, and 26 (100.0%) in the placebo group.
1.3.3.3.2. Safety  Results
Treatment with GS -
0976 20 or 5 mg was generally  well tolerated. The most common AEs in 
each treatment group were nausea, abdominal pain, and diarrhea (GS- 0976 20 mg); diarrhea, 
headache, and h ypertrigly ceridemia (GS -0976 5 mg); and fatigue, sinusitis, nausea, chest 
discomfort, constipation , and dy spnea (placebo). Most AEs were Grade 1 or 2 in severit y. 
Overall, 5 subjects had a Grade 3 AE; none of the Grade 3 AEs was reported in > 1subject, and 
all but 1 were considered unrelated to stud y drug. One Grade 4 AE, which was not considered 
treatment -related, was reported. SAEs were reported for 4 subjects and included transient 
ischemic attack, sepsis, pyrexia, abdominal pain, HE, and diverticulitis. There were no trends in 
SAE ty pe or time of onset, no SAE was reported in > 1subject, and all S AEs were considered 
unrelated to stud y drug. Two subjects had AEs leading to premature discontinuation of study 
drug; for 1 of these subjects, the AEs leading to study  drug discontinuation (pruritus, rash 
papular , and night sweats) were considered treatment-related. No deaths occurred during the 
study .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 36 25 April 2019The majority of subjects had at least 1 graded laboratory  abnormality . The majority  of laboratory  
abnormalities were Grade 1 or 2 in severity. Overall, the most common Grade 3 or 4 laboratory  
abnormalities in subjects receiving GS -0976 were elevated trigl ycerides (h ypertriglyceridemia; 
16.0%, 16 of 100 subjects) and elevated glucose (hy pergly cemia; 10.0%, 10 of 100 subjects), 
which only  occurred in subjects who received GS- 0976. The majorit y of subjects with G rade 3 or 
4 hypertrigly ceridemia had a medical history  of hy perlipidemia or hy pertrigl yceridemia, and had 
graded elevations in triglycerides at baseline. Grade 3 or 4 h ypergl ycemia was reported for 
10subjects, all of whom had a medical history  of diabetes and were taking medication for 
diabetes, and 7 of whom had HbA 1c> 9.0% at baseline.
A total of 8 subjects met criteria for Drug Induced L iver Injury  (DILI )monitoring, 4 of whom 
experienced liver -related laboratory  abnormalities that were at least Grade 3 in severity , 
including Grade 3 elevated ALT, Grade 3 elevated AST, and /orGrade 3 elevated GGT. All 
4subjects had graded abnormalities in the respective anal ytes at baseline. No AEs associated 
with the liver- related laboratory  abnormalities were reporte d for any  of the 4 subjects, and all 
4subjects completed treatment with study  drug.
No notable changes in vital sign measurements or body  weight were reported during the study . 
No clinically  significant ECG abnormalities were reported. No subject pregnanc ies were 
reported.
1.3.3.3.3. Efficacy Results
Larger median ( quarter ( Q) 1, Q3) decreases from baseline in liver steatosis as measured by  
MRI -PDFF (in %) were observed in the GS -0976 groups compared with the placebo group, with 
the largest decrease in the GS-0976 20 mg group: −4.99 (−8.15, −0.78) in the GS -0976 20 mg 
group, −2.22 (−4.33, 0.07) in the GS- 0976 5 mg group, and −0.94 (−1.94, 1.41) in the placebo 
group. These decreases corresponded with median (Q1, Q3) percent decreases of −28.9% 
(−47.7%, −11.9%) in the GS-0976 20 mg group, −13.0% (−28.5%, 0.6%) in the GS -0976 5 mg 
group, and −8.4% (−18.2%, 9.6%) in the placebo group. The difference (GS -0976 vs placebo) in 
least squares mean ( LSM )change from baseline in MRI -PDFF at Week 12 was statisticall y 
significant f or the GS -0976 20 mg group ( −3.42 %[95% CI: −5.73, −1.11; p =0.004]). 
Larger proportions of subjects in both GS- 0976 groups had at least 30% reduction in MRI -PDFF 
at Week 12 compared with the placebo group: 47.8% (22 of 46 subjects) in the GS-0976 20 mg 
group, 23.4% (11 of 47 subjects) in the GS -0976 5 mg group, and 15.4% (4 of 26 subjects) in the 
placebo group. The difference in proportions between the GS -0976 20 mg and placebo groups 
was statistically  significant (31.8% [95% CI : 10.5%, 53.2%; p = 0.004] ).
In contrast, no statistically  significant differences between the GS -0976 groups and the placebo 
group were observed for the MRE endpoints. The proportions of subjects with at least 15% 
reduction in MRE at Week 12 were 32.6% (15 of46 subjects) in the G S
-0976 20 mg group, 
40.4% (19 of 47 subjects) in the GS-0976 5 mg group, and 34.6% (9 of 26 subjects) in the 
placebo group.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 37 25 April 2019At Week 12, larger median (Q1, Q3) percent decreases from baseline in liver stiffness b y 
FibroScan®were observed in both GS -0976 gr oups compared with the placebo group: −11.1% 
(−34.1%, 13.5%) in the GS -0976 20 mg group, −8.4% (−29.7%, 8.8%) in the GS -0976 5 mg 
group, and −3.1% (−21.6%, 22.3%) in the placebo group.
Slightly  smaller median percent decreases from baseline in ELF™Test score at Week 12 were 
observed in the GS -0976 groups compared with the placebo group : −0.8% (−4.5%, 2.1%) in the 
GS-0976 20 mg group, −0.9% (−5.0%, 3.0%) in the GS -0976 5 mg group, and −1.7% (−3.2%, 
0.7%) in the placebo group. At Week 12, median (Q1, Q3) per cent changes from baseline in each 
component of ELF™Test score were as follows:
Hyaluronic acid ( HA): −6.9% (−22.2%, 35.0%) in the GS -0976 20 mg group, −0.7% 
(−29.0%, 30.3%) in the GS -0976 5 mg group, and −15.3% (−25.4%, 20.9%) in the placebo 
group
Tissue inhibitor of metalloproteinase 1 ( TIMP1 ):−7.9% (−17.2%, 0.1%) in the GS -0976 
20mg group, −2.9% (−13.9%, 5.8%) in the GS -0976 5 mg group, and 1.5% ( −9.0%, 10.6%) 
in the placebo group
Procollagen III amino terminal peptide ( PIIINP ): −13.9% (−23.6%, 9.4%) in the GS -0976 
20mg group, −7.0% (−15.3%, 10.9%) in the GS -0976 5 mg group, and −0.5% (−7.9%, 
4.3%) in the placebo group.
Larger median (Q1, Q3) percent decreases from baseline in ALT at Week 12 were observed in 
both GS-0976 groups compared with the place bo group: −20.5% (−41.1%, 8.0% ) in the GS -0976 
20mg group, −9.8% (−26.2%, 5.1%) in the GS -0976 5 mg group, and −6.7% (−17.6%, 2.7%) in 
the placebo group. Larger median (Q1, Q3) percent decreases from baseline in AST were also 
observed in both GS -0976 groups compared with the placebo group: −5.6% (−38.6%, 19.4%) in 
the GS -0976 20 mg group, −9.3% (−18.2%, 6.3%) in the GS -0976 5 mg group, and −3.5% 
(−23.7%, 10.8%) in the placebo group. Changes from baseline in other liver biochemistry  
parameters (ALP, GGT, and total bilirubin) were not clinically  relevant.
At Week 12, median (Q1, Q3) percent increases from baseline in trigl ycerides were observed in 
both GS-0976 groups compared with a decrease in the placebo group: 10.8% (−4.2%, 48.0%) in 
the GS -0976 20 mg grou p, 12.9% ( −9.9%, 57.2%) in the GS -0976 5 mg group, and −4.3% 
(−18.3%, 16.5%) in the placebo group. No notabl e changes from baseline to Week 12 in other 
lipid parameters, HbA1c ,or glucose were observed in any  treatment group.
Please refer to the GS -0976 IB for additional details.
1.4. GS-9674
1.4.1. General Information for GS -9674
GS-9674 is a potent agonist of f arnesoid X r eceptor (FXR) whose activity  in intestinal epithelial 
cells results in the release of fibroblast growth factor 19 ( FGF19). FGF19 is an endocrine peptide 
which drives a signaling cascade to decrease lipogenesis, gluconeogenesis, hepatic triglyceride 
accumulation, and bile acid sy nthesis. 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 38 25 April 2019Please refer to the GS -9674 IB for additional details , including:
In vitro FXR agonism
Nonclinical in vivo efficacy  studies
Nonclinical pharmacokinetics and in vitro metabolism
Nonclinical pharmacology  and toxicology
1.4.2. Nonclinical 
Pharmacology and Toxicology
In vivo pharmacology studies have demonstrated that GS -9674 preferentially  activa tes intestinal 
FXR and reduces liver fibrosis. I n cynomolgus monkey s, there was an increase in circulating 
FGF19 levels after oral dosing of GS -9674 but not after intravenous ( IV)dosing despite greater 
exposure to GS- 9674 after IV dosing. These data sugge st that intestinal FXR agonism by  
GS-9674 causes FGF19 production, whereas low sy stemic free drug concentrations limit effects 
following IV administration of GS -9674. In addition, the oral administration of GS- 9674 to 
monkey s directl y activated intestinal FXR, as measured b y the expression of FXR -target genes in 
the ileum (FGF19, organic solute transporter alpha ( OSTα ), organic solute transporter beta 
(OSTβ )mRNA ). In a mouse model of NASH induced b y a diet enriched in fat, cholesterol and 
sugar, GS -9674 re duced hepatic steatosis and normalized bile acid levels in plasma. In a 
CDHFD
/sodium nitri te (NaNO 2)rat model of liver fibrosis that utilizes “2 hits” to mimic the 
metabolic and oxidative stress components of NASH in humans, GS- 9674 dose dependently  
reduc ed both biochemical and histological measures of liver fibrosis. Overall, the results from 
these pharmacology  studies demonstrate that GS -9674 is a potent and selective agonist of 
intestinal FXR with the potential to benefit NASH patients by  inducing FGF19 production.
The nonclinical toxicity  profile of GS- 9674 has been assessed in mice and cy nomolgus monkey s 
administered GS -9674 orally  for up to 26 and 39 weeks, respectivel y. Findings attributed to 
GS-9674 administration were primarily  related to the liver (increases in alkaline phosphatase ;
decreases in serum bile acids, cholesterol and trigly cerides ; increases in liver weight and 
hepatocellular h ypertrophy ) and were likel y related to the pharmacology of GS -9674. These 
findings were minimal to mild, non- adverse, and reversible after discontinuation of treatment. 
The NOAELs after 26 and 39 weeks of dosing in mice and monkey s, respectively , were 
associated with exposures (AUC 24h) that were 22- and 32- fold higher in mice and monkey s, 
respectivel y, than t he observed exposure in humans administered 100 mg GS- 9674 QD with 
food.
Please r efer to the GS -9674 IB for additional details.
1.4.3. Clinical Trials of GS-9674
As of 1 November 2017, 6 Phase 1 clinical studies have been completed or are ongoing and 
4Phase 2 st udies in subjects with NASH, PBC, and PSC are ongoing.
Information about completed and ongoing clinical studies can be found in the current GS -9674 
IB.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 39 25 April 20191.4.3.1. Study  GS-US-454- 4315: A Phase 1 Study  to Evaluate the Relative Bioavailability  
and Food Effect of Singl e Agent Tablets an d Fixed Dose Combinations of 
GS-9674, GS -0976, and/or Selonsertib in Healthy Subjects Study  
GS-US-
454-4315 is an ongoing Phase 1 open -label, multiple cohort, crossover study  to assess 
the relative bioavailability  (rBA) (Part A) of fixed 
dose combination (FDC) tablets of GS -9674, 
GS-0976, and/or SEL  compared to single agent tablets administered in combination in healthy  
subjects. Food effect was evaluated in Part A on SEL  and GS -0976 administered as an FDC 
tablet (SEL /GS- 0976) and GS -9674 and GS -0976 each administered as single agent tablets. 
Supratherapeutic exposure (Part B) of GS -9674 was also assessed. Approximately  90 subjects 
were enrolled into 4 pre -
specified cohorts: Cohorts 1 to 3 in Part A and Cohort 4 in Part B.
1.4.3.1.1. Subject Dispositi on 
Of the 90 enrolled subjects, all received at least 1 dose of study  drug. A total of 89 of 90 subjects 
(98.9%) completed treatment with study drug and completed t he study . One subject in Cohort 2 
prematurel y discontinued the study  due to an AE of urtica ria.
1.4.3.1.2. Preliminary  Safet y Results
Administration of GS- 9674, SEL , and GS -0976 was generally  well tolerated in healthy subjects. 
No deaths, SAEs, Grade 4 AEs, or pregnancies were reported during this study . 
One subject experienced a Grade 2 AE of acute urtic aria on Day  13 following treatment with 
SEL + GS -0976 (single agent tablets) on Day  1 and SEL /GS- 0976 (FDC) on Day  9.This led to 
the discontinuation of study  participation, and this event was considered related to study  drug b y 
the investigator. 
A total of 12 of 90 subjects (13.3%) experienced at least 1 AE, and the most commonly  reported 
AEs overall were lower abdominal pain (4 subjects, 4.4%) and headache (2 subjects, 2.2%). No 
trends in the overall frequency  or type of AEs were observed between the FDC tablets and 
coadministration of their respective single agent tablets, between administration of therap y in the 
fed versus fasted state, and between supratherapeutic do sing of GS -9674 at 100 mg TID, with 
1.0
hr separation versus 0.5 hr separation. 
Overall, 6 of 90 subjects (6.7%) experienced an AE that was considered to be related to study  
drug b y the investigator. The most commonly  reported study  drug -related AEs overall were 
lower abdominal pain (4 subjects, 4.4%) and headache (2 subjects, 2.2%). With the exception of 
the Grade 2 AE of acute urticaria, all other study  drug -related AEs were Grade 1 in severity  and 
did not require discontinuation from the study . 
A total of 47 of 90 subjects (52.2%) experienced a graded laboratory  abnormality . The ma jority 
of laboratory  abnormalities were Grade 1 or 2 in severit y, and no Grade 4 laboratory 
abnormalities were observed. Eight of the 90 subjects (6.5%) had a Grade 3 laboratory  
abnormality : increased LDL  cholesterol (2 subjects) and occult blood in urine (6 subjects). Both 
subjects who had a Grade 3 increased LDL cholesterol had Grade 1 or 2 increased LDL 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 40 25 April 2019cholesterol at baseline and at all other on -study  measurements. The Grade 3 laboratory  
abnormalities of occult blood in urine were not associated with a ny AEs, all occurred in females 
of childbearing potential, and were deemed b y the investigator to be due to menses. 
No notable changes in vital sign measurements or clinically significant ECG abnormalities we re 
observed during the study.
1.4.3.1.3. Preliminary  PK Re sults
Preliminary  results on the effect of food on GS -9674 PK are presented below and in Table 1-4.
The effect of food on GS -9674 single agent tablets has previously  been evaluated using a 
moderate fat meal, which demonstrated a 33% to 35% decrease in GS -9674 exposure (AUC). 
The changes in the primary
 PK parameters for GS -9674 and its metabolite, GS-716070, 
following a single dose administration of GS-9674 single -agent tablet under fed (light meal or 
high-fat meal) versus fasting conditions were evaluated in this study  and the preliminary  results 
are summarized in the table below. Both SEL and GS
-0976 have previously been shown to not 
significantl y affec t GS-9674 PK when administered as single agent tablets. Thus, comparison of 
GS-9674 PK following co- administration of GS -9674 with SEL  or GS -0976 and a high- fat meal 
(Treatments A and G, respectivel y) to administration of GS -9674 alone in the fasted state 
(Treatment C) was considered acceptable to evaluate the effect of food on GS -9674 single agent 
tablets. Administration of GS- 9674 alone (Treatment I) with a light meal decreased both AUC inf
and C maxof GS -9674 (63% and 68%, respectivel y) as compared to adm inistration of GS-9674 
alone (Treatment C) under fasted conditions. Administration of GS -9674 with a high -fat meal 
increased GS -9674 exposure (AUC inf) 37% to 42% as compared to fasted conditions with 
minimal changes in C max(-7% to 1%). Changes in PK of th e metabolite, GS -716070, were 
similar to those of parent.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 41 25 April 2019Table 1-4. GS-US- 454-4315: Summary of Changes in Primary PK Parameters 
for GS -9674 and GS-716070 Following Administration of GS-9674 
Single Agent Table ts with a Light Meal or High -Fat Meal as 
Compared to Fasted State
Light Meal vs Fasted
(Treatm ent I vs C)High -Fat Meal vs Fasted
(Treatm ent A vs C)High -Fat Meal vs Fasted
(Treatm ent G vs C)
GS-9674
AUC inf ↓ 63% ↑ 42% ↑ 37%
AUC last ↓ 63% ↑ 44% ↑ 39%
Cmax ↓ 68% ↑ 1%a↓ 7%
GS-716070
AUC inf ↓ 65% ↑ 34% ↑ 23%
AUC last ↓ 66% ↑ 37% ↑ 24%
Cmax ↓ 68% ↑ 1%a↓ 11%
The 90% CIs of the %GLSM ratios for test versus reference treatments were within ( ↔), extended above (↑), or extended below 
(↓) the predefined lack of PK alteration boundaries of 70% to 143%. Percentages indicate the increase or decrease in the 
geometric mean for the respective PK parameter for test treatment relative to reference treatment.
a The 90% CIs of the %GLSM ratio for test versus reference treatment extended both above and below the predefined lack of 
PK alteration boundaries of 70% to 143%.
1.4.3.2. Study  GS-US-402-3885: A Phase 1 Open- Label, Parallel - Group, Adaptive, 
Single -Dose Study  to Evaluate the Pharmacokinetics and Pharmacodynamics of 
GS-9674 in Subjects with Normal and Impaired Hepatic Function
Study  GS-US-402- 3885 is an ongoing Phase 1, open -label, parallel -group, single dose stud y 
evaluating the safet y, tolerability, PK, and PD of GS -9674 in subjects with normal hepatic 
function and mi ld, moderate, or severe hepatic impairment. Up to 60 subjects are planned for 
enrollment in 1 of 3 hepatic impairment cohorts: Cohort 1 (m ild hepatic impairment ,CP A ), 
Cohort 2 (moderate hepatic impairment
,CP B ), and Cohort 3 (severe hepatic impairment, CP C ). 
Within each cohort, each subject with impaired hepatic function (N=10 per cohort) will be 
matched for age (± 10years), sex, race, and bod y mass index (BMI : ± 15%) with a control 
subject with normal hepatic function (N=10 per cohort). Data from heal thy subjects may  be used 
in >1 cohort if a subject was an appropriate match for a subject with hepatic function in 
>1cohort. All subjects will receive a single oral dose of GS -9674 30 mg in the fed state on 
Day 1 with PD collected on Day -1 and Day  1.
1.4.3.2.1. Subject Disposition 
As of 1 November 2017, a total of 37 subjects were enrolled and36 subjects had completed 
study  treatment. One subject prematurely  discontinued study  treatment due to quality  issues at 
the site that justified a suspension in dosing at the site. No subjects prematurely  discontinued due 
to an AE, withdrew consent, or were lost to follow -up.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 42 25 April 20191.4.3.2.2. Preliminary  Safet y Results 
Overall, 8.8% of subjects had a treatment- emergent adverse event (TEAE) of Grade 1 or 2. There 
was 1 SAE of gastrointestinal bleed that was not related to study  drug. This subject had a history  
of esophageal variceal bleeding and experienced bleeding requiring hospitalization and blood 
transfusion. There were no pregnancies or deaths.
In the mild hepatic im pairment cohort, there were 2 subjects (20%) that had Grade 3 lab 
abnormalities of elevated GGT and low platelets. The Grade 3 GGT was stable from the 
subject’s baseline. There was 1 healthy  matched cont rol subject (10%) who had Grade 3 lab 
abnormalities in total cholesterol and LDL cholesterol, which were stable from their baseline. In 
the moderate hepatic impairment cohort, 2 subjects (20%) had Grade 3 lab abnormalities.
One subject had low l ymphocy tes, and the other subject had elevated total bilirubin a nd low 
platelets. The platelet count was not changed from the subject’s baseline. One subject, who had a 
SAE of gastrointestinal bleeding in the moderate hepatic impairment cohort (described above) ,
had a Grade 4 lab abnormality of low hemoglobin.
1.4.3.2.3. Prelimin ary PK Results
Preliminary  PK results are presented below and in Table 1-5:
Cohort 1 ( mild hepatic i mpairment; CP A): GS -9674 exposure (AUC infand C max) was higher 
in subjects with mild hepatic impairment (approximately  76% and 57%, respectively ) as 
compared to subjects with normal hepatic function. I n subjects with mild hepatic impairment, 
exposure (AUC infand C max) of the metabolite GS -
716070 was simi larly higher 
(approximately  64% and 25%, respectively ). Both anal ytes had minor changes in plasma 
protein binding (unbound fraction [ fu] increased ~30%). GS-9674 is a hepatic OATP 
substrate and OATP expression/activity  may  be altered in patients with cirrhosis. Thus, 
altered OATP expression/activity  may  contribute to the observed higher s ystemic exposure 
of GS -9674. At a dose of 30 mg QD in subjects with m ild hepatic impairment, exposure 
margins relative to preclinical NOAEL exposures for both parent and metabolite are expected 
to remain adequate.
Cohort 2 ( moderate hepatic impairment; CP B): GS -9674 exposure (AUC infand C max) was 
higher in subjects with mo derate hepatic impairment (approximately  2.3- and 1.6-fold, 
respectivel y) as compared to subjects with normal hepatic function. Exposure (AUC inf) of the 
metabolite GS -716070 was 
alsohigher (approximately  1.6-fold) with minimal change in 
Cmax. Plasma unbound fraction (f u) of GS -9674 and GS -716070 was increased ~96% and 
~85%, respectivel y, in moderate hepatic impairme nt, leading to a > 4-fold and > 3-fold 
increase in free drug exposures of parent and metabolite, respectively . 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 43 25 April 2019Table 1-5. GS-US- 402-3885: Preliminary GS -9674 and GS -716070 PK 
Parameters Following a Single Dose of GS
-9674 30 mg in Subjects 
with Hepatic Impairment or Normal Hepatic Function
Cohort AnalyteMean (%CV) PK 
Param eterMatched Healthy 
Control (N=10)Hepatic 
Impairment 
(N=10)%GMR
(90% CI)
1GS-9674AUC inf(hr ng/mL)3030
(40.5 )5410
(40.2)176
(127, 25 3)
AUC last(hr ng/mL)2970
(41.4)5380
(40.4)178
(128, 247 )
Cmax(ng/mL)604
(45.6)994
(53.7)157
(108, 229)
GS-716070AUC inf(hr ng/mL)1440
(49.7
)2330
(44.8
)164
(104, 259)
AUC last(hr ng/mL)1400
(51.1)2300
(44.8)169
(115, 247 )
Cmax(ng/mL)179
(42.6)234
(50.8)125
(85.0, 188)
2GS-9674AUC inf(hr ng/mL)2810
(30.3)8280
(91.4)230
(163, 324 )
AUC last(hr ng/mL)2460
(30.9)8220
(91.1)249
(169, 367)
Cmax(ng/mL)496
(40.2)909
(52.5)164
(115, 233)
GS-716070AUC inf(hr ng/mL)1380
(47.7)3160
(81.8)163
(95.1, 280)
AUC last(hr ng/mL)1340
(48.8)3090
(80.9)197
(117, 329)
Cmax(ng/mL)168
(51.6)181
(61.5)89.5
(54.3, 147)
Data reported to 3 significant figures
Preliminary  PD results for Cohort 1 are also available for change from baseline (Day -1) in 
plasma FGF19 and serum 7 -alpha -hydroxy-4-cholesten - 3 -one (C4) levels following a single 
30-mg dose o f GS-9674. Changes in FGF19 and C4 following a single dose of GS- 9674 were 
similar in the mild hepatic impairment subjects as compared to the health y matched controls as 
indicated b y the PD parameter ratios (mild hepatic impairment/health y) for C maxand AU C2-12hr
for FGF19 (1.1 and 1.1, respectivel y) and for C minand AUC 2-12hrfor C4 (0.82 and 0.87, 
respectivel y) that were not significantl y different from 1.
Based on the preliminary PK and PD data from this study  as well as the overall safet y profile of 
GS-9674, dose adjustments are not considered necessary  in subjects with mild hepatic 
impairment.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 44 25 April 20191.4.3.3. Study  GS-US-402-1852: A Phase 2, Randomized, Double -Blind, 
Placebo
-Controlled Study  Evaluating the Safet y, Tolerability, and Efficacy of 
GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH)
GS-US-402- 1852 is an ongoing Phase 2, randomized, double -blind, placebo -controlled study  
evaluating the safet y, tolerability, and efficacy of GS -9674 in subjects with NASH and fibrosis. 
Eligibility  of potential subjects is based upon a clinical diagnosis of NAFLD , a historical liver 
biopsy  within the previous 12 months consistent with NASH and non
-cirrhotic fibrosis, or a
MRI -PDFF with ≥ 8% steatosis and MRE with liver stiffness ≥ 2.5 kPa.
1.4.3.3.1. Subject Disposition 
As of September 2017, study  GS-US- 402- 1852 randomized 1 40 subjects, with 128 active, 
8completed, and 4 earl y terminated from the study . The number of subjects with ≥ 12 weeks of 
study  drug exposure was 112/140 (80%) and 17/140 (12.1%) had completed 24 week s of study  
drug treatment .
1.4.3.3.2. Preliminary  Safet y Data
As of September 2017, four subjects have earl y terminated from the stud y due to AEs . 
One patient developed right upper quadrant pain two weeks into the study  and was subsequently  
found to have a duodenal l ymphoma. Three patients discontinued the study  due to pruritus with 
resolution of sy mptoms after study  drug discontinuation . 
1.5. Combination Studies of SEL, GS -0976, and GS-9674
1.5.1. Nonclinical Pharmacology, Pharmacokinetics, Drug Metabolism, and 
Toxicology
Given that ASK1, FXR ,and ACC mediate distinct biological pathway s and cellular mechanisms 
that contribute to NASH pathophy siology , it is hypothesized that combinations of SEL , 
GS-9674, and GS - 0976 will provide greater benefit to reduce or reverse NASH progression. 
In support of this hy pothesis, pairwise combinations of an ASK1 inhibitor, an FXR agonist, and 
an ACC inhibitor were well tolerated and caused a greater reduction in fibrosis compared to the 
respective single agents in a rat choline- deficient, high -fat diet (CDHFD) model of fibrosis. Rats 
were fed a CDHFD for 6 weeks to induce severe lipotoxicity  in the liver and moderate fibrosis. 
The animals were then maintained on the CDHFD for another 6 weeks while being treated 
therapeutically  with a vehicle control, ASK1 inhibitor, FXR agonist, ACC inhibitor or pairwise 
combinations of each drug . Fibrosis was assessed histologically  by staining extracellular matrix 
with picrosirius red (P SR). Additionally , the number of activated hepatic stellate cells was 
quantified by  staining liver sections with antibodies against SMA and desmin. Quantitative 
morphometry  was performed to determine the percent positive area for each marker. Treatment 
with the ASK1 inhibitor monotherapy or FXR agonist monotherapy led to small and 
nonsignificant reductions in PSR area whereas the ACC inhibitor monotherapy  led to a 
significant reduction in PSR area of about 50% relative to vehicle control animals. The FXR and 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 45 25 April 2019ASK1 combination significantly  decreased PSR area by  69% relative to vehicle control animals, 
which was significantl y greater efficacy  than that for each respective single agent. Combinations 
of the ACC inhibitor with either the ASK1 inhibitor or the F XR agonist trended towards greater 
reduction in PSR % area than the ACC inhibitor alone, each reaching 60% reduction. All 
pairwise combinations significantly  reduced alpha smooth muscle actin (-SMA )and desmin 
area to a greater extent than the single agen ts alone. In addition, all pairwise combinations led to 
greater reductions in plasma markers of fibrosis TIMP1 and PIIINP compared to each respective 
single agent. These data demonstrate that pairwise combinations of each of the agents increased 
anti-fibro tic efficacy  assessed by  multiple different markers. Therefore, combinations of SEL , 
GS-9674 and GS -0976 have the potential to induce a greater magnitude of fibrosis reversal in 
subjects with NASH. 
Pairwise c ombinations of an ASK1 inhibitor ,anFXR agonis t, and an ACC inhibitor also 
increased efficacy  relative to the respective monotherapies in a mouse model of NASH. Mice 
were fed a diet high in fat, sugar and cholesterol for five months to induce hepatic steatosis and
expression of fibrogenesis-related ge nes as well as elevated plasma ALT levels. The animals 
were then treated for 28 days with a vehicle control, ASK1 inhibitor, FXR agonist, ACC 
inhibitor or pairwise combinations of each drug. All c ombination sresulted in significantl y 
greater reductions in hepatic steatosis, hepatic cholesterol and triglyceride levels, and plasma 
ALT levels compared to animals treated with the respective monotherapies. In addition, the 
combination therapies caused a greater reduction in mRNA levels of genes associated with 
fibrogenesis 
collagen ty pe 1 alpha 1 ( COL1A1 ), TIMP1, and platelet -derived growth factor beta 
(PDGF -).
Pharmacod ynamic anal ysis for ASK1, FXR ,and ACC signaling confirmed that these targets 
regulate independent pathway s that contribute to NASH pathogenesis. Treatment of mice with an 
ASK1 inhibitor did not agonize the FXR pathway  or inhibit the ACC pathway . Similarl y, 
treatment of mice with an FXR agonist did not impinge on the ASK1 or ACC pathway s and the 
ACC inhibitor did not agonize the FXR pa thway  or inhibit the ASK1 pathway . Therefore, each 
agent is expected to cause a therapeutic benefit indepen dent of the other monotherapies.
In a 13 -week repeat -dose combination toxicity  mouse study , GS-0976 and GS -9674, when 
administered separatel y or in combination, resulted in no adverse findings. The NOAEL for the 
combination groups was considered to be 20/3 mg/kg/day  GS-9674/GS- 0976, the highest dose 
group tested. Exposures of GS -0976 and GS -9674 in the highest combination mouse group were 
approximatel y 6-fold higher than the clinical exposure of each compound.
GS-0976 was also administered in combination with SEL  to rats for 13 consecutive weeks. 
Microscopic findings of hy perkeratosis and hy perplasia, edema, ulceration, erosion, and/or focal 
squamous e pithelial degeneration of the non -glandular stomach were observed at 30 mg/kg/day  
GS-0976 alone and in all combination groups. The non- glandular stomach findings occurred in a 
dose-dependent manner were considered adverse in the 5/10 and 15/30 mg/kg/day  SEL/GS -0976 
groups. However, the findings do not have an y relevance to humans since humans do not have a 
non-glandular stomach. In the lung, aggregates of macrophages, with or without interstitial 
mononuclear infiltrates and cholesterol clefts, were noted in
all groups, including the vehicle 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 46 25 April 2019control group. While this finding was considered adverse in the high dose combination group 
due to increased incidence and severity , an increased occurrence after gavage dosing can also be 
indicative of mechanically  induc ed reflux. The NOAEL for this study  that is relevant to human 
safet y is the 5/10 mg/kg/day SEL/GS -0976 group with corresponding SEL and GS -0976 
exposure margins of 5 and 36- times above the clinical exposures, respectively .
In a 13 -week repeat dose combinat ion toxicity  study  in monkey s, SEL and GS -9674 when 
administered separatel y or in combination resulted in no adverse findings. Observed findings 
with the combination (increases in platelets, shortened prothrombin time (PT) and activated 
partial thromboplas
tin time (aPTT) , increases in alkaline phosphatase, decreases in serum bile 
acids, increases in liver weight and hepatocellular hy pertrophy ) were non- adverse and attributed 
to GS- 9674 and were consistent with those observed with GS -9674 administered alone. There 
was no exacerbation of the findings when GS -9674 was dosed in combination with SEL . The 
NOAEL for the combination was 10/300 mg/kg/day  SEL/GS -9674, the highest dose group 
tested. Exposures of SEL and GS -9674 in the highest combination group were 2- and 34- fold
higher , respectivel y, than the clinical exposures.
1.5.2. Clinical Trials
1.5.2.1. Study  GS-US-402-2101: A Phase 1 Study  to Evaluate Potential Drug -Drug 
Interactions Between GS -9674, SEL , and GS -0976
Study GS-US-
402-2101 is a Phase 1, open -label, multiple -coho rt, multiple -dose study  designed 
to evaluate potential drug- drug interactions between SEL  18 mg, GS- 9674 100 mg, and GS -0976 
20 mg in healthy subjects (Cohorts 3- 5). Cohorts 1 and 2, designed to evaluate potential 
combination DDIs using a lower dose of GS -9674, and Cohort 6, designed to evaluate the 
potential DDIs between all three agents, were not conducted based on preliminary  data from 
Cohorts 3 through 5. A total of 108 subjects were enrolled in Cohorts 3 through 5.
1.5.2.1.1. Subject Disposition and Demographics
A total of 108 subjects were enrolled; 104 subjects completed study  treatment. Four subject s
prematurel y discontinued study  treatment, with 1 subject prematurel y discontinuing due to an 
AE. Two subjects withdrew consent and 1 subject was lost to follow-up. 
1.5.2.1.2. Safety  Results 
Administration of SEL , GS-0976 and GS -9674 was generally  well tolerated in healthy subjects. 
No deaths, SAEs, Grade 4 AEs, or pregnancies were reported during this study . One subject 
experienced a Grade 3 AE of increased blood creatine phosphokinase during GS -9674 treatment 
that led to the discontinuation of study  drug; t his event was considered related to study  drug b y 
the investigator.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 47 25 April 2019A total of 31 of 108 subjects (28.7%) ex perienced at least 1 AE, and the most commonly  
reported AEs overall were headache (9 subjects, 8.3%), constipation (4 subjects, 3.7%), and 
dizziness (3 subjects, 2.8%). No trends in the overall frequency  or type of AEs across the cohorts 
or between the sin gle-agent and combination treatments within the cohorts in this small number 
of subjects were observed.
Overall, 24 of 108 subjects (22.2%) experienced an AE that was considered to be related to study  
drug b y the investigator. The most commonly  reported study  drug -related AEs overall were 
headache (8 subjects, 7.4%), constipation (4 subjects, 3.7%), and dizziness (3 subjects, 2.8%). 
With the exception of a Grade 3 AE of increased blood creatine phosphokinase, all other study  
drug-related AEs were Grade 1 in severity  and did not require modification of study  drug dose.
A total of 70 of 108 subjects (64.8%) experienced a graded laboratory  abnormality . The majority  
of laboratory  abnormalities were Grade 1 or 2 in severit y, and no Grade 4 laboratory  
abnormalit ies were observed. 7 of 108 subjects (6.5%) had a Grade 3 laboratory  abnormalit y: 
increased LDL cholesterol (5 subjects), increased creatine phosphokinase (1 subject), and occult 
blood in urine (1 subject ). All subjects who had a Grade 3 increased LDL chol esterol had 
Grade 1 or 2 LDL cholesterol at baseline and at all other on -study  measurements. The Grade 3 
laboratory  abnormality  of increased creatine phosphokinase was associated with an AE that led 
to discontin uation of study drug. The Grade 3 laboratory  abnormality  of occult blood in urine 
was not associated with an AE and was considered not clinically  significant by  the investigator.
No notable changes in vital sign measurements or clinically  significant ECG abnormalities were 
observed during the study.
1.5.2.1.3. Summary  of PK Results
The changes in the primary  PK parameters for SEL, GS
-9674, and GS -0976 and their respective 
metabolites (GS -607509, GS -716070, and GS -834773) following once -daily  administration of 
SEL, GS-9674, and/or GS -0976 in combination for 7 day s compared with the single agent for 
7days are summarized in the Table 1-6. None of modest changes observed were considered 
clinically  significant, an
d no dose modifications were needed upon co- administration of SEL , 
GS-9674, and/or GS -0976.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 48 25 April 2019Table 1-6. GS-US- 402-2101: Changes in primary PK parameters for SEL, 
GS-
9674, and GS- 0976 and t heir respective metabolites (GS -607509, 
GS-716070, and GS- 834773) following once daily administration of 
SEL, GS -9674, and/or GS -0976 in combination for 7 days compared 
with the single agent for 7 days
Cohort 3: SEL+GS -0976 GS-0976 GS-834773 SEL GS-607509
AUC tau ↔ ↔ ↔ ↔
Cmax ↔ ↔ ↔ ↔
Ctau ↑ 38% ↑ 69% ↔ ↓ 9%
Cohort 4: GS -9674+SEL GS-9674 GS-716070 SEL GS-607509
AUC tau ↔ ↔ ↔ ↑ 28%
Cmax ↑ 25% ↑ 26% ↔ ↑ 28%
Ctau ↑ 25% ↔ ↔ ↑ 24%
Cohort 5: GS -9674+GS -0976 GS-9674 GS-716070 GS-0976 GS-834773
AUC tau ↔ ↔ ↔ ↔
Cmax ↔ ↔ ↔ ↔
Ctau ↑ 59% ↑ 24% ↓ 24% ↑ 3%a
The 90% CIs of the %GLSM ratios for test versus reference treatments were within ( ↔), extended above (↑), or extended below 
(↓) the predefined lack of PK alteration boundaries of 70% to 143%. Percentages indicate the increase or decrease in the 
geometric mean for the respective PK parameter for test treatment relative to reference treatment.
a The 90% CIs of the %GLSM ratio for test versus reference treatment extended both above and below the predefined lack of 
PK alteration boundaries of 70% to 143%.
1.5.2.2. Study  GS-US-384-3914: A Proof of Concept, Open -Label Study Evaluating the 
Safety , Tolerabilit y, and Efficacy of Regimens in Subjects with Nonalcoholic 
Steatohepatitis (NASH)
Study GS-US-
384-3914 is an ongoing proof of concept, op en-label, multiple -cohort stud y 
designed to evaluate the safet y and efficacy of SEL 18 mg , GS-
0976 20 mg , and GS -9674 30 mg
alone and in combination in subjects with NASH . Cohorts 1 through 6 include subjects with 
NASH and stage 2 to 3 fibrosis as evaluate d by a MRE ≥ 2.88 kPa and an MRI -PDFF ≥10% o r a 
historical biopsy  (by NASH CRN criteria or equivalent ) within 12 months of Screening. 
Cohorts 1 through 3 are monotherap y cohorts, and Cohorts 4 through 6 are combination cohorts.
Cohorts 7 and 8 includes subjects with cirrhosis due to NASH as evaluated by  MRE 
≥ 4.67 kPa, 
FibroScan®≥ 14 kPa, FibroTest®≥ 0.75, or a historical biopsy  consistent with stage 4 fibrosis 
(by NASH CRN criteria or equivalent) within 12 months of Screening .All c ohorts were planned 
to receive study drug for 12 weeks duration .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 49 25 April 20191.5.2.2.1. Cohort 1 (SEL ), Cohort 2 (GS -0976) and Cohort 3 (GS-9674) Subject Disposition 
and Demographics
As of January  12, 2018, a total of 30 subjects were enrolled ( N=10 for each cohort) and all had 
completed study  treatment. No subjects prematurely  discontinued study  drug ,withdrew consent, 
or were lost to follow -up. 
1.5.2.2.2. Preliminary  Safet y Results 
Fifty  percent ( 50% [5/10])of subjects had a TEAE in Cohorts 1 and 3, and 60% (6/10) of 
subjects had an AE in Cohort 2 . There were no Grade 3 or 4 AEs, and no SAEs . In Cohort 1 and 
Cohort 2, the most common AEs occurred in the sy stem organ class of GI disorders, with 20% 
(2/10) of subjects in each c ohort experienci ng this ty pe of AE. In Cohort 3, the sy stem organ 
class of infections and infestations included the most common AEs at 40% (4/10). 
One subject in Cohort 1 had a Grade 4 h yperuricemia. There was one subject in Cohort 2 who 
had a Grade 3 lab abnormality  of hypertrigl yceridemia. There was one subject in Cohort 1 and 
two subjects in Cohort 3 who had Grade 3 h yperglycemia. One subject in Cohort 2 had a Grade 3 
elevation of ALT and AST (Study  Day  112), after stopping the study  drug at Day  84. This was in 
the context of a viral illness. There was no concurrent increase in bilirubin or INR, and the ALT 
and AST decreased on repeat testing. In Cohort 3, there were two subjects with Grade 3 ALT 
and AST. These subjects’ lab abnormalities were not associated with change s in bilirubin or 
INR. The subjects were asy mptomatic and continued study  drug with a decrease in their liver 
biochemistry  while on treatment. 
1.5.2.2.3. Cohort 4 (SEL  + GS -9674), Cohort 5 (SEL  + GS-0976) and Cohort 6 
(GS-0976 + GS-9674) Subject Disposition and Demo graphics
As of January  12, 2018, a total of 60 subjects were enrolled (N=20 for each cohort). In Cohorts 4 
and 5, all subjects had completed treatment. In Cohort 6, 16 subjects had completed study  drug 
dosing, and the remaining 3 subjects had been dosed fo r at least 8 weeks. No subjects have 
prematurel y discontinue d study  drug due to AE. One subject in Cohort 6 withdrew consent on 
Day 62, but this was not related to an AE.
1.5.2.2.4. Preliminary  Safet y Results 
In Cohort 4, 25% (5/20) of subjects experienced a TEAE, a nd one subject had a Grade 3 
treatment -
emergent SAE (TESAE) . This serious event was cellulitis and was not -related to stud y 
drug. In Cohort 5, 4 0% ( 8/20) of subjects experienced a TEAE , but these were all Grade 1 or 2 . 
One subject had a Grade 2 SAE of a to oth abscess that was not- related to study  drug. In 
Cohort
6, 50% ( 10/20) of subjects experienced an AE . Most of these AEs were Grade 1 or 2, and 
one subject experienced a Grade 3 serious event of a urinary  tract infection (UTI), which was 
deemed not -related to study  drug. The most common AEs were in the sy stem organ class of 
infections and infestations (15%, 3/20) for Cohort 4, GI disorders for Cohort 5 (20%, 4/20) ,and 
infections and infestations (25%, 5/20) for Cohort 6. 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 50 25 April 2019No su bjects in Cohorts 4 through 6 have discontinued study  drug due to AEs .One subject in 
Cohort 6 had an interruption of drug while hospit alized due to the AE of a UTI. This UTI was 
exacerbated b y excessive diuresis and subsequent electrol yte abnorma lities, n ausea, and 
dizziness. None of these events were deemed related to the study  drug, and the subject continued 
on study  drug after initiating treatment for the UTI.
Cohorts 4 and 5 each had two subjects (10%, 2/20) with G rade 3 h yperglycemia . One subject in 
Cohort 5 had an as ymptomatic Grade 3 elevation in GGT with no concurrent elevation in other 
liver b
iochemistry  laboratory  values. In Cohort 6, 10% (2/ 20) of subjects have had Grade 3 
hypertrigly ceridemia. In Cohort 5 10% (2/20) of subject have had Grade 4 h ypertriglyceridemia. 
All subjects were as ymptomatic and were started on lipid lowering medication (fish oil or 
fibrate) with a decrease in their trigl yceride levels. 
The safet y parameters in the 6 cohorts for this study as of January  12, 2018 have demonst rated 
that there is no clinicall y significant increase in the percent ages of AEs (Table 1-7) or Grade 3 or 
above lab abnormalities ( Table 1-8) for any combination of study  drugs compared to the 
monotherap y. There has been one SAE in each of Cohort 4
, Cohort 5, and Cohort 6, but these 
have been unrelated to study  drug and not resulted in the discontinuation of either subject from 
the study . Grade 3 or above trigl yceride elevations have been present in both monotherap y and 
combination cohorts including GS -0976 in similar percentages and all subjects have been 
asymptomatic. 
1.5.2.2.5. Cohort 7 (GS -
0976) and Cohort 8 (GS-9674) Subject Disposition and 
Demographics 
As of January  12, 2018, a tota l of 20 cirrhotic subjects were enrolled (N=10 for each cohort). In 
Cohort 7, 10 subjects had completed 12 week sof study  drug. In Cohort 8, 8 subjects had 
completed 12 weeks of treatment, and the remaining 1 ongoi ng subject had taken at least 
8weeks of s tudy drug. One subject in Cohort 8 prematurel y discontinued study  drug due to a n 
AE.
1.5.2.2.6. Preliminary  Safet y Results 
In Cohort 7, 80% (8/10) subjects experienced a treatment emergent AE, and one of these was a 
Grade 3 SAE of intestinal obstruction that was dee med not -related to stud y drug. In Cohort 8, 
70% ( 7/10) subjects experienced a treatment emergent AE, and all of these were Grade 1 or 2 in 
severit y.In Cohort 8, one subject experienced Grade 2 worsening of pruritus that led to study  
drug discontinuation. In Cohort 7, the largest percentage of AEs occurred in the sy stem organ 
class of infections and infestations (30%, 3/10). In Cohort 8, the sy stem organ classes of skin and 
subcutaneous tissue disorders and GI disorders both had the largest incidence (30%, 3/10 for 
each class ). 
In Cohort 7, 4 subjects (40%) experienced Grade 3 laboratory  abnormalities. One subject had a 
transient decrease in their neutrophils. Two subjects had hy pergl ycemia, and one of these 
hypergly cemia subjects had concurrent Grade 3 hy ponatremia that resolved with improved 
glycemic control. One subject had as ymptomatic hy pertrigly ceridemia that resolved with fibrate 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 51 25 April 2019treatment. In Cohort 8, 3 subjects (30%) had Grade 3 lab abnormalities. One subject had a 
transient hy pophosphatemia and o ne subject had hy pergly cemia. One subject had an increase in 
their INR on Day  84 that was believed to be a lab error and normalized on repeat testing without 
intervention .Also, there were no concurrent changes in liver biochemistry  testing with this 
transi ent increase in INR .
The safet y parameters of these subjects demonstrate that both GS -0976 and GS -9674 can be 
dosed 
safel y in subjects with cirrhosis due to NASH for 12 week sduration. The single SAE in 
these cohorts was not-related to study  drug GS-0976 , and the subject who discontinued GS- 9674
had Grade 2 worsening of pre-existing pruritus. The laboratory  abnormalities of hy pergl ycemia 
and hy pertrigl yceridemia were due to poor baseline metabolic control and were as ymptomatic .
There are no clinically  significant trends in safety  parameters when comparing subjects with 
moderate fibrosis (ie, Cohorts 2 and 3) and cirrhosis (ie, Cohorts 7 and 8) in terms of AEs 
(Table 1-7) or Grade 3 or above lab abnormalities ( Table 1-8) dosed with either GS -0976 or 
GS-
9674.
Table 1-7. GS-US- 384-3914: Safety Summary
n (% )Cohort 1
SEL
(N=10)Cohort 2
GS-
0976 
(N=10)Cohort 3
GS-9674 
(N=10)Cohort 4
SEL+
GS-9674
(N=20)Cohort 5
SEL+
GS-0976
(N=20)Cohort 6
GS-0976+
GS-9764
(N=20)Cohort 7
GS-
0976 
[F4]
(N=10)Cohort 8
GS-9674 
[F4]
(N=10)
TEAEs 5 (50%) 6 (60%) 5 (50%) 5 (25%) 8 (40%) 10 (42.9%) 8 (80%) 7 (70%)
TEAEs 
Grade 3 
or above 0 0 0 1 (5%) * 0 1 (5%)+1 (10%)#0
TESAEs 0 0 0 1(5%) * 1(5%)@1 (5%)+1 (10%)#0
Treatment 
D/C due 
to AE0 0 0 0 0 0 01 (10%)^
* Unrelated cellulitis from an inse ct bite 
+Unrelated urinary tract infection
# Unrelated intestinal obstruction
^ Grade 2 worsening pruritus 
@Unrelated tooth abscess
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 52 25 April 2019Table 1-8. GS-US- 384-3914: Treatment -Emergent Grade 3 and 4 Lab 
Abnormality Summary
n (% )Cohort 1
SEL
(N=10)Cohort 2
GS-
0976 
(N=10)Cohort 3
GS-9674 
(N=10)Cohort 4
SEL+
GS-9674
(N=20)Cohort 5
SEL+
GS-0976
(N=20)Cohort 6
GS-0976+
GS-9764
(N=20)Cohort 7
GS-0976 
[F4]
(N=10)Cohort 8
GS-9674 
[F4]
(N=10)
Total 2 (20%) 2 (20%) 4 (40%) 2 (10%) 4 (20%) 2 (10%) 4 (40%) 3 (30%)
ALT 0 1 (10%) 2 (20%) 0 0 0 0 0
AST 0 1 (10%) 2 (20%) 0 0 0 0 0
GGT 0 0 0 0 1 (5%) 0 0 0
Urate 1 (10%) 0 0 0 0 0 0 0
Triglycerides 0 1 (10%) 0 0 2 (10%) 2 (10%) 1 (10%) 0
Glucose 1 (10%) 0 2 (20%) 2 (10%) 2 (10 %) 0 2 (20%) 1 (10%)
Neutrophils 
(Decreased)0 0 0 0 0 0 1 (10%) 0
Hypophosphatemia 0 0 0 0 0 0 0 1 (10%)
Hyponatremia 0 0 0 0 0 0 1 (10%) 0
Increased INR 0 0 0 0 0 0 0 1 (10%)
1.6. Rationale for This Study
NASH involves a complex interplay  between hepatocy tes, immune cells, and hepatic stellate 
cells that perpetuates a pathological cy cle of hepatocy te injury , inflammation and fibrosis 
{Caligiuri 2016 }. Increased sy nthesis and accumulation of fatt y acids in hepatocy tes leads to 
lipotoxicity , a state characterized by  increased production of toxic lipid metabolites, bile acids, 
ROS , growth factors, and ultimately  hepatocy te cell death {Neuschwander -Tetri 2010 }. These 
metabolic stress signals directly
 promote the activation and differentiation of hepatic stellate 
cells into my ofibroblasts, the primary  source of collagen and extracellular matrix that causes 
fibrosis. I n addition, hepatocy te lipotoxicity  promotes an immune response by  resident 
macrophages, which produce ROS, growth factors and cytokines such as transforming growth 
factor beta (TGF -and PDGF, that further increase my ofibroblast a ctivation, migration, 
proliferation and survival ,and result in fibrosis { Lee 2015 }. Based on the multiple biological 
pathway s involved in the pathogenesis of NASH, and the heterogeneit y of the patient population, 
it is likely  that a combination of drugs that have distinct mechanisms of action will be needed to 
achieve optimal therapeutic benefit , particularl y in patients with advanced fibrosis.
ASK1 inhibition with SEL reduces oxidative stress -induced hepatocy te apoptosis, infla mmation 
and fibrogenesis by  reducing activation of JNK and p38 stress -response kinases. Thus, SEL  is 
postulated to halt several instigating triggers for NASH. ASK1 inhibition reduces hepatic 
steatosis and fibrosis in obese mice fed a fat and carboh ydrate r ich diet, and reduces liver fibrosis 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 53 25 April 2019in rats fed a choline -deficient, high -fat diet. In a completed Phase 2 study  insubjects with NASH 
(GS-US-384- 1497), SEL dose -dependently  reduced liver fibrosis, demonstrating that ASK1 
inhibition causes regression of liver fibrosis in humans. I ncreased rates of hepatic DNL and 
insufficient fatt y acid oxidation lead to hepatic steatosis and associated lipotoxicity , which are 
also implicated in the etiology  and progression of NASH. By inhibiting ACC, GS-0976 has been 
sho
wn to reduce steatosis and fibrosis in animal models of NASH and to reduce DNL b y >70% 
atdoses of 20 mg daily  in humans. In a recentl y-completed Phase 2 study  in subjects with NASH 
(GS-US-426- 3989), GS - 0976 led to improvement in hepatic steatosis, liver b iochemistry , and 
markers of fibrosis . FXR agonism has been shown to reduce hepatic lipid and bile acid sy nthesis 
due to down regulation of sterol regulatory  element binding protein -1c (SREBP -1c)and 
cytochrome P450 7A1 ( CYP7A1) , respectivel y, as well as re duce insulin resistance and hepatic 
gluconeogenesis {Zhang 2006}. Animal models have demonstrated the ability  of GS -9674 to 
reduce hepa tic fibrosis in a choline -deficient high fat diet/NaNO 2rat model of NASH and to 
reduce hepatic steatosis in obese mice fed a fat and carboh ydrate rich diet. In the proof of 
concept stud y (GS -US-384-3914), GS -9674 led to statistically  significant reduction s in hepatic 
steatosis and GGT, and t hus, GS -9674 is postulated to have these and other benefits with longer 
duration of dosing. Preclinical studies in animal models of NASH have demonstrated that 
combinations of an ASK1 inhibitor and ACC inhibitor, ASK1 i nhibitor and FXR agonist, and 
FXR agonist and ACC inhibitor lead to greater efficacy  to reduce hepatic steatosis and measures 
of liver fibrosis compared to the respective monotherapies . Combination toxicology  studies have 
revealed no new toxicities of SEL  and GS -9674, SEL  and GS -0976, or GS -9674 and GS - 0976. 
NASH with fibrosis is a condition with a high risk of progression to cirrhosis which may  lead to 
end-stage liver disease and increases the risk of HCC . Thus, reversing the fibrotic process in 
addition to ameliorating the metabolic d ysfunction that drives NASH pathogenesis is paramount 
to improving the prognosis of this condition. 
The current gold standard for assessing fibrosis isliver biopsy . As such, improvement in liver 
fibrosis without worsening of NASH as assessed by liver biops y will be evaluated as the primary  
efficacy  parameter in this 48 -week stud y.However, liver biopsy  has numerous limitations 
including its invasiveness and the potential for serious complications, which deter many  patients 
from seeking evaluation for NAFLD or enrolling in clinical trials of novel therapies. Liver 
biopsy  is also limited by  cost, sampling error, and variability  in histopathological interpretation. 
Due to these limitations, the development and validation of noninvasive markers of liver injury
has emerged as a clinical and research priority . To further the development of such tools , this
study  will also incorporate noninvasive endpoints for the assessment of fibrosis including serum 
markers (eg, ELF™test, FibroSURE /FibroTest®, pro-C3)andimaging (eg, liver stiffness b y 
FibroScan®andMRE ). Noninvasive markers of other histological lesions such as hepatic fat b y 
MRI -PDFF and hepatocellular apoptosis by  CK18 will a lso be measured. A key  exploratory  
objective of the stud y is to correlate these markers with liver histology at baseline and determine 
their utility  for monitoring histological responses that occur during the course of the study .
Moreover, a subset of patients will be enrolled in the study  based entirel y on noninvasive 
markers of fibrosis; specifically  a liver stiffness by FibroScan®XL probe ≥ 14.0 kPa and ELF™
test score 
≥ 9.8 during screening. These criteria have been selected to increase the likelih ood of 
enrolling patients with advanced fibrosis (F3 -F4) rather than those with mild fibrosis (F0 -F2), in 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 54 25 April 2019whom the urgency  for treatment is lower {Miele 2017 , Shadab Siddiqui 2017 }. This novel 
approach will help inform the design of future clinical trials in NASH based entirely  on 
noninvasive par ameters for enrollment and the evaluation of treatment response. 
1.6.1. Rationale for Dose Selection of SEL
SEL 18 mg once daily  was selected for evaluation in this study  based on a combination of safet y 
and efficacy  data in the Phase 2 NASH study  (GS-US-384-1497) as well as PK/PD modeling of 
predicted inhibition of p38 phosphory lation. In study  GS-US- 384- 1497, SEL 6 mg and 18 mg 
(±SIM 125 mg) for 24 weeks were evaluated. While both doses demonstrated a ≥ 1-stage 
decrease in NASH CRN fibrosis stage fro
m baseline at a rate higher than subjects treated with 
SIM alone (20%) or compared to historical placebo response rates, SEL 18 mg ( ±SIM 125 mg) 
had a slightl y higher response rate (43%) than SEL 6 mg ( ±SIM 125 mg) (30%) . In addition, an 
exposure -respons e relationship was identified for SEL  exposure and percent change from 
baseline of blood phosphory lated p38 measured in subjects in Phase 2 studies in PAH and DKD 
after administ ration of SEL  2 mg, 6 mg, or 18 mg once dail y. Utilizing this model, plasma SEL
AUC tauobserved in the NASH subjects after administration of SEL
 18mg ±SIM 125 mg was 
associated with 78% (7.5%) of maximal inhibition (E max) of phosphory lated p38 [mean (%CV)]. 
A study  of SEL in subjects with cirrhosis and hepatic impairment demonstrated no clinicall y 
relevant differences in SEL  exposure which allows for treatment without dose adjustment in 
patients with advanced fibrosis. 
Across the clinical development program, SEL  has been 
well-tolerated in Phase 1 and Phase 2 studies up to 48 weeks in duration with no clear 
dose-safety  relationships for incidences or severit y of AEs or laboratory  abnormalities. Thus, the 
efficacy  and safet y profile of SEL  support dosing of 18 mg once daily in this study.
1.6.2. Rationale for Dose Selection of GS -0976
The dose of GS -0976 chosen for evaluation in this study , 20 mg QD, is supported by the safety , 
tolerability  and effects of GS -0976 on DNL from studies 0976 -101, 0976- 102, and 0976 - 103 
described in the IB, the efficacy  observed in the Phase 2 NASH stud y (GS -US-426- 3989), and 
the safet y of GS -0976 in subjects with cirrhosis due to NASH (proof of concept study
 
GS-US-384-3914), including those with mild hepatic impairment (GS-US- 426-3988). In healthy  
subjects, s ingle doses of GS -0976 up to 1000 mg or multiple daily doses (10 days) of GS -
0976 
up to 200 mg were administered . In healthy  but overweight or obese subjects, a single GS -0976
dose of 20 mg resulted in a mean inhibition of fractional DNL  of 71% . In study  
GS-US-426-3989, GS -0976 5 mg and 20 mg were evaluated f or 12 weeks in subjects with mild 
to moderate fibrosis due to NASH .Both dose levels demonstrated similar safety  profiles, but 
only the 20 mg dose showed statistically  and clinically  significant reductions in MRI -PDFF.
GS-0976 20 mg also had larger reducti ons in liver biochemistry  (ie,ALT) and serum markers of
fibrosis (ie ,TIMP-1 and PIII NP). In study  GS-US-426-3989, approximately  40% of subjects 
were presumed to have advanced fibrosis at baseline based on MRE values ≥
3.64 kPa and/or 
ELF™Test scores ≥ 9.8. T hese subjects showed similar efficacy  and safet y profiles as subjects 
with less advanced fibrosis according to these noninvasive markers of fibrosis. Also, subjects 
with cirrhosis due to NASH have been dosed with GS -0976 20 mg for 12 weeks in the pro
of of 
concept stud y described above with similar safety as subjects with less advanced fibrosis.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 55 25 April 2019Additionally , nonclinical toxicology  studies up to 26 and 39 weeks in duration have been 
conducted in rats and dogs , respectivel y,at exposure margins multiple folds above the expected 
clinical exposure. GS -0976 exposures in non -cirrhotic subjects are expected to remain > 48-and 
206-fold lower than the GS -0976 exposures observed at the NOAELs in the 39 -week dog and 
26-week rat toxicity  studies, respectivel y. Based on preliminary  data from Study  
GS-US-
426-3988, GS - 0976 exposures in subjects with mild hepatic impairment (CP A) are 
expected to remain ≥ 22 and≥105 -fold lower than the GS -0976 exposures observed at the 
NOAELs in the 39-week dog and 26 -week rat toxicity studies, respectivel y. Based on 
preliminary  PK data in subjects with mild hepatic impairment and the overall safet y profile of 
GS-0976, dose adjustments are not considered necessary  for subjects with compensated cirrhosis 
in this study .
1.6.3. Rationale for Dose Selection of GS -9674
A GS -9674 dose of 30 mg administered without regard to food has been selected for this study  
based on PK, PD, safet y, and efficacy data from Phase 1 studies in health y subjects and subjects 
with hepatic impairment (GS- US-402- 1851, GS -US- 454-4315, and GS -US- 402-3885) and 
Phase 2 studies in subjects with NASH with or without cirrhosis (GS- US-402-1852 and 
GS-US-
384-3914). GS -9674 exposure at this dose is expected to provide sufficient FXR 
agonism and result in histologic impro vements in subjects with NASH.
In the Phase 1 stud y GS -US-
402-1851, GS -9674 was tested at doses ranging from 10 to 300 mg 
once dail y for up to 14 days and was well tolerated. Across the range of GS -9674 doses 
evaluated, doses 
≥ 30 mg provided comparable intestinal FXR agonism as assessed by  increases 
in FGF19 exposure. Food effect data in studies GS -US-402- 1851 and GS -US- 454-4315 shows 
that fasted exposure is contained within the range of exposures observed across meal ty pes. 
In ongoing studies, subjects with stage 1 to 3 fibrosis and compensated cirrhosis due to NASH 
have been dosed with 30 mg GS -9674 for 12 weeks with food, without regard to meal ty pe. In 
non-cirrhotic NASH subjects 30 mg GS-9674 was well tolerated and associated with significant 
decreases i n hepatic fat as assessed b y MRI -PDFF and liver biochemistry  (ie, GGT) over 
12weeks (GS -US-
384-3914). Though GS -9674 exposures are increased in mild hepatic 
impairment (1.8 -fold), GS-9674 30 mg was well tolerated following 12 weeks of treatment in 
subject s with compensated cirrhosis due to NASH (GS
-US-384- 3914). Additionally , adequate 
exposure margins (12 -to 30 -
fold relative to preclinical NOAEL exposures) are expected after 
30mg GS -9674 administration to subjects with compensated cirrhosis due to NASH. Data 
supports that no GS -9674 dose adjustment is required for compensated cirrhosis in this study .
1.6.4. Rationale for Dose Selection of Combinations
SEL, GS-9674, and GS-0976 can be co -administered without dose modification . This is based on 
the available prec linical and clinical safety  information o feach single agent , as well as the 
combination s.The PK results from study  GS-US-402- 2101 show edno clinically  meaningful 
changes in SEL, GS -9674, and GS -
0976 exposure when co- administered (Section 1.5.2.1). In 
study  GS-US-
384-3914 described above (Section 1.5.2.2), combinations of SEL  18mg once 
daily , GS-9674 30 mg once dail y, and GS -0976 20 mg once dail y,alone or in combination ,were
dosed in subjects with 
mild to advanced fibrosis due to NASH , wit h safet y profiles that are 
similar to the monotherapies .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 56 25 April 20191.7. Risk/Benefit Assessment for the Study
This study  will provide information regarding the safety and efficacy of SEL ,GS-0976, 
GS-
9674, alone or in combination for the treatment of patients with bridging fibrosis and 
compensated 
cirrhosis due to NASH. These patients are at the highest risk for clinical 
complications related to their liver disease. As there are currently  no approved therapies for 
NASH, there is a large unmet medical need for this g rowing population of patients.
The potential benefits of SEL  for the treatment of NASH were shown in the Ph ase2 study  
GS-US-384-1497. As described above, fibrosis regression was observed in a greater proportion 
of SEL -treated versus SIM -treated subjects a fter only  24weeks of treatment. Although this study  
did not include a placebo control arm, these response rates to SEL are substantially  higher than 
reported in the placebo groups of Phase 2 trials for other compounds in development for NASH 
{Neuschwander -Tetri 2014 , Ratziu 2016 }. In addition, reductions in liver biochemistries
(eg,ALT, AST, GGT
), liver fat content by  MRI -PDFF, lobular inflammation, l iver stiffness b y 
MRE, 
and biomarkers of apoptosis and necrosis (serum CK -18 M30 and M65 levels) were 
observed, particularl y in fibrosis responders.
The potential benefits of GS -0976 for the treatment of NASH were shown in the Phase 2 study  
GS-US-
426-3989. As described above, significant and clinically  meaningful reductions in 
hepatic fat b y MRI -PDFF and decreases in ALT, TI
MP-1, and PIIINP were observed in the 
subjects who received GS -0976 20 mg for onl y 12 weeks of treatment. Based on these results, 
improvements in liver histology  including hepatic fibrosis would be expected to ensue in studies 
of longer duration
. A subset of subjects who received GS-0976 in the Phase 2 study  had 
asymptomatic Grade 3 or 4 elevations in trigl ycerides that resolved spontaneously  or with 
treatment with fibrates or fish oil. These subjects had abnormal trigl ycerides at baseline, and so 
strategies to mitigate this risk in the proposed study will consist of exclusion criteria for 
triglyceride elevations above 250 mg/dL and close monitoring of lipid testing with a plan to 
initiate treatment with fibrates or fish oil if clinically  indicated (see Figure 7-3).
Subjects randomized to GS- 9674 may  benefit from an improvement in their underl ying NASH 
which may  manifest as improvements in liver biochemistry , hepatic steatosis
,andfibrosis. In the 
proof of concept stud y (GS -US-384- 3914), 10 subjects with m ild to moderate fibrosis and 
10subjects with cirrhosis due to NASH have been dosed with GS -9674 for 12 weeks. These 
subjects have shown decreases in hepatic fat b y MRI-PDFF and liver biochemistry  (ie,GGT). 
One subject with cirrhosis discontinued the study  due to worsening pruritus, an d to mitigate this 
potential risk with GS
-9674, close monitoring of clinical signs and s ymptoms with a plan to 
initiate treatment for pruritus if clinically  indicated has been recommended (see Section 7.5.5). In 
the Phase 1 stud y, 94 subjects have received GS -
9674 in single or multiple doses (14 days) up to 
300 mg. All TEAEs were mild to moderate (Grade 1 or 2), and overall, the rate of an y AEs was 
similar between subjects treated with GS -9674 or placebo. The predominant toxicities were 
anemia, back pain, diarrhea, and headache. Grade 2 or 3 elevations in serum AL T were seen in 
five (5%) GS -9674 treated subjects and one (4%) placebo treated subj
ect. Grade 2 or 3 
ALT elevations that occurred on- treatment were observed in 2/23 (9%) twice dail y (BID) treated 
subjects, but none of the 71 subjects who received QD GS -9674 dosing. In these cases, 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 57 25 April 2019elevations in serum bilirubin or prolongation of INR were not observed, serum ALT levels 
normalized upon treatment cessation, and no evidence of drug hypersensitivity  syndrome 
(eg,fever, rash, eosinophilia) was noted. In nonclinical studies, effects on the liver have been 
limited to non -adverse mild increases i n alkaline phosphatase and liver weights and minimal 
hepatocellular h ypertrophy  that are likel y a pharmacological response to FXR agonism. There 
were no elevations in liver transaminases or changes in liver pathology  (degeneration/necrosis) 
in the nonclini cal studies to suggest direct cellular damage. In order to mitigate the potential risk 
of hepatotoxicity  with GS -9674, QD dosing of GS -9674 has been chosen for this study . 
Moreover, close monitoring of liver biochemistry values will be performed and parame ters for 
discontinuation of the study  drugs due to liver test abnormalities have been defined 
(seeSection 7.5) and will be closel y followed.
Subjec ts with advanced fibrosis who are randomized to the placebo control arm in the study  may  
benefit from frequent medical monitoring and close assessment of their NASH (eg, surveillance 
for HCC and hepatic decompensation) and associated pathologies during the duration of placebo 
treatment. 
Additional risks to study  subjects include those attributable to study  participation in general, 
including risks associated with frequent clinic visits and laboratory  blood draws, and the 
associated pain and discomfort of p hlebotomy . Strategies to mitigate these risks include close 
monitoring of lab values as well as AEs. Parameters for discontinuation of the study  drugs due to 
AEs and non
-hepatic laboratory  abnormalities are also defined and will be closely  followed.
Overal l, the nonclinical and preliminary  clinical data show a positive benefit/risk ratio in support 
of the study in subjects with bridging fibrosis and compensated cirrhosis due to NASH. 
Appropriate safet y monitoring will be conducted throughout the stud y to further characterize the 
safet y profile of SEL, GS-0976, and GS -9674, alone or in combination, in this patient 
population. 
In summary , there are no approved treatment options av ailable for patients with NASH. Based 
on clinical experience with SEL , GS-0976, and GS -
9674, alone or in combination, the 
risk/benefit ratiois positive and supports the continued evaluation of these monotherapies and 
combination therapies in this patient population. 
1.8. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
2. OBJECTIVES 
The prima1y objectives of this study are: Final 
Amendment4 
• To assess the safety and tolerabi lity of SEL, GS-0976 , and GS-9674, admini stered alone or in 
combin ation , in subject s with bridging fibro sis or compensated cinhosis due to NASH 
• To evaluate changes in liver fibro sis, as measured by the NAS H CRN classificatio n, without 
worsening of NASH (defined as any increase in hepatocellu lar ballooning or lobular 
inflamm ation) 
I 
I 
I 
I 
I 
I I 
I 
I 
I 
CONFIDENTIAL Page 58 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
3. STU DY DESIGN 
3.1. Study Design Final 
Amendmen t 4 
This is a Phase 2, randomized , double-blind, placebo -contrnlled study evalua ting the safety and 
efficacy of SEL, GS-0976, GS-9674, and combina tions in subjects with bridging fibrosis or 
compensated cinhosis due to NAS H. 
The overall study design is prese nted graphically in Figure 3-1. 
Figure 3-1. Overall Study Design 
3.2. 8 We eks 48 Weeks 
C 
QO .2 
.!: 1v 
C N 
CII 'e 
0 .., "CJ 
Ill C 
IV a: A: SEL 18 mg+ GS-097620 mg+ PTM GS-967430 mg (N N 70) 
8: SEL 18 mg+ PTM GS-0976 20 ma+ GS-9674 30 ma (N N 70) 
C: SEL18 mg+ PTM GS-097620 mg+ PTM GS.9674 30mg (N N 35) 
D: PTM SEL 18 mg+ GS-0976 20 mg+ PTM GS-9674 30 ma (N N 35) 
E: PTM SEL 18 mg+ PTM GS-0976 20 mg+ GS-9674 30 mg (N N 35) 
F: PTM SEL 18 mg+ PTM GS-097620 m, + PTM GS-9674 30 mg (N N 35) 
G: PTM SEL 18 mg+ GS-0976 20 mg+ GS·9674 30 mg (N N 70) 
Study Treatment s 
Subj ects meet ing the stu dy's ent:Iy criteria will be assigned randomly in a 2:2:1:1:1:1:2 ratio to 
1 of 7 ti·eatmen t groups (Group A, Group B, Group C, Group D, Group E, Group F, or Group G), 
with approxima tely 70 subjects in each combina tion ti·eatment group and approximately 35 
subjects in each single agent or placebo group, as shown in Figure 3-1. Randomizatio n wi ll be 
sti·atified by the prese nce or absence of diabetes mellitus, as detennined by medical histo1y or 
based on the Scree ning lab values if previo usly undiagnosed (HbAlc 6.5% or fasting plasma 
glucose~ 126 mg/dL) and by the prese nce or absence of cinhosis (F4) as detennined by the 
centi·al biopsy reader at Scree ning. 
CONFIDENT IAL Page 59 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Study chugs will be admin istered for a total of 48 weeks from the Day 1 visit. Dosage and 
admin istration of the study chugs and reference products are d escribed in Section 5.2.4 . 
3.3. Duration of Study 
Paiiic ipation can last up to 60 weeks , which includes an 8-week Screening period, a 48-week 
On-Treatme nt period, and a 4-week Follow-Up period. 
3.4. End of Study 
End of study is considered to be completion of the Follow -Up visit. 
3.5. Post Study Care 
There is no offered post study care. 
-
CONFIDENTIAL Page 60 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
-
-
CONFIDENTIAL Page 61 Final 
Amendment4 
25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
CONFIDENTIAL Page 62 Final 
Amendment4 
25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 63 25 April 20194. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
This study  will enroll approximately  350 subjects with bridging fibrosis and compensated 
cirrhosis due to NASH .Approximately 60% of the enrolled subject population will have 
cirrhosis on the Screening liver biops y, and approximately 40% of these subjects will have 
cirrhosis due to NASH with < 5% steatosis
. Approximately 70 subjects who do not have 
historical liver biopsies may be enrolled based on noninvasive fibrosis markers (FibroScan®and 
ELF™Test score) regardless of fibrosis stage determined on the Screening liver biopsy .
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)Males and non- pregnant, non -lactating females between 18 –80 years of age inclusive, based 
on the date of the Screening visit ;
2)Willing and able to give written informed consent prior to an y study specific procedures 
being performed ;
3)Bridging fibrosis or cirrhosis due to NASH as defined by  one of the following ; all subjects 
must not have documented weight loss > 5% between the date of the biopsy  and Screening:
a)NASH (defined as the presence of a steatosis grade ≥ 1, hepatocellular ballooning grade 
≥ 1,and lobular inflammation grade ≥ 1,according to the NAS) and bridging 
fibrosis (F3) within 6 months of Screening, in the opinion of the central reader; 
b) Compensated cirrhosis (F4) due to NASH (defined as the presence of a steatosis grade
≥1, hepatocellular ballooning grade ≥ 1, and lobular inflammation grade ≥ 1, according 
to the NAS) within 12 months of Screening, in the opinion of the central reader;
c)Compensated cirrhosis (F4) due to NASH with < 5% steatosis (defined as a steatosis 
grade of 0, hepatocellular ballooning grade ≥ 1, and lobular inflammation grade ≥ 1, 
according to the NAS )within 12 months of S creening, in the opinion of the central 
reader ; and at least two of the following criteria for metabolic syndrome, modified from 
the NCEP ATP III, 2005 Guidelines at Screening:
i)Fasting glucose ≥ 100 mg/dL or receiving drug treatment for elevated glucose ;
ii)Fasting HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women or receiving 
drug treatment forlow HDL cholesterol ;
iii)Fasting trigl ycerides ≥ 150 mg/dL or receiving drug treatment for elevated 
triglycerides ;
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 64 25 April 2019iv)Waist circumference ≥102 cm for men or ≥88 cm for women or BMI ≥30kg/m2;
v)Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or
receiving drug treatment for h ypertension;
d)In subjects who have never had a liver biopsy , liver stiffness by  FibroScan®XL probe 
≥14.0 kPa, Enhanced Liver Fibrosis (ELF™) Test score ≥ 9.8, and at least two of the 
criteria for metabolic s yndrome modified from the NCEP ATP III Guidelines, at 
Screening. In subjects eligible based on this criterion, a liver biopsy  must be performed 
during Screening and must be deemed evaluable for fibrosis stage and NAS by  the central 
reader; however, the reported stage of f ibrosis will not determine eligibility  for the study ;
4)Screening laboratory  parameters, as determined by  the central laboratory :
a)eGFR ≥60 mL /min, as calculated by  the Cockcroft -Gault equation ;
b)HbA1c ≤ 9.5% (or serum fructosamine ≤381 µmol if HbA1c is unable to be resulted) ;
c)Hemoglobin ≥ 10.6 g/dL ;
d)INR ≤ 1.4, unless due to therapeutic anticoagulation ;
e)Total bilirubin ≤ 1.3 x ULN , unless due to an alternate etiology  such as Gilbert ’s 
syndrome or hemol ytic anemia ;
f)Platelet count ≥ 125,000/µL ;
g)Serum trigl yceride level ≤
250 mg/dL ;
h)ALT
< 5x UL N;
5)BMI ≥ 18 kg/m2at Screening;
6)Female subjects of childbearing potential (seedefinition in Appendix 3) must have a negative 
pregnancy test at Screening and Day  1;
7)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol spec ified method(s) of contraception as described in 
Appendix 3.
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)Known hy persensitivity  to SEL,GS-0976, GS-9674, themetabolites, or formulation 
excipient s;
2)Prior history  of decompensated liver disease including ascites, HE, or variceal bleeding ;
3)CPscore > 6 at Screening, unless due to an alternate etiology  such as Gilbert’s s yndrome or 
therapeutic anticoagulation ;
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 65 25 April 20194)MEL D score > 12 at Screening , unless due to an alternate etiology  such as therapeutic 
anticoagulation ;
5)Chronic HBV infection ( HBsAg positive) ;
6)Chronic HCV infection (HCV Ab and HCV RNA positive). Subjects cured of HCV infection 
less than 2 years prior to the S creening visit are not eligible ;
7)Other c auses of liver disease based on medical history and/or centralized review of liver 
histology , including but no t limited to: alcoholic liver disease, hepatitis B, hepatitis C, 
autoimmune disorders (eg, PBC , PSC, autoimmune hepatitis), drug -induced hepatotoxicity , 
Wilson disease, clinically  significant iron overload, or alpha -
1-antitry spin deficiency  
requiring treat ment ;
8)History  of liver transplantation
;
9)Current or prior history  ofHCC ;
10)Any weight reduction surgery  within 2 years prior to Screening or malabsorptive weight loss 
surgery  (eg, Roux -en-Y or distal gastric bypass) at any time prior to Screening. Weight 
reduction surgery  is disallowed during the study ;
11)Intestinal resection that could result in malabsorption of study  drug s;
12) Weight loss > 10% within 6 months prior to Screening ;
13)HIVinfection ;
14)History  of symptomatic chronic pulmonary  disease (eg, chronic ob structive pulmonary  
disease, interstitial lung disease) within 6 months prior to Screening;
15)Unstable cardiovascular disease as defined b y any of the following:
a)Unstable angina, myocardial infarction, coronary artery b ypass graft surgery  or coronary  
angiopl asty within 6 months prior to Screening ;
b) Transient ischemic attack or cerebrovascular accident within 6 months prior to Screening ;
c)Symptomatic obstructive valvular heart disease or hy pertrophic cardiom yopathy ;
d)Symptomatic congestive heart failure ;
e)Uncontrolled or recurrent ventricular tach ycardia or other arrh ythmia requiring an 
automatic implantable cardioverter defibrillator (AI CD). Stable, controlled atrial 
fibrillation is allowed;
f)An emergency  room visit or hospitalization for confirmed cardiova scular disease within 
6months prior to Screening ;
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 66 25 April 201916)Males who habituall ydrink greater than 21 oz/week of alcohol or females who habitually  
drink greater than 14 /oz week of alcohol (
1oz/30 mL of alcohol is present in:
a 12 oz/360 mL beer, a 4oz/120 mL glass of wine, and a 1 oz/30 mL measure of 40 proof 
alcohol );
17)Positive urine drug screen for amphetamines, cocaine or opiates (eg ,heroin, morphine) at 
Screening. Subjects on stable methadone or buprenorphine maintenance treatment for at least 
6months pri or to Screening may  be included in the study . Subjects with a positive urine drug 
screen due to prescription medication (eg, opioids, methy lphenidate) are eligible if the 
prescription and diagnosis are reviewed and approved by  the investigator ;
18)Use of an y prohibited concomitant medication as described in Section 5.3. Subjects on 
Vitamin E regimen 
≥800 IU/day  must be on a stable dose (defined as no changes in 
prescribed dose, new Vitamin E containing medications, or discontinuation) for at least 
6months prior to the diagnostic liver biops y and subjects on antidiabetic medications must 
be on a stable dose for at least 3 months prior to the diagnostic liver biopsy ;
19)History  of a malignancy  within 5 y ears of Screening with the following exceptions:
a)Adequatel y treated carcinoma in situ of the cervix ;
b)Adequatel y treated basal or squamous cell cancer or other localized non -melanoma skin 
cancer ;
20)Unable to safely  undergo a liver biopsy ;
21) Concurrent participation in another therapeutic clinical study ;
22)Presence of an y laboratory  abnormality  or condition that could, in the opinion of the 
investigator, compromise the subject’s ability  to participate in the study , including a history  
of substance abuse 
and/or a ps ychiatric condition requiring hospitalization and/or emergency  
room visit within 2 y ears of Screening ;
23)Unavailable for follow -up assessment or concern for subject’s compliance with the protocol 
procedures .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 67 25 April 20195. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
An Interactive Mobile/ Web Response Sy stem (I XRS) will be used for centralized randomization 
and treatment assignment. Randomization will be stratified by  the presence o r absence of 
diabetes mellitus, as determined by  medical history  or based on the Screening lab va lues if 
previously  undiagnosed ( HbA1c ≥ 6.5% or fasting plasma glucose ≥
126mg/dL ), and the 
presence or absence of cirrhosis ( F4)as determined by  the central biops y reader at Screening. 
Investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the I XRS. Subjects and all personnel directl y involved in the conduct of the 
study  will be blinded to treatment assignment.
Study  drugs will be dispensed in a blinded fashion to the subjects.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emerg ency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the I XRS for that 
subject. Gilead recommends but does not require that the investigator contact the Gilead medical 
monitor before breaking the blind. Treatment assignment should remain blinded unless that 
knowledge is necessary  to determine subject emergency  medical care. The rationale for 
unblinding must be clearly explained in source documentation, along wit h the date on which the 
treatment assignment was obtained. The investigator is requested to contact the Gilead medical 
monitor promptly  in case of any  treatment unblinding .
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by the subject.
In the event that GS- US-384- 1943 and GS -US-384-1944 demonstrate lack of efficacy  and are 
discontinued after the Week 48 Interim Anal ysis, unblinding of the SEL monotherapy  treatment 
group will occur. Unblinded SEL  monotherapy  treatment assignments will be generated b y the 
external reporting statistician. Investigators will receive subject -specific SEL monotherap y 
treatment assignments upon applicable regulatory  authority  and IRB/IEC/EC approval to 
discontinue subjects from study  drug and complete assessments f or premature discontinuation 
from study  (refer to Section 6.8).
The rationale for unblinding must be clearl y explained in source documentation, along with the 
date on which treatment assignment was obtained.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 68 25 April 2019The Pharmacovigilance & Epidemiology  (PVE) department at Gilead Sciences may 
independentl y unblind cases for expedited reporting of suspected unexpected serious adverse 
reactions (SUSARs).
5.2. Description and Handl ing of SEL, GS -0976, GS - 9674
5.2.1. Formulation
5.2.1.1. Selonsertib (SEL ) 18 mg
SEL will be supplied as 18 mg strength tablets. The tablets are round, film -coated gray  tablets 
debossed with an underscored “18” on one side and “GSI” on the other side. In addition to the 
active ingredient, SEL tablets contain the following inactive ingredients: lactose monohy drate, 
microcry stalline cellulose, crosc armellose sodium, magnesium stearate, poly vinyl alcohol, 
polyethylene gly col, titanium dioxide, talc, and iron oxide black. 
PTM SEL  tablets are identical in size, shape, color and appearance to their corresponding 
strength of active SEL tablets and contai n the same inactive ingredients. 
5.2.1.2. GS-0976 20 mg
GS-0976 will be supplied as 20 mg strength tablets. The tablets areround, plain -faced, 
film-coated white tablets containing 20 mg of GS-0976. In addition to the active ingredient, 
GS-0976 tablets contain the following inactive ingredients: lactose monohydrate, 
microcry stalline cellulose, croscarmellose sodium, magnesium stearate, polyvin yl alcohol, 
titanium dioxide, poly ethylene gly col, and talc, which are common pharmaceutical excipients.
PTM GS -0976 tablets are identical in size, shape, color and appearance to their corresponding 
strength of active GS -0976 tablets and contain the same inactive ingredients. 
5.2.1.3. GS-9674 30 mg
GS-9674 will be supplied as 30 mg strength tablets. The tablets are capsule -shaped , plain -faced, 
film-coated orange tablets. The tablets contain GS -9674 -02 (tromethamine salt) and inactive 
ingredients microcry stalline cellulose, mannitol, crospovidon e, magnesium stearate, and 
film-coating material comprised of poly vinyl alcohol, poly ethylene gl ycol, talc, titanium dioxide, 
yellow iron oxide, red iron oxide, and ferrosoferric oxide . 
PTM GS -9674 tablets are identical in size, shape, color, and appearance to their corresponding 
strengths of active GS -9674 tablets. PTM GS -9674 tablets contain the following ingredients: 
microcry stalline cellulose, lactose monoh ydrate , croscarmellose sodium, magnesium stearate, 
and film -coating material comprised of pol yvinyl alcohol, polyeth ylene gl ycol, talc, titanium 
dioxide, y ellow iron oxide, red iron oxide, and ferrosoferric oxide .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 69 25 April 20195.2.2. Packaging and Labeling
SEL and PTM SEL tablets are packaged in white, high -densit y pol yethylene (HDPE) bottles. 
Each bottle contains 30 tablets, silica gel desiccant and poly ester packing material. Each bottle is 
enclosed with a white, continuous- thread, child- resistant poly propy lene screw cap fitted with an 
induction- sealed and aluminum- faced liner.
GS-0976 and PTM GS -0976 tablets are packaged in white, HDPE bottles. Each bottle contains 
30 tablets and poly ester packing material .Each bottle is enclosed with a white, continuous 
thread, child- resistant poly propy lene screw cap with an induction -sealed and aluminum -faced 
liner.
GS-9674 and PTM GS -9674 tablets are packaged in white, HDPE bottles. Each bottle contains 
30 tablets, a silica gel desiccant, and pol yester packing material. Each bottle is enclosed with a 
white, continuou s thread, child -resistant, poly propy lene screw cap with an induction- sealed, 
aluminum -faced liner.
Study  drugs to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Fo od and Drug Administration 
(FDA) and/or other local regulations.
5.2.3. Storage and Handling
SEL, PTM SEL , GS-0976, PTM GS -0976, GS -9674, and PTM GS - 9674 tablets should be stored 
at controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C 
(59°F and 86°F). Storage conditions are specified on the label. Until dispensed to the subjects, all 
bottles of study  drugs should be stored in a securely  locked area, accessible only  to authorized 
site personnel. 
To ensure the stabilit y and pro per identification, study  drugs should not be stored in a container 
other than the container in which they  were supplied. Keep the bottle tightly closed to protect 
from moisture.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure when handling.
5.2.4. Dosage and Administratio n
The administration of study  drug swill be recorded in the source documentation an d in the eCRF.
SEL, PTM SEL , GS-0976, PTM GS -0976, GS -9674, and PTM GS -9674 tablets will be provided 
by Gilead Sciences. S ubjects will take one tablet of each drug (or PTM) together at 
approximately  the same time each day. Drug sshould be taken with or without food, and
swallowed whole with water. A dose will be considered missed if the subject cannot take the
complete 3 tablet dose within 12 hours of their regular dosing time. If a subject misses a dose, 
the subject should take their next dose at the regular dosing time.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 70 25 April 2019Study  drug dosing and administration will occur as follows, based on treatment group 
randomization:
Treatment Group A: one SEL  18 mg tablet , one GS -0976 20 mg tablet , and one PTM 
GS-9674 30 mg tablet administered orally  once daily with or without food
Treatment Group B: one SEL  18 mg tablet , one PTM GS -0976 20 mg tablet, one GS -9674 
30mg tablet administered orally  once daily with or without food
Treatment Group C: one SEL  18 mg tablet , one PTM GS -0976 20 mg tablet, and one PTM 
GS-9674 30 mg tablet administered orally  once daily with or without food
Treatment Group D: one PTM SEL  18 mg tablet, one GS -0976 20 mg tablet, and one PTM 
GS-9674 30 mg tablet administered orally  once daily with or without food
Treatment Group E: one PTM SEL  18 mg tablet , one PTM GS -0976 20 mg tablet , and 
oneGS-9674 30 mg tablet administered orall y once dail ywith or without food
Treatment Group F: one PTM SEL  18 mg tablet, one PTM GS -0976 20 mg tablet , and 
onePTM GS-9674 30 mg tablet administered orally  once dailywith or without food
Treatment Group G: one PTM SEL  18 mg tablet, one GS-0976 20 mg tablet, and 
oneGS-9674 30 mg tablet administered orall y once dail y with or without food
5.3. Prior and Concomitant Medications
All concomitant medication will be recorded in the source documents and eCRFs. This includes 
concomitant medications taken within 30 day s prior to Screening and any  taken during the study
until the end of the follow -up period.
Caution should be exercised when co -administering sensitive P- gp substra tes with narrow 
therapeutic index (eg, digoxin) with study  drugs, as it may  increase the concentrations of these 
agents. The Investigator should review the prescribing information of the concomitant 
medication for guidance on co -administration with a weak P-gp inhibitor. 
Subjects on Vitamin E ≥ 800 IU/day  must be on a stable dose (defined as no changes in 
prescribed dose, new Vitamin E containing medications, or discontinuation) for at least 6 months 
prior to the diagnostic liver biopsy .
Subjects on antidiabetic medication(s) must be on stable 
dose(s) for at least 3 months prior to the diagnostic liver biopsy . If possible, the doses of these 
medications should remain stable through the end of treatment.
Any investigational medication within 30 day s orwithin 5 half -lives prior to Screening and 
throughout the stud y (eg, obeticholic acid, elafibranor, and cenicriviroc) is prohibited. Subjects 
enrolled in the current protocol may participate concurrentl y in a HepQuant™ sponsored 
investigational device stu dy at participating US sites only  (Investigational Device Exemption 
#G170034/S002), once approved b y the applicable I RB/IEC.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 71 25 April 2019The following medications are prohibited for all treatment groups, from 30days prior to Day 1 
up to and including the day  of the last dose of study  drugs:
Chronic sy stemic immunosuppressants including but not limited to :corticosteroids 
(prednisone equivalent of > 10 mg/day  for > 2 weeks), azathioprine, or monoclonal 
antibodies (eg, infliximab). Use for ≤ 2 weeks total is allowed.
H
ematologic stimulating agents (eg,erythropoiesis -stimulating agents [ESAs ]; granulocy te 
colony  stimulating factor [GCSF ]; thrombopoietin [TPO ]mimetics)
Any medication or supplement prescribed for weight loss
Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducers 
of drug transporters OATP1B
1or 1B3 , potent or moderate inducers of CYP2C8, or potent 
inducers of CYP3A4) with study  drug(s) may result in PK interactions resulting in increa ses 
or decreases in exposure of study  drug(s)
Examples of representative medications that are prohibited or which should be used with caution 
are listed below in Table 5-1.
Table 5-1. List of Representative Disallowed and Use with Caution Medicationsa
Agents Disallowed
Drug Class Disallowed 30 days prior to Day 1 through the end of treatment
Immunosuppressants Chronic systemic corticosteroidsb, tacrolimus, sirolimus, cyclosporine, 
mycophenolate mofetil, and methotrexate
Acid Reducing Agents H2-Receptor antagonistsd
Antibioticscazithromycin, clarithromycin, erythromycin
Anticonvulsantscphenobarbital, phenytoin, carbamazepine, oxcarbazepine
Antimycobacterialscrifamycins, isoniazid
Endothelian Receptor AntagonistscBosentan
Herbal/Natural SupplementscSt. John’s Wort, Echinacea, milk thistle (ie ,silymarin), Chinese herb sho-saiko -to 
(or Xiao -Shai -Hu-Tang)
Othercgemfibrozil, m odafinil
Agents to be used with Caution
Drug ClassAgents to be used with Caution from 30 days prior to Day 1 through end of 
treat ment
Cardiac Medicationsedigoxinf, dabigatran etexilate, aliskiren
Acid Reducing Agents antacidsg
Bile Acid Sequestrantshcholestyramine, colestipol, colesevelem
a Not all of these example medications may be approved in each of the countries where the study is being conducted; 
please refer to local product information .
b Intra -articular, topical, nasal, or inhaled routes are allowed. Chronic systemic use of corticosteroids equivalent to prednisone
>10mg/day for > 2 weeks is not allowed. Use for ≤2 weeks total is allowed.
c May result in a n increase or decrease in the conce ntration of study drugs .
d H2-Receptor antagonists can be taken up to 3 days prior to Day 1 .
e SEL may increase the exposure of these medications .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 72 25 April 2019f For subjects on digoxin at start of study: obtain digoxin level prior to starting study drug and at the Week 1 Visit with 
digoxin level checks during the study period per Investigator discretion. Monitor and adjust digoxin dose as necessary based 
on prescribing information.
g Antacids that directly neutralize stomach pH (ie, Tums, Maalox) are permitted but may not be taken within 4 hours 
(before or after) study drug administration.
h Bile acid sequestrants are permitted but may not be taken within 4 hours (before or after) study drug administration.
5.4. Accountability forSEL, GS - 0976, and GS-9674
The Investigator is responsible for ensuring adequate accountability  of all used and unused 
Investigational Medicinal Product ( IMP
).This includes acknowledgement of receipt of each 
shipment of IMP(quantity  and condition). All used and unused IMP dispensed to subjects must 
be returned to the site.
IMP accountability  records will be provided to each study  site to:
Record the date received and quantity  of IMP kits
Record the date, subject number, the IMP kit number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information.
5.4.1. I nvestigational M edicinal Product Return or Disposal
At the start of the stud y, the study monitor will evaluate the study center’s study drug disposal 
procedures and provide approp riate instruction for return or destruction of unused study  drug 
supplies. I f the site has an appropriate Standard Operating Procedure (SOP) for drug destruction, 
the site may  destroy  used (empty  bottles) and unused study  drug supplies performed in 
accorda nce with the site’s (hospital/pharmacy ) SOP. I f the site does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
Gilead Sciences (or Gilead Sciences’ representative) for return of unused study  drug supplies. A 
copy  of the site’s SOP will be obtained for central files. Where possible, study  drug s will be 
destroy ed at the site. Upon study  completion, a copy  of the Investigational Drug Accountability  
records must be filed at the site. Another cop y will be returned to Gilead Sciences. If drug is 
destroy ed on site, the Investigator must maintain accurate records for all study  drug bottles 
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and per son who disposed of the drug. All study  drug records must be maintained 
at the site and copies must be submitted to Gilead Sciences at the end of the study .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 73 25 April 20196. STUDY  PROCEDURES
The study  procedures to be conducted for each subject screened and/or enrolled in the study  are 
presented in tabular form in Appendix 2and described in the text that follows. Additional 
information is provided in the S ite Operations Manual.
The Investigator must document any  deviation from protocol procedures and notify  the sponsor
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
Entry  into Screening does not guarantee enrollment into the study .In order to manage the total 
trial enrollment, Gilead at its sole discretion may  suspend screening and/or enrollment at any  site 
or trial -wide at any  time.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 8 weeks before randomization to determine eligibility  for 
participation in the study .The Screening period may  be extended under special circumstances 
with the explicit approval of the Gilead Medical Monitor.
Screening laboratory  tests may be repeated once within the Sc reening period, at the discretion of 
the Investigator, prior to Randomization.
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Screening visit to ensure an 
approximate 8- hour fast prior to the blood sample collection the next morning.
The following will be performed and documented at Screening:
Obtain written informed consent prior to initiation of any  Screening procedures
Obtain Screening number f rom I XRS
Obtain medical history
Record all concomitant medications that the subject has taken within 30 day s prior to 
Screening
Complete PE
Vital signs, bod y weight, andheight
Assess ascites and HE
CCI
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
• 12-Lead ECG 
I 
• Obtain blood samples for: 
-Chemist:Iy 
-Hemat ology 
-Coag ulation 
-Insulin and lipids 
-HIV-1 , HBV, and HCV serology 
-HbAlc (if unable to be resulted , sernm fiuctosamine will be teste d) 
-Sernm pregnancy test (for females of childbearing potential) 
I 
• Collect urine samples for: Final 
Amendment4 
-Urine drng screen for amphetamin es, cocaine and opiates (ie, heroin , morphine ) 
I 
• Perfo1m liver biopsy (if required) and provide liver tissue for centi·al reading. A historical 
biopsy that meets eligibility criteria may be accepted as the Scree ning biopsy if the samp le is 
deemed acceptable for interpretatio n by the cent:I'al reader. The historical sample must be 
within 6 months of Scree ning for F3 subjects and within 12 months of Screening for 
F4 subjects. 
I 
• Record in the source documents and eCRFs all SAEs and any AEs related to protocol 
mandated procedures that occu ned after signing of the consent f01m . All other untoward 
medical occunences observe d durin g the Scree ning period, including exacerbation or 
changes in medical histo1 y are to be captured on the medi cal histo1y eCRF. See Sectio n 7 
Adverse Events and Toxicity Management for additional details . 
CONFIDENTIAL Page 74 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
• Confom subject's liver histolog ical findings, including fibrosis stage , on the centra lly 
read biop sy repo1i 
I 
• Review and document the subject's eligib ility status 
Subjects meeting all of the inclusion criter ia and none of the exclusion cr iteria will return to the 
clinic after Scree ning for randomizatio n into the study. 
6.3. Day 1 A ssessment s 
All Day 1 assess ments must be completed before su bject dispe nsation/dosing of study diugs. 
6.3.1. Day 1: Randomization and Assessment s 
Subjects returning to the clinic for randomizatio n at Day 1 shou ld be instmcted to fast (no food 
or di·ink, exce pt wate r), sta1iing from midnight (00:00) or earlier, as appropriate, on the evening 
prior to th e visit to ensm e an approximate 8-hom fast prior to the bl ood sample collectio n under 
fasting cond ition the n ext morning. 
After review of inclu sion and exclusion cr iteria to confom continued eligibility, subjec ts will be 
randomized to stud diu assi nment and receive a Sub'ect Identification N umber via the IXRS. 
The following will be perfonned and docume nted at the D ay 1 visit p rior to dosing: 
I 
• Lifestyle questio nnaire 
I 
• Symptom di· iven PE 
• Vital signs and body weight 
I 
CONFIDENTIAL Page 75 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
• Assess ascites and HE 
• P rovide lifestyle modificatio n counseling 
• Obtain blood samples for: 
-Chemist:Iy 
-Hemat ology 
-Coag ulation 
-Insulin and lipids 
-HbAlc 
I Final 
Amendment4 
Note: For subjects on digox in at staii of study: obtain digoxin level prior to staiiing study 
dmg and at the Week 1 Visit, with digox in level checks during the study period per 
Investigato r discretion . Monitor and adjust digoxin dose as necessaiy based on 
prescribing infonnation. 
• Collect urine samples for: 
-Albumin 
-Creat inine 
-Albmnin/c reatinine ratio 
-Pregn ancy test (for females of childbea ring poten tial only) 
I 
• Record all concomita nt medicatio ns th at the subject has taken since the previous visit 
• Record all SAEs and any AEs related to protocol mandated procedures occunin g since the 
Scree ning visit 
CONFIDENTIAL Page 76 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
• Dispense study chugs and prov ide instruc tion on approp riate dosing and admin istr·ation; 
subject will take the Day 1 dose of study ch11gs on-site at the end of the visit, with or without 
food 
I 
I 
6.4. 
6.4.1. On-Tr eatment Assessments 
Week 1 Vis it(± 3 days) 
Subjects shou ld be instructed to fast (no food or ch·ink, except wate r), starting from 
midnight (00:00) or earlier, as approp riate, on the evening prior to the Week 1 visit to ensure an 
approximate 8-hour fast prior to the blood sample collectio n the next morning. 
The following assessme nts will be perfonned and docume nted at this visit: 
• Lifestyle questio nnaire 
Note: It is recommended that the questio nnaire be completed prior to any study procedures 
being perfo1med and prior to the subject seeing a h ealth care prov ider. 
• Symptom ch·iven PE 
• Vital signs and body weight 
• Assess ascites and HE 
• Obta in blood samples for: 
-Chemistry 
- H emato logy 
-Coag ulation 
Note: For subjects on digoxin at staii of study: obtain digoxin level prior to staiiing study 
chug and at the Week 1 Visit , with d igoxin level checks during the study period per 
Investigato r discretion. Monitor and adjust digoxin dose as necessaiy based on 
presc ribing infonnation. 
CONFIDENTIAL Page 77 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
• Reco rd all concomita nt medicat ions th at the su bject has taken since the previous visit 
• Record all SAEs and any AEs occmTing since the previo us visit 
• Review of study chug dosing comp liance (pill count) and prov ide instruc tion on approp riate 
dosing and achninish'atio n 
I 
I 
6.4.2. Wee k 4, We ek 12, and Wee k 36 Visits (±3 days) 
Subj ects should be instructed to fast (no food or ch·ink, excep t wate r), sta1ting from 
midnight (00:00) or earlie r, as appropria te, on the evening prior to the visit to ensme an 
approximate 8-hom fast prior to the blood sample collectio n the next morning. 
The following will be perfo1med and documented at this visit: 
I 
• Lifestyle questio nnaire 
I 
Note: It is recommended that the questio nnaires be completed prior to any study procedmes 
being perfo1med and prior to the subject seeing a health care prov ider. 
• Symptom ch·iven PE 
• Vital signs and body weig ht 
I 
• Assess ascites and HE 
• Provide lifestyle modificatio n counse ling 
• Obta in blood samples for: 
-Chemistry 
- H emato logy 
-Coagulation 
-Insulin and lipids 
-HbAlc 
CONFIDENTIAL Page 78 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
• Collect urine samples for : 
-Albumin (Weeks 12, 36) 
-Creat inine (Weeks 12, 36) 
-Albumin/c reatinine ratio (Wee ks 12, 36) 
-Biomarkers (Weeks 12, 36) 
-Pregnancy test (for females of childbea ring potential only) Final 
Amendment4 
• Reco rd all concomita nt medicat ions th at the su bject has taken s ince the previo us visit 
• Reco rd all SAEs and any AEs occmTin g since the previo us visit 
• Review of study drng dosing compliance (pill count) 
• Dispe nse study drng and provi de instrnction on approp riate dosing and admini stratio n 
I 
I 
6.4.3. Week 8, Week 16, Week 20, Week 28, Week 32, Week 40, and Week 44 Visits 
(±3 days) 
Subjects shou ld be instructed to fast (no food or drink, except water), staiiing from midnight 
(00:00) or eai·lier, as appropriate, on the evening prior to the visit to ensure an approx imate 
8-hour fast prior to the blood sample collec tion the next morning. 
The following will be perfonned and docume nted at this visit: 
• Lifestyle questio nnaire 
Note: It is recommended the q uestionnaire be completed prior to any study proced ures being 
perfo1med and prior to the su bject seeing a h ealth care prov ider. 
CONFIDENTIAL Page 79 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
• Vital signs and body weight 
• Symptom driven PE 
• Assess ascites and HE 
• Lifestyle modificatio n counseling 
• Obtain blood samples for: 
-Chemistiy 
-Hemat ology 
-Coag ulation 
I 
I 
• Collect urine sample s for: 
-Pregnancy test (for female s of childbearing potential only) Final 
Amendment4 
• Record all concomita nt medicat ions t hat the s ubject has taken s ince the previou s visit 
• Record any SAEs and all AEs occun ing since the previou s visit 
• Review of study chug dosing complian ce (pill count) 
• Dispense study chug s to the subject and provide instrnction on appropriate dosing and 
admin isti·ation 
I 
I 
6.4.4. Week 24 and Week 48 (±7 days) 
I 
• Lifestyle questionnaire 
I 
Note: It is recommend ed the que stionnaire s be completed prior to any study procedures being 
perfo1med and prior to the s ubject seeing a health care provider. 
• Vital signs and body weight 
CONFIDENTIAL Page 80 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
• Complete PE 
• H ip and waist circumference 
• 12-lead ECG (Week 48 only) 
• Assess ascites and HE 
• Lifestyle modification counseling 
• Obta in blood samples for: 
I -Chemist:Iy 
- H emato logy 
-Coag ulation 
-Insulin and lipids 
-HbAlc 
I 
I 
I 
I 
• Collect urine sample s for: 
-Albumin 
-Creat inine 
CONFIDENTIAL Page 81 Final 
Amendment4 
25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454- 4378 
Gilead Sciences , Inc. 
I 
I 
I -Albumin/c reatinine ratio 
-Pregnanc y test (for females of childbe aring potential only) 
• Liver biopsy and provide liver tissue for central reading (Wee k 48 only) Final 
Amendment4 
• Record all concomita nt medicati ons that the subjec t has taken since the previous visit 
• Record all SAEs and any AEs occmTin g since the previous visit 
• Review of study drng dosing compliance (pill count) 
• Dispense study drng and provide instrnction on appropriate dosing and administration 
(Week 24 only ) 
I 
I Note: Subjects shou ld not exceed the allowe d dosing period of 48 weeks (336 days) . All 
effo1i should be made for the Wee k 48 visit to coincide with the subject's last dose of study 
diug. If it is not possible to schedule the Week 48 visit on Day 336 of dosing , detailed dosing 
instructions should be provided to subjects on the precise day to complet e their dosing before 
or after their Week 48 visit. 
6.4.5. Early Termination (ET) Visit 
I 
• Lifestyle questionnaire 
I 
Note: It is recommend ed that the questionnaires be complet ed prior to any study procedmes 
being perfo1med and prior to the subject seeing a health care provider. 
• Complet e PE 
CONFIDENTIAL Page 82 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
• Vital signs and body weight 
I 
• 12-lead ECG 
• Assess ascites and HE 
• Lifestyle modificatio n counseling 
• Obtain blood samples for: 
-Chemi st:Iy 
-Hemat ology 
-Coag ulation 
-Insulin and lipids 
-HbAlc 
-ELFn1 Test 
• Collect urine sample s for: 
-Albumin 
-Creat inine 
-Albumin/c reatinine ratio 
-Pregn ancy test (for females of childbe aring poten tial only) 
CONFIDENTIAL Page 83 Final 
Amendment4 
25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
I Final 
Amendment4 
• Record all concomita nt medication s that the s ubject has taken since the previo us visit 
• Record all SAEs and any AEs occmT ing since the previou s visit 
• Review of study drng dosing comp liance (pill count) 
• At the discretion of the Investigator , perfonn the following assess ment s: 
I 
I -Liver biopsy and provide liver tissue for central reading 
6.4.6. Unscheduled Visits 
Additio nal unscheduled assess ment s may be perfo1med at the discretion of the Investigator. 
At a minimum , the following will be perfonned and docume nted: 
• Symptom driven PE 
• Obta in blood sample s for: 
-Chemistiy 
- H emato logy 
-eGFR 
• Record vital signs and body weig ht 
• Record all concomita nt mediation s that the subject has taken since the previous visit 
• Record any serious adve rse events and all adverse events occunin g since the previou s visit 
If the Un scheduled visit is perfonned for the sole pmpose of disti·ibution of study dm g, the 
assessments noted above do not need to be perfonned. 
CONFIDENTIAL Page 84 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 85 25 April 20196.5. Post-treatment Assessments
6.5.1. Follow -Up Visit (±5 days)
Subjects will return for a Follow -Up visit four weeks after the date of last dose of study  drug.
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Follow -Up visit to ensure an 
approximate 8-hour fast prior to the blood sample collection the next morning.
The following will be performed and documented at this visit:
Symptom driven PE
Vital signs and body  weight
12-lead ECG
Obtain blood samples for:
Chemistry
Hematology
Coagulation 
Insulin and 
lipids
HbA1c 
Collect urine samples for:
Albumin 
Creatinine 
Albumin/creatinine ratio
Pregnancy  test (for females of childbearing potential only )
CCI
CCI
CCI
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
• Reco rd all concomita nt medicat ions th at the su bject has taken since the previo us visit 
• Reco rd all SAEs and any AEs occmTing since the previo us visit 
I 
6.6. Criteria for Discontinuation of Study Drug 
Study chugs must be disco ntinued in the following instances: 
• Sub ject progression to decompe nsated cnThosis, as defined by any of the following: 
- C linically appa rent ascites requii·ing treatment 
- HE of Grade 2 or above (acco rding to the West Haven criteria as defined in Appendix 4) 
requii·ing treatment 
-Portal hype1 iensio n-related upper gastro intestinal bleed ing identified by endoscopy and 
requii·ing hospitalizatio n, including events of bleeding from esop hageal varices, gastric 
varices, and po1ial hype1iensive gastropathy 
I 
• Liver transplantatio n 
• Subj ect develops an SAE consist ing of a serious hypersensitivity reaction to study chug 
• IntercmTe nt illness that would, in the judgme nt of the Inves tigato r, affect assessments of 
clinical sta.tus to a significa nt degree. Following resolution of intercunent illness, the su bject 
may resume study dosing at the di scretion of the Investigator, in cons ultation with the 
Med ical Mon itor 
• Una cceptable toxicity or toxicity that, in the judgment of the Investigato r, compromises the 
ability to continue study-specific proced mes or is considered to not be in the subject 's best 
interest 
• Sub ject or Investig ator request to disco ntinue for any r eason 
• Sign ifican t subject non compliance 
• Sign ifican t protocol violation th at impacts subject safety 
• Pr egnancy dming the study; refer to Appendix 3 
• Discont inuation of the study or treatme nt groups at the r equest of Gilead, a regulato1y 
agency, or an IRB/IEC/EC . 
CONFIDENTIAL Page 86 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
6.7. Interruption of Study Drug Final 
Amendment4 
If dosing is intenupted (ie, as a result of an AE), the s ubject must stop dosing of all three study 
diugs. Eve1y attempt sho uld be made to keep the subject in the study and continue to perfo1m the 
required study -related procedures . Discussion with the Medical Monitor is recommended. If this 
is not possib le or acceptable to the s ubject or Investigator , the s ubje ct may be withdi·awn from 
the study. 
6.8. Assessments for Premature Discontinuation from Study 
Subjects prematurely discont inuin g from the study ( eg, as a result of an AE or a tr eatment group 
closure) should h ave an ET visit upon discontinuing, as well as a Follow-U p visit 4 weeks after 
the date of the last dose of study diugs (refe r to Sectio n 6.4.5 and 6.5.1 ). Discussion with the 
Medical Monitor is recommend ed. 
The subject will be considered off-study after the comple tion of these visits. 
If these visits are not possible or acceptable to the subject or Investigator , the subject may be 
withdi·awn from the study. 
CONFIDENTIAL Page 87 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
6.11. 
6.11.1. Description of Assessment s 
Clinical Laborator y Anal ytes Final 
Amendment4 
Fasting is required prior to all study visits. Subjects shou ld be instmcted to fast (no food or d rink, 
except water) , staiiing from midnight (00:00) or eai·lier, as appropr iate, on the evening prior to 
the visit to ensure an approximate 8-hour fast prior to the bl ood sample collectio n the next 
morning. Please refer to the Cova nce Labo rato1y Manual or the individual subject Cova nce 
laborato1y repo1i for gender and age speci fic refere nce ranges. 
Chemistiy: 
, bicai· bonate, blood urea niti·oge n (BUN), calcium, chloride, 
creatinin- te dehydroge nase (LDH) ~ esium, phosphom s, potassi um, 
sodium ,_ , total protein , uric acid, 1111 , eGFR as calculated by the 
Cockcroft -Gault equation , and creatine phosphokinase (CPK) 
Hem atology: 
Hem atocrit (Hct) , hem oglobin (Hgb ), platelet count , red blood cell count (RBC) , white blood 
cell count (WBC) with diffe rential (abso lute and perce ntage) including lymphocytes , monocytes , 
neutl'ophils, eosinophils, basop hils, and m ean co1 p uscular volume (MCV) 
Coag ulation Panel: 
INR, PT, and activated paiiia l thromboplastin time (APTT) 
Additio nal Tests: 
HIV-1 antibody (reflex to HIV-1 RNA), HBV (HBsAg) , HCVa ntibody (reflex to HCV RNA) , 
semm pregna ncy testing, FSH, eGFR as calculated by M DRD , hom eostasis model assess ment of 
insulin resistance (HOMA- IR, based on fasting glucose and insulin), C-peptide , lipid panel 
(cholesterol , high-density lipoprotein [HDL ], LDL, ti·iglycerides, and other lipid tests), free fatty 
acids, digox in testing, HbAlc (semm fmctosa mine will be tested if HbAlc is unable to be 
resulted) 
CONFIDENTIAL Page 88 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
Urine Samples: Final 
Amendment4 
Urine will be collected for albumin, creatinine, albumin/crea tinine ratio, ~ 
(for amphetamines, cocaine , methadone, and opiates) , pregna ncy testin-
6.11. 2. Physical Examination 
A complete PE shou ld include source docume ntation of general appeara nce, and the following 
body systems: head, neck, and thyroid ; eyes (incl uding an ophthalmoscopic exam ination), ears, 
nose , throat, mouth, and tongue; ch est ( excluding breas ts); respirato 1 y ; cardiovascu lar; l ymph 
nodes; abdome n; skin, hair, nails; musculoske letal; neurological. 
The focus of a symptom drive n PE wi ll be determined by the Investiga tor based on subject 
compla int. For example , if a sub ject compla ins of a cough, a lung exam shou ld be perfonned. If 
consistent with pneu monia (rales/crack les on exam) then an AE would be docume nted. 
All comp lete and symptom drive n examinatio ns shou ld include assessme nts to detennine the 
prese nce of ascites and HE, and a pulmonaiy examinatio n with questio ning regarding pulmona1 y 
symptoms. 
6.11. 3. Vital Sign 
Assessme nt of vital signs will include meas urement of resting blood pressure, pulse, respirato1y 
rate and tempera ture. 
Blood pressure will be meas ured using the following standa rdized process: 
• Subj ect shou ld sit for 5 minutes with feet flat on the floor and meas urement aim suppo1 ied 
so that the midpo int of the manomete r cuff is at heaii level; 
• Use a mercmy sphygmomanomete r or au tomat ic blood press ure device with an appropr iately 
sized cuff with the bl adder centered over the brachia l a1ie1y; 
CONFIDENTIAL Page 89 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Measure and record the blood pressure to th e nearest 2 millimeter of mercmy (nnnH g) mark on 
the mano meter or to the nearest whole number on an automatic device. 
6.11.4. Medical History 
Medical histo1 y , includin g details regarding illnes ses and allergies, date(s) of onset, whether a 
conditi on(s) is cmTen tly ongoing, and medica tion histo1y, will be collected on all subjects during 
Scree ning. 
CONFIDENTIAL Page 90 25 Apri l 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 91 25 April 20196.11.6. Creatinine Clearance
Creatinine clearance will be calculated b y the Cen tral Laboratory , using the Cockcroft -Gault 
equation {Cockcroft 1976
}.
Male: CL cr(mL/min) = [140 − age (y ears)] BW(kg)
                                                        72 Scr
Female: CL cr(mL/min) =[140 −age (y ears)] BW(kg) 0.85
                                                        72 Scr
Scr= serum creatinine (mg/dL)
Actual bod y weight will be used for the CL cr.
CCI
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
6.11. 7. Pregnanc y Testing Final 
Amendment4 
All females of childbearing potential will have a sernm pregna ncy test at Scree ning; FSH m ay be 
tested to determine a female subject's postmenopausal state (refe r to Appendix 3). All females of 
childbearing potential will have a urine preg nancy test at Day 1 (prior to dosing) and eve1 y 
4 weeks ther eafter. In the event of a positive pregna ncy result, subjects will be instructed to stop 
study diugs imm ediately (if applicable) and complete a sernm pregnancy test. 
6.11.9. Health Related Quality of Life (HRQoL) 
It is recommended that these questio nnaires be completed prior to the clinical and laborato1y 
assess ments. The subject shou ld read the questio nnaires by himsel f/herse lf and r ecord the 
answers by himself/herself. 
6.11.9.1. Sho1t Fonn 36 Health Survey (SF-36) 
The S F-36 asks 36 questio ns to measure functional h ealth and well-being from the subj ect's 
point of view. It consists of eight health domains: physical functioning, role-physical , bodily 
pain, gene ral health, vitality, socia l functioning, role-emotional, and men tal health. These health 
domain scales conti·ibute to th e physical health and me ntal health summ a1 y m easures. 
6.11.9.2. Chronic Liver Disease Questio nnaire-No nalcoholic Fatty Liver Disease 
(CLDQ-NAF LD) 
The CLDQ-NAF LD asks questio ns related to liver disease and speci fically NAFL D, to measure 
health related quality of life in subjects with chronic liver disease . 
6.11.9.3. Work Productivity and Activity Impainnent (WPAI) 
The WP AI questionnaire asks questions regarding the effec t of NAS H on a person's ability to 
work and perfo1 m regular activ ities. 
6.11.9.4. EuroQol Five Dimensions (EQ-5D) 
The EQ-5D questionnaire is a standard m easure of health status developed by the EuroQol 
Group to prov ide a simple, generic measure of health for clinical and econoinical appraisa l {The 
EuroQol Group 1990 }. The EQ-5D is not disease specific and h as been validated in num erous 
healt h states. The tool consists of the EQ-5D descr iptive syste m and the EQ Visual Analog Scale 
(VAS). The descr iptive part comprises 5 dimensions (mobi lity, self-care, usual activities , 
pain/d iscomfo1t, and a nxiety/depressio n). Each of th ese 5 dimensions h as 5 levels (no prob lem, 
slight problems , moderate prob lems, severe proble ms and unable to). Results for each of the 
5 dimensions are combined into a 5-digit num ber to descr ibe the subject's health state . The VAS 
records the su bject's health on a 0-100 mm VAS scale , with 0 indicat ing "the wors t healt h you 
can imagine " and 100 indicating "the best health you can imag ine". 
CONFIDENTIAL Page 92 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
6.11.10. Pruritus Assessments Final 
Amendment4 
It is recommended that these questionnaires be comple ted prior to the clinical and laborato1y 
assess ments. The subject should read the ques tionnaires by himself/hersel f and record the 
answers by himself/herself. 
6.11.10.1. Visual Analogue Scale -Itch (VAS -itch) 
The VAS -itch is a tool for measuring the intensity of pmritus. 
6.11.10.2. 5-D itch 
The 5-D itch is multi dime nsional measure of itching that allows changes in chronic prnritu s to be 
detected over time. The ques tionnaire measures the d egree, duration, directio n, disab ility, and 
distribution of prnritu s. 
6.11.11. Electrocardiogram 
Standar d 12-lead ECG assess ments will be perfo1med. The Investigator will review the ECGs for 
any clinically significant abno1malities to ensure subject safety. Abno1mal ECG findin gs that are 
considered clinically significant by the Investigator and meet the defini tion of an AE should be 
repo1 ied and recorded in the AE eCRF page . -... 
-
CONFIDENTIAL Page 93 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
-
6.11.15. Liver Biop sy Final 
Amendment4 
All possib le attempts shou ld be made to acquire a liver biopsy speci men of at least 2.0 cm in 
length to ensure accurate staging of fibrosis and ot her histolog ical lesio ns. It is recommended 
that a 16 gauge needle is used to collect the tissue sample. A historical biopsy within 6 months of 
the Screening visit (that is consistent with NAS H and bridging fibrosis [F3]) or within 12 mont hs 
of the Screening visit (that is consistent with NAS H an dcinhosis (F4) or cinhosis due to NAS H 
with < 5% steatosis [F4, NAS steatos is grade = O]) may be accep ted as the Scree ning biopsy. The 
liver biopsy sample must be deemed adequate for evaluat ion by the central reader for inclu sion. 
Liver biopsi es will be sent to a centrnl laborato1y and then read by a central reade r. The central 
reader will read all Screening biopsies for eligibility. This assess ment will include an assess ment 
of the adeq uacy of the speci men as well as the fibrosis stage and a d etennination that the biop sy 
is consistent with NAS H or cinhosis due to NAS H with < 5% steatosis. If liver biopsy results are 
deemed unevaluab le by the central reade r, a repeat biopsy may be perfo1 med at the discretion of 
the Investigato r. 
If a liver biopsy is peifonned per standa rd of care outside of protoco l mandated assess ments, all 
possible attempts should be made to submit the biop sy specime n to the central reader for 
evaluation. 
Please refer to the Site Operat ions Man ual for additional infonnatio n. 
6.11.16. Lifestyle Modification Counseling 
Lifestyle modificat ions such as weight loss via diet and increased exercise can be effective in the 
treatment of NAS H. At each study visit, all subjects will receive counseling regarding lifesty le 
modificat ions including the m ainte nance of a healt hy diet and paiiicipatio n in regulai· exerc ise. 
6.11.1 7. Lifestyle Questionnaire 
This questio nnaire will assess the quanti ty of alcoho l intake, dieta1y patterns, and physical 
activity of subjects before staiiing study mugs and betwee n study visits. 
It is recommended that this questionnaire be completed prior to the clinical and laborato1y 
assess ments. The subject shou ld read the questio nnaire by himself/herself and record the answers 
by himself/herse lf. 
CONFIDENTIAL Page 94 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
• 
CONFIDENTIAL Page 95 Final 
Amendment4 
25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 96 25 April 20197. ADVERSE EVENTS AND T OXIC ITY MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product ,which does not necessarily  have a causal relationship with th
e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose, drug abuse/misuse reports , or 
occupational exposure . Preexisting events that increase in severit y or change in nature durin g or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (eg, hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medica l condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical h istory  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability /incapacit y
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 97 25 April 2019A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not record ed as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an S AE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described i n Sections 7.1.1 and7.1.2. If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abno rmalities in this study , 
please refer to Section 7.2.2.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The Investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The Investigator or qualified subinvestigator is responsible for assessing the relationship to IMP 
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 98 25 April 2019It should be emphasized that ineffective treatment should not be consi dered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg,venipun cture )
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, 4, or 5 according to the
Common Terminology Criteria for Adverse Events (CTCAE), which can be found in the Site 
Operations Manual .
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying condi tions; this may  or may  not be in agreement 
with the grading of the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity; thus, a severe reaction is not necess arily a serious reaction. For 
example, a headache may be severe in intensity, but would not be classified as serious unless it 
met one of the criteria for serious events listed above.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  drugs , the following ty pes of events 
should be reported on the eCRF: all SAEs and 
adverse events relat ed to protocol -mandated 
procedures.
Adverse Events
Following initiation of study  drug, until 30 day s after last administration of study  drug s, all AEs 
regardless of cause or relationship, must be collected and reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow-up 
period.
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
Seriou s Adverse Events Final 
Amendment4 
All SAEs, regardless of cause or relatio nship, that occur after the subject first consents to 
paiiicipate in the study (ie, signing the infonned consent) and throughout the duration of the 
study , includin g the protocol -required post treatment follow -up period , must be reported to the 
eCRF database and Gilead PVE as instmcted. This also inclu des any SAEs resulting from 
protocol -associated procedures perfonn ed after infonn ed consent is signed. 
Any SAEs and deaths th at occur after the Follow-Up visit but within 30 days of the last dose of 
study diugs , regardless of causality , sho uld also be repo1ied . 
Investigators ai· e not o bligated to actively seek SAEs after the protocol defined follow-up period ; 
however , if the Investigato r learns of any SAEs that occur after study paiiicipation has concluded 
and the event is deemed relevant to the use of IMP, he/s he should prom ptly documen t and repo1 i 
the even t to Gilead PVE. 
Electronic Serious Adve rse Event (eSAE) Repo1i ing Process 
• Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
infonnation to Gilead PVE within 24 hours of the Investigator 's knowledge of the event. 
Detailed instructio ns can be found in the eCRF comple tion guidelines . 
• If for any reason it is not possib le to record the SAE infonnation electr · onically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
fo1m and submi t within 24 hours : 
Gilead Sciences PVE : Fax: 
Email : PD 
PD 
As soon as it is possible to do so, any SAE reported via paper must be tr·anscribed into the 
eCRF Database accord ing to instruc tions in the eCRF completion guidelines. If an SAE has 
been repo1ied via a paper f 01m because the eCRF database has been locked, no fmih er action 
1 s necessa1y. 
• For fatal or life-thre atening events, copies of h ospital case repo1is, autopsy repo1is, and other 
documen ts ai· e also to be submitted by e-mail or fax when re quested and applicable . 
Transmission of such docume nts sho uld occur witho ut personal subject identification, 
maintainin g the tr·aceability of a document to the subject identifier s. 
• Additio nal infonn ation may be requested to ensure the timely completion of accurate safety 
repo1is. 
• Any medications necessaiy for tr·eatment of the SAE must be recorded onto the co ncomitant 
medicat ion section of the subject's eCRF and the even t description section of the SAE fonn. 
CONFIDENTIAL Page 99 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
Gilead Medical Monitor contact info1mation is as follows: 
Name :PPD 
Telephone: 
Mobile : 
Fax: 
Email : 
7.4. PD 
PPD 
PPD 
PPU 
Gilead Reporting Requirements Final 
Amendment4 
Depending on relevant local legislation or regulations, includin g the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and releva nt updates, and 
other countiy-specific legislatio n or regulati ons, Gilead may be required to expedite to 
worldwide regulato1 y agencies reports of SAEs , serious adverse dmg reactions (SADRs), or 
susp ected unexpec ted serious adverse reactions (SUSARs) . In accor dance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulato1y 
agencies and the releva nt IEC in concerned Member States of applicable SUSARs as outlined in 
cmTent regulations . 
Assess ment of expectedness for SAEs will be dete1mined by Gilead using refer ence safety 
info1mation specified in the IB or releva nt local label as applicable. 
All Investigators will receive a safety letter notify ing them of relevant SUSAR repo1 is associated 
with any study IMP. The Investigator should notify the IRB or IEC of SU SAR repo1 is as soon as 
is practical , whe re this is required by local regulato1 y agencies, and in accor dance with the local 
institut ional policy . 
-
CONFIDENTIAL Page 100 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
7.5.2. Close Observation 
Close obse rvation includ es: 
I 
• Obtaining a mo re detailed histo1 y of s ymptom s and prior or concmTent disease Final 
Amendment4 
• Obtaining a histo1 y of concomitant diug use (includin g nonprescription medication s and 
herbal and dietaiy supplemen t prepai·atio ns), alcohol use, recreational dmg u se, and specia l 
diets 
• Obtaining a histo1 y of expo sme to environmental chemical agents 
• Ruling out other causes of liver disease as needed ( obtain viral hepatitis panel , imaging for 
evaluation of biliaiy tract disease, etc. if required in the op inion of the Inve stigator) 
• Cont inue to monitor liver biochemistrie s at least twice week ly. Frequency can decrea se to 
once a week or less if abno1ma lities stabilize or study mug s have been discontinu ed and the 
subject is asymptomat ic 
CONFIDENTIAL Page 101 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
During a per iod of close obse rvatio n for DILI, study diugs can be continued, if desired, at the 
discretion of both the Medical Monitor and Investigator. 
If study diugs are withheld, th ey may be reintrod uced with approva l from the Gi lead Medical 
Monitor. 
Treatment-emergent toxic ities will be noted by the Investigator and b rought to the attention of 
the Medical Monitor. Whet her or not considered treatment-related, all subjects experiencing AEs 
must be monitored periodica lly until symptoms subside, any abnonnal laborato 1 y values have 
resolved or returned to baseline levels or th ey are considered iITeversib le, or until there is a 
satisfacto1y explanation for the ch anges observed. 
CONFIDENTIAL Page 102 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. Final 
Amendment4 
Other than in the case of the liver enzymes noted above , Grade 3 or 4 clinically signifi cant 
laborato1y abno1ma lities should be confnm ed by repeat testing as soon as practical to do so, and 
preferably within 3 calendar days ofreceipt of the original test results. For AEs assoc iated with 
laborato1y abno1ma lities, the event should be graded on the basis of the clinical severity in the 
context of the underlying conditi ons; this may or may not be in agreement with the grading of 
the laborato1y abnonnality . 
Any questions regarding toxicity management should be directed to the Medical Monitor. - -
7.5.4. Hypertriglyceridemia 
Although some randoinized subject s will have baseline dyslipideinia , some subjects may 
expe rience fmther elevation s in their triglyce rides. Figure 7-3 describes the recommended 
monitoring and intervention strateg y for subjects that meet the criteria for on-treatmen t 
hype1trigl ycerideinia of Grade 3 or 4 (~ 500 mg/d.L). 
CONFIDENTIAL Page 103 25 Apri l 2019 
Selonsertib , GS-09 76, GS-9674 
Protoco l GS- US-4 54-4378 
Gilead Science s, Inc. Final 
Amendment4 
Figure 7-3. Algorithm for Monitorin g and Treatm ent of Hype rtriglyceridemia 
-
7.6. 
7.6.1. Triglycerides Grade 3 or 4 
(~ 500 mgld L) 
Repea t fasting testing - within 72 hours of -
receip t of results 
If repeat fasting testing If repeat fasting testing 
is .: 500 mg/d L 
Start fenofibrate 145 mg 
PO daily or equiva lent if 
fenofib rate is not available 
If patient has a contraind ication, cannot 
tolerate a fibrate, or a fibrate is not available, 
start Vascepa 2000 mg PO twice daily or 
equivalent if Vascepa is not available 
Repeat fasting testing 7 to 14 
days after initiation of treatment 
Special Situation s Report s 
Definition s of Special Situation s is < 500 mg/d L 
No treatment 
modifications 
Specia l situatio n repo1i s include all repo1i s of medicat ion enor, abuse, misuse, overdose, repo1i s 
of AEs associated with product compla ints, occupational expo sure with an AE, pregna ncy 
repo1is regard less of an associated AE, and AE in an infant following exposure from 
breastfeeding. 
Med icatio n enor is any unintentio nal enor in the prescribing , dispensing, or administratio n of a 
medic inal product while in the control of the health care provide r, subject , or consumer. 
CONFIDENTIAL Page 104 25 Apri l 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 105 25 April 2019Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as anaccidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in c ases in which the Investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
Occupational exposure is defined as exposure to a medicinal product as a result of one’s 
professional or non- professional occupation.
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The Investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  drugs and throughout the study , including the post study drug follow - up 
period, to Gilead PVE using the paper pregnancy  report form within 24 hours of becomin g aware 
of the pregnancy . Reports should be sent directl y to Gilead PVE at fax number  
or email 
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical r easons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Section 7.3. Furthermore, a ny SAE occurring as an adverse pregnancy  outcome post study must 
be reported to Gilead PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to or Gilead PVE 
using the pregnanc y outcome 
report form. If the end of the pregnancy  occurs after the study  has been completed, the outcome 
should be reported directly  to Gilead PVE . Gilead PVE contact in formation is as follows: 
Email:  and Fax: 
PPD
PPD
PPD
PPD
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 106 25 April 2019Pregn ancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to or Gilead PVE using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the pregnant partner 
should continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after 
the study  has been completed, the outcome should be reported directl y to Gilead 
PVE , 
faxnumber  or email 
Refer to Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.6.2.2. Reporting Other Special Situations
Site personnel must record all other special situations data in the eCRF database and from there 
transmit the special situations information to Gilead PVE within 24 hours of the Investigator’s 
knowledge of the event. Detailed instructions can b e found in the eCRF completion guidelines.
All special situations data will be recorded in the eCRF database within the timelines outlined in 
the eCRF completion guideline.
If it is not possible to record and submit the special situations information electronicall y, because 
the eCRF database cannot be accessed or is not available (including at study start), record the 
information on the paper special situations report form and submit b y e-mail or fax within 
24
hours of the investigator’s knowledge of the event to Gilead PVE. Gilead PVE contact 
information is as follows: Email:  and Fax: 
As soon as it is possible to do so, any  special situations reported via paper must be transcribed 
into the eCRF database according to instructions in the eCRF completion guidelines. If any  
special situations have been reported via a paper form because the eCRF database has been 
locked, no further action is necessary .
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form . Any  
inappropriate use of concomitant medications pr ohibited by  this protocol should not be reported 
as “misuse,” but may  be more appropriatel y documented as a protocol deviation.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
PPD
PPD
PPD
PPD
Selonsertib , GS-0976 , GS-9674 
Protocol GS-US-454 -4378 
Gilead Sciences , Inc. 
8. STATISTICAL CONSIDERATIONS 
8.1. Analysis Objectives and Endpoints 
Detai ls will be prov ided in the statistica l analys is plan (SAP). 
8.1.1. Analysis Objectives 
The prima1y object ives of this study are: Final 
Amendment4 
• To assess the safety and tolerabi lity of SEL, GS-097 6, and GS-967 4, administe red alone or in 
combination , in subject s with bridging fibro sis or compensated cinhosis due to NAS H 
• To evaluate changes in liver fibrosis , as measured by the NAS H CRN classification , without 
worsening of NAS H (defined as any increase in hepatocellu lar ballooning or lobular 
inflamm ation) 
I 
I 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 107 25 April 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
I 
I 
8.1.2. 
8.1.2.1. Endpoint s 
Primary Endpo int Final 
Amendment4 
The prima1 y endp oints are the safety and anti -fibrotic effec ts of SEL, GS-0976 , and GS-967 4, 
admin istered alone or in combination, in subjects with br idging fibrosis or compensated cinhosis 
due to NAS H. Safety endpoints include AEs and laborato 1 y evaluations. 
Anti-fibro tic respo nse will be evalua ted by the propo1 iion of subjects at Week 48 who achieve a 
I-stage improve ment in fibrosis (accor ding to the NAS H CRN classification) without 
worsening of NAS H ( d efined as a~ I-point increase in hepatocellular ballooning or lobular 
inflammatio n). -
I 
I 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 108 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
I 
I 
8.2. Analysis Conventions Final 
Amendment4 
All individual subject data will be listed as measured. All statistical summ aries and analyses will 
be perfo1m ed using Statistical Analysis Syste m (SAS®) software (SAS Institute, Caiy , 
No1th Carolina, USA) . 
8.3. 
8.3.1. Analysis Sets 
Efficacy 
The prima1y analysis set for efficacy analyses will be the Full Analysis Set (FAS) which include s 
all subjects who were randomized into the s tudy and receive d at least one dose of study diugs. 
Subjects who r eceive study diugs other than that to which they were randomized for the entire 
duration of treatmen t will be analyzed accord ing to th e treatmen t group to which th ey were 
randomized . 
8.3.2. Safety 
The prima1y analysis set for safety analyses will includ e all subjects who received at least 
one dose of study diugs. Subjects who r eceived study diug other than th at to which th ey were 
randomized for the entir e duration of treatme nt will be analyzed acco rding to the study diugs 
received. 
All data collected durin g treatment plus 30 days after last dose of study diugs will be includ ed in 
the safety summ aries . -
CONFIDENTIAL Page 109 25 Apri l 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 110 25 April 20198.3.2.2. Biomarkers
The Biomarker Anal ysis Set will include data from subjects in the Safety  Analy sis Set who have 
the necessary  baseline and on- study  measurements to provide interpretable re sults for the 
specific parameters of interest.
8.4. Interim Analysis
An administrative interim analy sis will be performed after all randomized subjects have 
completed Week 24 assessments or prematurel y discontinued the study.
8.5. Data Handling Conventions
Missing data can have an impact on the interpretation of the trial data. In general, values for 
missing data will not be imputed.
Where appropriate, safety  data for subjects that did not complete the study  will be included in 
summary  statistics. For example, if a s ubject received study  drugs , the subject will be included in 
a summary  of AEs according to the treatment received; otherwise, if the subject is not dosed then 
they will be excluded from the summary . If safet y laboratory
 results for a subject are missing for 
any reason at a time point, the subject will be excluded from the calculation of summary  
statistics for that time point. I f the subject is missing a pre -dose value, then the subject will be 
excluded from the calculation of summary  statistics for the pre -
dose value and the change from 
pre-dose values.
Values for missing safety laboratory data will not be imputed; however, a missing baseline result 
will be replaced with a Screening result, if available. If no pre -treatment laboratory  value is 
available, the baseline value will be assumed to be normal (ie, no grade [Grade 0]) for the 
summary  of graded laboratory  abnormalities.
Values for missing vital signs data will not be imputed; however, a missing baseline result will 
be replaced with a Screening result, if available.
Further details of data handling conventions and transformation will be provided in the SAP.
8.6. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods. 
Demograph ic summaries will include sex, race/ethnicity , and age.
Baseline data will include a summary  of bod y weight, height, BM I, waist -to-hip ratio,
randomization stratification groups (presence or absence of diabetes , fibrosis stage F3 or F4),
and other disease 
characteristic variables.
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
8. 7. E fficac y Anal ysis 
8.7.1. Primar y Efficac y Endpoint s Anal ysis Final 
Amendment4 
The point estimates and 95% confidence intervals for the p ropo1iion of subjects who achieve a 
:::: I-stage improvement in fibrosis without worse ning of NAS H at Week 48 will be calculated by 
treatment group. 
8.8. Safety Anal ysis 
All safety data collected on or a fter the date that study diugs were first dispe nsed up to the date 
of last dose of study di11gs plus 30 days will be summ arized by treatment group. D ata for the 
pretreatment and follow- up periods will be included in data listings. 
8.8.1. Extent of Expo sure 
Data of a subj ect's extent of expos ure to study diugs will be generated from the study di11gs 
adinin istration eCRF data. Expos ure data will be summ arized by treatment group. 
8.8.2. Adverse Events 
Clinical and laborato 1 y AEs will be coded using the Medical Dictionaiy for Regu lato1y 
Activities (MedD RA). Syste m Or gan Class (SOC) , High-Level Group Te1 m (HLGT), 
High-Leve l Te1m (HLT), Prefened Te1m (PT), and Lowe r-Level Te1 m (L LT) will be attac hed to 
the clinical database. AE sever ity will be graded using the CT CAE. 
Events will be summ arized on the basis of the date of onset for the event. A TEAE will be 
defined as one or both of the following: 
• Any AEs with an onset date on or a fter the study diugs staii date and no l ater than 30 days 
after pe1manent discont inuation of study diugs 
• Any AEs leading to pre mature discont inuation of study di11gs 
Summai· ies (numbe r and percentage of subjects) ofTEAEs by SOC and PT will be provided by 
treatment group. Treat ment-emer gent AEs will also be summ ai·ized by relatio nship to study 
diugs and severity. In addition, TEAEs leading to premature discontinuatio n of study diugs and 
study will be summ arized and listed. 
All AEs collected during the course of the study will be pr esented in data listings with a field for 
treatme nt-eme rgent event (Yes/No). 
CONFIDENTIAL Page 111 25 Apri l 2019 
Selonsertib , GS-0976 , GS-9674 
Protoco l GS-US-454 -4378 
Gilead Sciences , Inc. 
8.8.3. Laborator y Evaluation s Final 
Amendment4 
Selected laborato1y data will be summ arized (n, m ean, SD, me dian, QI, Q3, minimum, and 
maxi mum ) by tr eatme nt group and study visit along with the coITespond ing chan ge from 
baseline values. 
Graded laborato 1 y abnonnalities will be defined using the grading scheme in the CTCAE. 
Grad ing of laborato 1 y abnonnalities for anal ysis purposes will be defined in the Statistical 
Analysis Plan . 
The incide nce of treatme nt-emergent laborato1y abnonnalities, defined as values that increase at 
least one toxic ity grade from baseline at any time post baseline up to and including the date of 
last dose of study dmgs plus 30 days, will be summ arized by treatment group. If baseline data 
are missing, then any grade d abnonnality (ie, at least a Grade I) will be considered 
treatme nt-emergent. 
• 
8.11. Sample Size 
Due to the explorato1y nature of this study, no fo1mal power calculations were used to dete1min e 
sample size. The number of subjects was chosen based on clinical exper ience with other similar 
proof of concept studies ; howeve r, with a sample size of approx imately 70 subjects in each 
active combination treatment aim and approximately 3 5 in the p lacebo aim, the study has over 
80% power to detect a differe nce in the propo1iio n of subjects with a~ I-stage improvement in 
fibrosis without worse ning of NASH of25% or m ore at Week 48 at a significance level of 
0.05 (two-sided), assumin g the propor tion of subjects that meet the endpo int in the placebo an n 
is 7.2%. 
CONFIDENTIAL Page 112 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 113 25 April 20198.12. Data Monitoring Committee
An independent, external multidisciplinary  data monitoring committee (DMC) that consists of at 
least 
two hepatologists and a statistician will review the progress of the study  and perform 
interim reviews of safet y data.The initial meeting of the DMC will occur after 35 subjects
(approximately  5 per treatment group) have completed their Week 4 assessments and will meet 
at a minimum interval of every  6 months thereafter. The DMC will provide recommendation sto 
Gilead whether the nature, frequency , and severity  of adverse effects associated with study  
treatment warrant the early
 termination of the study  in the best interests of the participants, 
whether the stud y should continue as planned, or the study shoul d continue with modifications. 
The DMC may  also provide recommendations as needed reg arding stud y design.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which will define the 
DMC’s membership, conduct, and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on
all aspects of 
the study .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 114 25 April 20199. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Cl inical Practice
The Investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The Investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 Code of Federal Regulations ( CFR )312, subpart D, “Responsibilities of Sponsors 
and Investigators,” 21 CFR, part 50, 1998, and 21 CFR, part 56, 1998.
The Investigator and a ll applicable subinvestigators will comply  with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided pr ior to 
the Investigator ’s (and any  subinvestigator’s) participation in the study . The Investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study com pletion is defined as the date when the 
last subject completes the protocol
-defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) / 
Ethics Committee (EC) Review and Approval
The Investigator (or sponsor as appropriate accor ding to local regulations) will submit this 
protocol, ICF, and any  accompan ying material to be p rovided to the subject 
(such asadvertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC/EC . The Investigator will not begin an y study subject activities 
until approval from the IRB/IEC/EC has been documented and provided as a letter to the 
Investigator .
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC/EC any modifications made to the protocol or an y accompan ying material to be 
provided to the subject after initial IRB/IEC/EC approval, with the exception of those necessary 
to reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investiga tor is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB/IEC/EC -approved consent form for documenting 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 115 25 April 2019written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legall y authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by IRB/ IEC/EC
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to rec eive clinically  relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only partial date of birth (as applicable in
certain countries) , another unique identifier (as allowed by  local law) ,and an identification code
will be recorded on an y form or biological sample submitted to the Sponsor, IRB/IEC/EC ,or 
laboratory . Laboratory  specimens must be labeled in such a way
 as to protect subject identity  
while allowing the results to be recorded to the proper subject. Refer to specific laboratory  
instructions . NOTE :The investigator must keep a screening log showing codes, names, and 
addresses for all subjects scre ened and for all subjects enrolled in the trial. Subject data will be 
processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
IB, this protocol, eCRF s, the IMP, and any  other study  information, remain the sole and 
exclusive property  of Gilead during the conduct of the study  and thereafter. This information is 
not to be disclosed to any third party  (except employ ees or agents directl y involved in the 
conduct 
of the stud y or as required b y law) without prior written consent from Gilead. The 
investigator further agrees to take all reasonable precautions to prevent the disclosure by  any 
employ ee or agent of the study  site to an y third party or otherwise into the public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms,
IRB/IEC/EC and governmental approval with correspondence, informed consent, drug records, 
staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender)
Documentation that subject meets eligibility  criteria, ie, history , PE, and confirmation of 
diagnosis (to support inclusion and exclusion criteria)
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 116 25 April 2019Documentat ion of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number)
Study  discussed and date of informed consent
Dates of all visits
Documentation that protocol spe cific procedures were performed
Results 
of efficacy  paramete rs, as required b y the protocol
Start and end date (including dose regimen) of study  drugs , including dates of dispensing and 
return
Record of all AEs and other safety  parameters (start and end date, and including causality  
and severit y)
Concomitant medication (including start and end date, dose if relevant; dose changes)
Date of study  completion and reason for earl y discontinuation, if it occurs
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to lo cal laws, whichever is longer, 
after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified by  regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for 
this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the si te so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Electronic Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. eCRF sshould be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safet y data. The Eligibility  Criteria eCRF should be completed onl y after all data related to 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 117 25 April 2019eligibility  have been received. Subsequent to data entry , a study  monitor will perform source data 
verification within the EDC sy stem. Original entries as well as an y changes to data fields will be 
stored in the audit trail of the sy stem. Prior to database lock (or any  interim time points 
asdescribed in the clinical data management plan), the investigator will use his/her log in 
credential s to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture s the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff, 
who routinely  review the data for completeness, correctness, and consistency .The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entry, and providing the reason 
for the update (eg,data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a rea d-only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5 .
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, study  drug sshould be destro yed at the site. If the site does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
Gilead Sciences (or Gilead Sciences’ representative) for return of unused study  drug supplies.
The study  monitor will provide instructions for return.
The study  monitor will evaluate each study  center’s study  drug disposal procedures and provide 
appropriate instruction for destruction of unused study drug supplies. If the site has an 
appropriate standard operating procedure (SOP) for drug dest ruction as determined by Gilead , 
the site may  destroy  used (empty  or partiall y empty) and unused stud y drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained
for central files.
If study  drug saredestro yed on site, the investigator must maintain accurate records for all stud y 
drugsdestroy ed. Records must show the i dentification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug. Upon study  completion, 
copies of the stud y drug accountability records must be filed at the site. Another cop y will be 
returned to Gilead. Refer to the Pharmacy  Binder for study  drug disposal/return instructions. The 
study  moni tor will review study  drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , toIRB/IEC/EC , or to regulatory  authority  or health authority  
inspectors.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 118 25 April 20199.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IEC/EC
in accordance with local requirements and receive documented IRB/IEC/EC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agenc ies. Gilead 
will ensure that the report meets the standards set out in the I CH Guidel ine for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media onl y after the following conditions have been met: the results of the stud y 
in their entiret y have been publicly disclosed b y or with the consent of Gilead in an abstract, 
manuscript, or presentation form or the stud y has been completed at all study  sites for at least 
2years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation.
No such communication, presentation, or publication will include Gilead’s confi dential 
information (see Section 9.1.4).
The investigator will com ply with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 119 25 April 20199.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide service s performed under this 
protocol (eg,attendance at I nvestigator's Meetings). If required under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and a ny other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the
eCRF .
The monitor is responsib le for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected 
through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of G ilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the a ppropriate 
regulatory  authorities, IRBs, IECs , and ECs . In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 120 25 April 201910. REFERENCES
Afzali A, Berry  K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic 
steatohepatitis in the United States. L iver Transpl 2012;18 (1):29 -37.
Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. International journal of 
molecular sciences 2016;17 (9).
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Dietrich P, Hellerbrand C. Non -alcoholic fatty liver disease, obesity and the metabolic s yndrome. 
Best practice & research 2014;28 (4):637-53.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non -alcoholic fatty  liver disease. 
QJM 2010;103 (2):71-83.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up [Accepted Article]. Hepatology  2014.
Faramawi MF, Wildman RP, Gustat J, Rice J, Abdul Kareem MY. The association of the 
metabolic sy ndrome with QTc interval in NHANES III. Eur J Epidemiol 2008;23 
(7):459
-65.
Grund y SM, Cleeman J I, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and 
management of the metabolic sy ndrome: an American Heart Associatio n/National 
Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735 -
52.
Harwood HJ, Jr. Treating the metabolic sy ndrome: acet yl-CoA carboxy lase inhibition. Expert 
opinion on therapeutic targets 2005;9 (2):267 -81.
Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non -alcoholic steatohepatitis. Clin 
Chim Acta 2011;412 (15- 16):1297-305.
Lee YA, Wallace MC, Friedman SL . Pathobiology of liver fibrosis: a translational success story . 
Gut 2015;64 (5):830-41.
Makie T, Nagai S, Sas akawa A, Kawamura K, Kuwahara T. Predicting tenofovir concentration 
on the basis of renal factors determined b y routine tests. Am J Ther 2007;14 
(6):514-8.
Miele L , De Michele T, Marrone G, Antonietta Isgro M, Basile U, Cefalo C, et al. Enhanced 
liver fibr osis test as a reliable tool for assessing fibrosis in nonalcoholic fatty  liver 
disease in a clinical setting. Int J Biol Markers 2017;32 (4):e397 -e402.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 121 25 April 2019Neuschwander -Tetri BA. Hepatic lipotoxicity  and the pathogenesis of nonalcoholic 
steatohepatitis: the central role of nontrigl yceride fatty  acid metabolites. 
Hepatology  2010;52 (2):774-88.
Neuschwander -Tetri BA, L oomba R, Sany al AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et 
al. Farnesoid X nuclear receptor ligand obeticholic acid for non -cirrhotic, non -
alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo -controlled 
trial. Lancet 2014.
Ong JP, Younossi ZM. Epidemiology  and natural history  of NAFLD and NASH. Clin L iver Dis 
2007;11 (1):1 -16, vii.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfat y L, et al. Elafibranor, an 
Agonist of the Peroxisome Proliferator -Activated Receptor -alpha and -delta, 
Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
Gastroenterology 2016;150 (5):1147- 59 e5.
Rolo AP, Teodor o JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic 
steatohepatitis. Free Radic Biol Med 2012;52 (1):59-69.
Shadab Siddiqui M, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, et al. 
Case definitions for inclusion an d anal ysis of endpoints in clinical trials for 
NASH through the lens of regulatory  science [Accepted Article]. Hepatology  
2017.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in 
NAFLD/NASH. Free radical research 2
013;47 (11):869 -80.
Takeda K, Noguchi T, Naguro I, Ichijo H. Apoptosis signal- regulating kinase 1 in stress and 
immune response. Annu Rev Pharmacol Toxicol 2008;48:199 -225.
The EuroQol Group. EuroQol --a new facility  for the measurement of health- related qu ality of 
life. . Health Policy  1990;16 (3):199-208.
Tobiume K, Saitoh M, I chijo H. Activation of apoptosis signal -regulating kinase 1 by  the stress -
induced activating phosphory lation of pre -formed oligomer. Journal of cellular 
physiology  2002;191 (1):95-104.
Tong L, Harwood HJ, Jr. Acet yl-coenzy me A carboxy lases: versatile targets for drug discovery . 
J Cell Biochem 2006;99 (6).
Vernon G, Baranova A, Younossi ZM. S ystematic review: the epidemiology  and natural history  
of non- alcoholic fatty  liver disease and non-alcoholic steatohepatitis in adults. 
Aliment Pharmacol Ther 2011;34 (3):274 -
85.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopath y 
in chronic liver disease: 2014 Practice Guideline by  the American Association for 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 122 25 April 2019the Study  of Liver Diseases and the European Association for the Study  of the 
Liver. Hepatology 2014;60 (2):715-35.
Voulgari C, Tentolouris N, Papadogiannis D, Moyssakis I, Perrea D, Ky riaki D, et al. Increased 
left ventricular arrh ythmogenicity  in me tabolic s yndrome and relationship with 
myocardial performance, risk factors for atherosclerosis, and low -grade 
inflammation. Metabolism: clinical and experimental 2010;59 (2):159 -65.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of 
nonalcoholic fatt y liver disease and nonalcoholic steatohepatitis among a largely 
middle -aged population utilizing ultrasound and liver biopsy : a prospective study . 
Gastroenterology  2011;140 (1):124-31.
Wong RJ, Cheung R, Ahmed A. Nonalcoholi c steatohepatitis is the most rapidly  growing 
indication for liver transplantation in patients with hepatocellular carcinoma in the 
U.S. Hepatology  2014;59 (6):2188-95.
Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology  2014;1 47 
(4):754-64.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry  L, Wy mer M. Global epidemiology  of 
nonalcoholic fatt y liver disease -Meta -analy tic assessment of prevalence, 
incidence, and outcomes. Hepatology  2016;64 (1):73 -84.
Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear 
receptor FXR improves hypergly cemia and hy perlipidemia in diabetic mice. Proc 
Natl Acad Sci U S A 2006;103 (4):1006-11.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 123 25 April 201911. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. West Haven Criteria
Selonsertib, GS-0976 , GS-9674 
Protocol GS-US-454-4378 
Gilead Sciences, Inc. 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT Final 
Amendment4 
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and 
Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) 
Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) 
GS-US-454-4378, Amendment 4, 25 April 2019 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
tpPD 
PPD 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for me 
and my staff to conduct this study as described. I will conduct this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they 
are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDENTIAL Page 124 25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 125 25 April 2019Appendix 2. Study Procedures Table
Assessments ScreeningDay
1On-
Treatment Visits
ET Follow -UpWeek 
1Week 
4Week 
8Week 
12Week 
16Week 
20Week 
24Week 
28Week 
32Week 
36Week 
40Week 
44 Week 48
Clinical Assessments
Written Informed 
ConsentX
Determine 
EligibilityX X
Medical History X
Physical 
ExaminationXaX X X X X X X XaX X X X X XaXaX
Vital Signs 
including Body 
WeightX X X X X X X X X X X X X X X X X
Height X
12-lead ECG X X X X
Assess Ascites 
and HEX X X X X X X X X X X X X X X X
Abdominal 
UltrasoundXbX X X
Liver Biopsy XeX Xd    
CCI
CCI
CCI
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 126 25 April 2019Assessments ScreeningDay
1On-Treatment Visits
ET Follow -UpWeek 
1Week 
4Week 
8Week 
12Week 
16Week 
20Week 
24Week 
28Week 
32Week 
36Week 
40Week 
44 Week 48
Lifestyle 
Questionnaire X X X X X X X X X X X X X X X
Lifestyle 
Modification 
CounselingX X X X X X X X X X X X X X
Dispense Study 
DrugsX X X X X X X X X X X X
Review of Study 
Drug Dosing 
Compliance (Pill 
Count)X X X X X X X X X X X X X X
Concomitant 
MedicationsX X X X X X X X X X X X X X X X X
Adverse Events XiX X X X X X X X X X X X X X X X
Laboratory Assessments
Chemistry, 
Hematology, 
CoagulationX XjXjX X X X X X X X X X X X X X
Insulin and Lipids X X X X X X X X X
HbA1c XkX X X X X X X X
eGFR X X X X X X X X X X X X X X X X X
HIV-1, HBV, 
HCV SerologyX
CCI
CCI
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 127 25 April 2019Assessments ScreeningDay
1On-Treatment Visits
ET Follow -UpWeek 
1Week 
4Week 
8Week 
12Week 
16Week 
20Week 
24Week 
28Week 
32Week 
36Week 
40Week 
44 Week 48
Pregnancy 
Testingn X X X X X X X X X X X X X X X X
Urine Drug Screen X
Urine Collection 
(albumin, 
creatinine, 
albumin/creatinine 
ratio)X X X X X X X
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Selon sertib , GS-09 76, GS-9674 
Protocol GS-US-454-4378 
Gilead Science s, Inc. 
a Co mple te PE 
b Histo rical ultrasound wit hin 3 months inclusive to the date of Screening ma r 
d 
e r 
t 
I 
J 
k 
' n 
' 
CONFIDENTIAL On-Treatme nt Visits 
Page 128 Final 
Amendment4 
25 April 2019 
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 129 25 April 2019Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born s
ubject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postmenopausal sta te when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Fema le Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
SELis contraindicated in pregnancy as a malformation effect is suspected, based on non- clinical 
data. In rats and rabbits, SEL administration was associated with effects on embryo- fetal 
development at maternally toxic doses. This included total litter loss, increased resorptions and 
post implantation loss, reduced fetal weights, and visceral and skeletal malformations and 
variations. Embr yofetal effects were ob served in rats and rab bits at exposures (AUC 24hr) that 
were 62- and 12- fold higher, respective ly, than the projected SEL exposure at the proposed 
human dose of 18 mg/da y. The NOELs for embryofetal development in rats and rabbits were 
15and 10 mg/kg/da y, respective ly.TheSEL exposure margins at these doses as compared to the 
maximum proposed human dose are 12-and3-fold, respectivel y.
Preclinical data indicate that SELisunlikely to reduce the exposure of hormonal contraceptives 
through induction of human drug metabolizing enzymes or drug transporters. This is supported 
byclinical DDI data, which demonstrated multiple doses of SELdid not result in exposure 
changes of a representative oral hormonal contraceptive, indicating no loss of contraceptive 
efficacy  is expected upon administration of SEL  with hormonal contraceptives.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 130 25 April 2019No formal studies have been conducted to evaluate the reproductive toxicity of G
S-0976; 
therefore, the reproductive toxicity of GS-0976 in humans is unknown. However, mutant mice 
lacking A CC1, one of the targets of GS-0976, areembr yonical ly lethal. Therefore, GS-0976 is 
contraindicated in pregnanc y.
Preclinical data in human hepatoc ytes indicate that GS-0976 is a mild inducer of CYP3A4
isoenz ymes. Clinical data demonstrates no decrease in exposure of a representative oral 
hormonal contraceptive indicating no loss of contraceptive efficacy  is expected upon 
administration of GS -0976 with hormonal contraceptives. Please refer to Section 1.3.3.1 and the 
latest 
version of the Investigator’s Brochure for additional information.
G
S-9674 has not y et been studied in pregnant women. In initial dose range- finding studies in 
pregnant mice an d rabbits there were no effects on embr yofetal development other than a 
decrease in fetal bo dy weights in the pregnant rabbits administered 1000 mg/k g/day. The 
decrease in fetal bo dy weights are likely  secondary  to maternal toxicity rather than a direct ef fect 
of GS-9674. The NOEL for embr yo/fetal development is 300 mg/kg/day in mice and
200mg/kg/day in rabbits. These doses were associated with exposures that are > 50-fold higher 
than the anticipated human exposure at the maximum proposed human dose of 100 mg once 
daily
.
DDI data do not suggest a potential for interaction between GS-9674 and hormones used for 
contraception. 
Please refer to the latest version of the Inv estigator’s Brochure for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They  must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Baseline/Day  1 visit prior to enrollment. Pregnancy  tests will be 
performed at monthly  intervals thereafter. Female subjects must agree to one of the following 
from Screenin g until 90 days following the last dose of study drug.
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per ye ar
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 131 25 April 2019Essure®micro -insert s ystem (provided confirmation of success 3 months after procedure)
Vasecto my in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Should female subjects wish to use a hormonally based method, use of a male condom b ythe 
female subject's male partner is required. Subjects who utilize a hormonal contraceptive as one 
of their birth control methods must have used the same method for at least three months prior to 
study dosing. Hormonal l
y-based contraceptives permitted for use in this protocol are as follow s:
Oral contraceptives (either combined or progesterone only)
Injectable progesteron e
Implants of levonorgestrel
Transdermal contraceptive patch
Contraceptive vaginal rin g
Not all of these methods may be approved in each of the countries where thestudy is being 
conducted: please refer to local product information. Additional local regulatory requirements 
mayapply
.
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 90 days after the last dose of study drug.
3) Contraception Requirements for Male Subjects
It is theoretical ly possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid. The refore, male subjects with female 
partners of childbearing potential must use condoms during treatment until 90 da ys after the last 
dose of study drug. Female partners of male study subjects are asked to select one of the above 
methods.
Male subjects must also refrain from sperm donation during treatment and until at least 90 days 
after the last dose of study drug.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable inc lude periodic abstinence (eg ,calendar, ovulation, 
symptothermal, post
-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM). Female condom and male condom should not be used 
together.
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 132 25 April 20195)Procedures to 
be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 90days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspect s she is pregnant during the stud y must report the information to 
the investigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy outcome 
are outlined in Section 7.6.2.1 .
Selonsertib, GS -0976, GS -9674
Protocol GS -US-454-4378 Final
Gilead Sciences, Inc. Amendment 4
CONFIDENTIAL Page 133 25 April 2019Appendix 4. West Haven Criteria
http://www.mdcalc.com/hepatic -encephalopathy -grades -stages/
Grade of Hepatic 
Encephalopathy Description Suggested Operative Criteria
Grade ITrivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairm ent of addition or subtraction
Altered sleep rhythmDespite oriented in time and space 
(seebelow ), the patient appears to have some 
cognitive/ behavioral decay with respect to his 
or her standard on clinical examination or to 
the caregivers
Grade IILethargy or apathy
Disorientation for time
Obvious personality change
Inappropriate behavior
Dyspraxia
AsterixisDisoriented for time (at least three of the 
followings are w rong: day of the m onth, day 
of the week, month, season, or year) ± the 
other mentioned symptoms
Grade IIISomnolence to semistupor
Responsive to stimuli
Confused
Gross disorientation
Bizarre behaviorDisoriented also for space (at least three of the 
following wrongly reported: country, state [or 
region], city, or place) ± the other mentioned 
symptoms
Grade IV Com a Does not respond even to painful stimuli
Adapted from {Vilstrup 2014 }